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List of Abbreviations Used:
ABP -  androgen binding protein 
ADA -  American Diabetes Association 
AIA -  antiiflamatory agents 
ADH =AVP -  antidiuretic hormone 
ALT -  alanine amino-transferase 
ACTH -  adrenocorticotropin hormone 
AM -  morning
AM! -  acute myocardial infarction 
ANA -  antinuclear antibody 
BP -  blood pressure 
BM1 -  body mass index 
Ca -  calcium
CNS -  central nervous system
CRF -  corticotrophin releasing factor
CT -  computerized tomography
CS11 -  continuous subcutneous infusion
CVD -  cardiovascular disorder
D - dopamine
GDM -  gestational diabetes
GDT -gastrodigestive tract
GLP-1 -  glucagon-like peptide -1
GLUT -  glucose transporter
GnRF -  gonadotrophin releasing factor
DKA -  diabetic ketoacidosis
DM -  diabetes mellitus
DCCT -  The Diabetes Control and Complications Trial
ESRD -  end-stage renal disease
ECG -  electrocardiogram
FPG -  fasting plasma glucose
ER -  endoplasmic reticulum
GAD -  glutamic acid decarboxylase
GIP -  glucose-dependent insulinotropic peptide
GF1 -  growth hormone
Gm -  gram
HbA 1 c -  glycozylated hemoglobin 
HDL -high-density lipoproteins 
Hg -  mercury 
hr’s - hour
1APP -  islet amyloid polypeptide 
ICA -  ilet cell antibodies 
ICP -  intracranial pressure
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IGT- impaired glucose tolerance 
IGH -1 - inhibitor growth hormone -1 
IFG - impaired fasting glucose 
IRI -immunoreactive insulin 
IRG -immunoreactive glucagons 
IP3 -  inositol phosphate 3 
IV -  intravenous 
К -  potassium 
L -  liter 
m L - milliliter 
mm -  millimeter
LADA -  latent autoimmune diabetes of adulthood 
Lb = pounds (1 kg = 2,2 lb)
LDL -  low -density lipoproteins 
LH -  leutenizing hormone 
M - male
MEN -  multiple endocrine neoplasia 
MODY -  maturity-onset diabetes of the young 
MRI -  magnetic resonance imaging 
Na -  sodium
NPH -  neutral protamine Hagedom
OGTT -  oral glucose tolerance test
PAI-1 - plasminogen activator inhibitor type 1
PCOD -  polycystic ovarian disease
PTH - parathhormone
PRL -  prolactin
PPG -  postprandial glacemia
PM - afternoon
PVD - pulmonary vascular disease
TSI -  thyroid stimulating immunoglobulin
TSAb -thyroid stimulating antibodies
Tg -  triglycerides
T4 -  thyroxine level
T3 -  treiodothyronine level
ТВ -  tuberculosis
TSI — thyroid stimulating immunoglobulin
TSab - thyroid stimulating antibodies
TPH -  thyrotrophin realizing hormone
TSH -  thyroid-stimulating hormone
TSH -R  - thyroid-stimulating hormone receptor
TZDs -thiazolidindiones
F- female
FFA -  free fatty acids
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FNA -  fine needle aspiration
FSH -  follicle stimulating hormone
URTI -  urgent respiratory tract infection
UKPDS -  The United Kingdom Prospective Diabetes Study
TFT -  thyroid function test
VLDL -  very-low density lipoprotein
WHR -  waist:hip circumference ratio
WHO -  World Helth Organisation
URTI -  upper respiratory tract infection
V - volume
u - units
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Chapter I. Disorders o f Glucose M etabolism.
Diabetes Mellitus (DM).
General consideration
Glucose is a simple sugar found in food. Glucose is an essential nutrient 
that provides energy for the proper functioning of the body cells. Carbohydrates 
are broken down in the small intestine and the glucose is digested food is then 
absorbed by the intestinal cells into the bloodstream, and is carried by the 
bloodstream to all the cells in the body where it is utilized. Glucose cannot enter 
the cells alone and needs insulin to aid in its transport into the cells. In addition 
to helping glucose enter the cells, insulin is also important in tightly regulating 
the level of glucose in the blood. After a meal, the blood glucose level rises. In 
response to the increased glucose level, the pancreas normally releases more 
insulin into the bloodstream to help glucose enter the cells and lower blood 
glucose levels after a meal. When the blood glucose levels are lowered, the 
insulin release from the pancreas is turned down. It is important to note that 
even in the fasting state there is a low steady release of insulin than fluctuates a 
bit and helps to maintain a steady blood glucose level during fasting. Without 
insulin, the cells become starved of glucose energy despite the presence of 
abundant glucose in bloodstream. The cells’ inability to utilize glucose gives rise 
to the ironic situation of “starvation in the midst of plenty”. The abundant, 
utilized glucose is wastefully excreted in the urine.
There are two types of mutually antagonistic metabolic hormones 
affecting blood glucose levels:
• catabolic hormones (such as glucagon, growth 
hormone,catecholamines), which increase blood glucose - termed contrinsular 
hormones
• and one anabolic hormone (insulin), which decreases blood glucose
Anatomy of the pancreatic gland.
Tire pancreas located behind the stomach. It is deep-seated organ in the 
abdomen. Weight 70-80g, 15x7x3 cm. The pancreas consists of three parts: head 
(caput), body (corpus), and tail (cauda). The external secretory apparatus 
occupies the greater part of the pancreatic parenchyma and secretes different 
component of the pancreatic juice. The pancreas is innervated by branches of the 
vagus and sympathetic nerves, and is supplied with blood by the pancreatic- 
duodenal artery and by branches of the splenic artery.
Endocrine tissue making up the Langerhans islets (contains 
approximately 1-1,5 million islets).
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Anatono-Physiological Data
Langerhars islets cells and effects of hormons
• А-cell: produces glucagons( 12 -18 all of its, located nearer to the 
periphery of the island)
Glucagon effects
antagonist of insulin 
stimulate glycogenolysis 
lipolysis 
gluconeogenesis
biosynthesis glucose from amino acids
Slow down
glycogen synthesis
• В-cell: produces insulin ( 60 -70% all of its, located nearer to the 
centre of the island) and amylin, which similar to insulin
Insulin is a peptide hormone composed of 51 amino acid residues and has 
a molecular weight of 5808 Da. Iinsulin is synthesized from the proinsulin 
precursor molecule by the action of proteolytic enzymes, known as prohormone 
convertases (PCI and PC2), as well as the exoprotease carboxypeptidase E. 
These modifications of proinsulin remove the center portion of the molecule, or 
C-peptide, from the C- and N- terminal ends of the proinsulin. The remaining 
polypeptides (51 amino acids in total), the B- and A- chains, are bound together 
by disulfide bonds. Both C-peptide and mature insulin are biologically active. 
Insulin binds to its receptor which in turn starts many protein activation 
cascades. These include: translocation of Glut-4 transporter to the plasma 
membrane and influx of glucose glycogen synthesis .glycolysis and fatty acid 
synthesis ,
Insulin effects 
Stimulate
- entering glucose the cells
- reabsorbtion H20, Na+ in the kidney
- regulation the level of glucose in the blood
- lypogenesis
- glycogenesis
- DNA replication and protein synthesis and via control of amino acid 
uptake.
- potassium uptake -  forces cells to absorb serum potassium; lack of 
insulin inhibits absorption
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- arterial muscle tone -  forces arterial wall muscle to relax, increasing 
blood flow, especially in micro arteries; lack of insulin reduces flow by allowing 
these muscles to contract.
Slow down
- Glyconeogenesis
- Ketogenesis
- Glycogenolysis
- Lipolisis
- Proteolisis
Amylin, or Islet Amyloid Polypeptide (1APP): is a 37-residue peptide 
hormone secreted by pancreatic В-cells at the same time as insulin (in a roughly 
100:1 ratio). Complete function may not yet be known. , and therein
Amylin effects
glucose control during the postprandial period 
reduce the total insulin demand1 
to slow gastric emptying 
promote satiety
inhibit secretion of glucagon during hyperglycemia
• D-cell: produces somatostatin ( 2-8% all of its, regulator of 
insulin secretion)
Mechanism for release of insulin and regulation
Beta cells in the islets of Langerhans are sensitive to variations in blood 
glucose levels through the following mechanism (see figure to the right):
• Glucose enters the B-celis through the glucose transporter 
GLUT2
• Glucose goes into the glycolysis and the respiratory cycle where 
multiple high-energy ATP molecules are produced by oxidation
• Dependent on ATP levels, and hence blood glucose levels, the 
ATP-controlled potassium channels (K+) close and the cell membranes 
depolarize
. On depolarisation, voltage controlled calcium channels (Ca2+) open 
and calcium flows into the cells
• An increased calcium level causes activation of phospholipase C. 
which cleaves the membrane phospholipid phosphatidyl inositol 4.5- 
bisphosphate into inositol 1.4.5-triphosphate and diacvlglvcerol.
• Inositol 1,4,5-triphosphate (1P3) binds to receptor proteins in the 
membrane of endoplasmic reticulum (ER). This allows the release of Ca2+ from 
the ER via IP3 gated channels, and further raises the cell concentration of 
calcium.
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• Significantly increased amounts of calcium in the cells causes 
release of previously synthesised insulin, which has been stored in secretory 
vesicles
This is the main mechanism for release of insulin and regulation of insulin 
synthesis. In addition some insulin synthesis and release takes place generally at 
food intake, not just glucose or carbohydrate intake, and the В-cells are also 
somewhat influenced by the autonomic nervous system. The signalling 
mechanisms controlling this are not fully understood.
Other substances known which stimulate insulin release are acetylcholine, 
released from vagus nerve endings (parasympathetic nervous system!. 
cholecvstokinin. released by enteroendocrine cells of intestinal mucosa and 
glucose-dependent insulinotropic peptide (GIP). The first of these acts similarly 
to glucose through phospholipase C, while the last acts through the mechanism 
of adenylate cyclase.
The sympathetic nervous system (via оь-adrenergic agonists such as 
norepinephrine! inhibits the release of insulin.
When the glucose level comes down to the usual physiologic value, 
insulin release from the B- cells slows or stops. If blood glucose levels drop 
lower than this, especially to dangerously low levels, release of hyperglycemic 
hormones (most prominently glucagon from Islet of Langerhans' A- cells) forces 
release of glucose into the blood from cellular stores, primarily liver cell stores 
of glycogen. By increasing blood glucose, the hyperglycemic hormones correct 
life-threatening hypoglycemia. Release of insulin is strongly inhibited by the 
stress hormone norepinephrine (noradrenaline), which leads to increased blood 
glucose levels during stress.
Classification of the diseases of the islet apparatus of the pancreas
• Diabetes mellitus -absence or insufficient production of insulin
• Insulinoma- hypersecretion of insulin by hormon active tumor
• Glucagonoma- hypersecretion of glucagon by hormon active tumor
• Terminology and classification of the Disorders of Glucose
metabolism
Difenition
Diabetes mellitus is a common refer accumulated a group of the disorders 
of glucose metabolism which differ by etiology, pathogenesis and complications 
but with one common manifestation: hyperglycemia . Chronic hyperglycemia 
causes damage to the eyes, kidneys, nerves, and blood vessels.
• Is a group of metabolic diseases characterized by fasting 
hyperglycemia
• Which result from defects in insulin secretion, or action, or both
• Is chronic diseases
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• It lasts a lifetime
• Is characterized as a consequence by disorders of all kinds of 
metabolism
• Is characterized as a micro-and macro veselpathy and neuropathy
•  Patients with DM1 wasl994 -  1 l,5millions and by the year 2010 it 
will reach 23,7 millions
• Patients with DM2 was 1994 -  99 millions and by the year 2010 it 
will reach 216 millions
• over time, DM lead to blindness, kidney failure, nerve damage
• 3% of the patients have DM1 and 97% have DM2
Two variants of disorders of Glucose metabolism
1. Diabetes mellitus.
2. Pre-diabetes or Other Categories of Hyperglycemia .
In 1997, the ADA issued new diagnostic and classification criteria ; in 
2003, modifications were made regarding the diagnosis of impaired fasting 
glucose (IFG). This etiologic classification indentifies four types of a diabetes 
mellitus : type 1, type 2, “other specific types” and gestational diabetes. Arabic 
numerals used to minimize the occasional confusion of type “II” as the number 
“11”. Each of the types of DM identified extends across a clinical continuum of 
hyperglycemia and insulin requirements.
Classification of Diabetes Mellitus (DM). ADA, 2003
1. Type 1 Diabetes (results from В-cell destruction, usually leading to 
absolute insulin deficiency):
A - idiopathic 
В - auto-immune.
2. Type 2 Diabetes (results from a progressive insulin secretory defect on 
the background of insulin resistance).
3. Other Specific types of Diabetes Mellitus 
Genetic defects of pancreatic В cell function:
MODY1 (HNF-4alfa); rare
MODY2 (glucokinase); less rare
MODY3 (HNF-1 alfa); accounts for two-thirds of all MODY 
MODY4(IPF-l); very rare 
MODY5 (HNF-1 beta): very rare 
MODY 6 (neuroDl); very rare 
Mitochondrial DNA 
Genetic defects in insulin action 
Type A insulin resistance 
Leprechaunism
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Rabson-Mendenhall syndrome 
Lipoatrophic diabetes 
Diseases of the exocrine pancreas 
Endocrinopathies
Drug- or chemical-induced diabetes
Other genetic syndromes (Down’s, Klinefelter’s, Turner’s, others) 
sometimes associated with diabetes.
4. Gestational diabetes (GDM): diagnosed during pregnancy.
l.Type 1 Diabetes Mellitus:
3% of general DM
formerly called type I, insulin-dependent diabetes mellitus, juvenile
diabetes.
Type 1 DM is due to the pancreatic islet В-cell destruction predominantly 
by an autoimmune process, and these patients are prone to ketoacidosis. This 
form of diabetes is immune-mediated in over 90% of case and idiopathic in less 
than 10%.
Epidemiology DM 1 type
Type 1 DM incidence tends to increase to the north from equator -  a 
northern-southern latitude gradient phenomenon. Almost simultaneously the 
seasonal fluctuations were revealed, manifesting with the grouse of DM1 
incidence in a cold season in different countries of the world sharp peaks of 
DM1 new cases not meeting to natural variability of the incidence are registered 
periodically.
Etiology and Pathogenesis of Immune-mediated type 1 diabetes 
mellitus
Genetics
associated with HLA II classis: DR3, DR4, DQ allelea
concordance in monozygotic twins (40%)
genes located in the short shoulder of VI chromosomes which ( 
diabetigenic lokus). Nowadays known 10 diabetigenic loki.
Risk factors (diabetogenic factors) DM 1 type
- Personal history of autoimmune diseases increases likelihood of 
developing DM (e.g. Grave’s disease, myasthenia gravis, Addison’s disease, 
pernicious anemia)
- В - cytotropic viruses: coxsackie, parotitis, rubella, reovirus
- Toxins (alloxan, streptozotocin)
- Vaccination
- Dietary factors
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Immune-mediated type 1 diabetes mellitus is a result from an infectious 
(mumps, coxsackie B4 virus) or toxic insult to persons whose immune system is 
genetically predisposed to develop a vigorous autoimmune response either 
againt altrered pancreatic В cell antigens or against molecules of the В cell 
resembling the viral protein (molecular mimicry). Most islet cell antibodies 
(1CA) are directed against glutamic acid decarboxylase (anti -GAD - marker of 
type 1 DM). This action released from sensitized immunocytes. Specific HLA 
immune response genes are believed to predispose patients to a destructive 
autoimmune response against their own cells (autoaggression) which is 
mediated primarily by cytotoxic T cells. Autoimmune destroyed В-cell is 
referring as insilitis is a complex multitude processes.
6 stages of pathogenesis DM type 1
DM type 1 appears when more than 90% of В-cells of pancreas are 
destroyed by an autoimmune process.
1. Genetic predisposition:
- About 95% of patient with DM type 1 have either HLA DR3 and /or 
DR4.
- genetics markers only;
- prolonged 1-2 months to 1-3 years;
- glucose metabolism normal.
2. Triggering/initiation of autoimmune processes:
- infection or toxic insult in neonatal life period:;
- very short time;
- clinically unrecognized.
3. Third step in the sequence is an inflammatory response in the pancreas 
called “insilitis”. There is infiltration of the islets with activated T 
lymphocytes.
- ICA, anti -GAD present but glucose metabolism normal;
- prolonged 2-3 months to 2-3 years.
4. Active immunological processes:
- Involving both cellular and humoral components of immune system.
- Alteration of the surface of the В-cells such that it is no longer 
recognized as “self’, but is seen by the immune system as a foreign cell or 
“nonself’.
- Clinically -  “latent diabetes”.
- OGTT +.
- Clinical symptoms and sign absent.
- Prolonged 2-4 years.
5. Development of an immune response and progressive reduction of 
insulin secretion:
- Activated T lymphocytes present in the islets release cytokines (tumor 
necrosis factor @,interferon & and interleukin 1) which destroy В-cells. CD8+
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cell-induced cytotoxicity and apoptosis are also involved. This results in an im­
mune attack on В-cells, which resultant destruction of B-cells.
- clinic and laboratory manifested diabetes;
- В-cell mass diminishes progressive; А-cells remain intact.
- - Prolonged 2 months -  1,5 years.
6. Clinically manifested diabetes:
- Destruction > 95% B-cells;
- Occur during stress, infection or puberty
- During the early “honeymoon phase”, they may not require insulin for 
control, but are still ketosis prone, need and most need insulin acutely and long 
time;
- Prolonged from 4 years for very long time;
- Long-term complication of DM.
Pathogenesis of DM typel - summary
1. Genetic predisposition.
2. Environmental event
3. Insulitis
4. Activation of autoimmunity
5. Immune attack on B-cells
6. Diabetes mellitus
CLINICS DM Type 1
An absolute deficiency of insulin results in accumulation of circulating 
glucose and fatty acids, with consequent hyperosmolality and hyperketonemia.
• Polyuria (abundant urination) is a consequence of osmotic diuresis 
secondary to sustained hyperglycemia. This results in a loss of glucose as well 
as free water and electrolytes in the urine.
• Polydipsia (thirst) is a consequence of the hyperosmolar state.
• Dryness in the mouth.
• Weight loss and weakness is due to depletion of water, glyco­
gen,and triglycerides; thereafter, redused muscle mass occurs as amino acids are 
diverted to form glucose and ketone bodies.
• Blurry vissiori is a consequence of the hyperosmolar state when the 
lenses are exposed to hyperosmolar fluids.
• Skin itching is a consequence of ketoacidosis.
Ceneral Characterictic of DM Type 1
- Onset usually before age 30
- Acute or subacute onset
- Body habitus typically normal to wasted
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- Genetics: associated with HLA DR3, DR4 and DQ alleles
- Absolute insulin deficiency
- Circulating Islet cell antibodies 50%-85%: IAA, ICA, GAD, IA2-1A2 В
- Prone to ketoacidosis
- Pharmacological therapy -  insulin required
2. Type 2 Diabetes Mellitus:
97% of general DM
formerly called non-insulin-dependent diabetes mellitus, type II or
adult-onset.
Definition
Type 2 DM is the more prevalent form of relative insulin deficiency and 
results from insulin resistance. This represents a heterogeneous group compris­
ing milder forms of diabetes that occur predominatly in adults but occasionally 
in juveniles.
Circulating insulin is sufficient to prevent ketoacidosis but is inadequate 
to prevent hyperglycemia in the face of increased needs owing to tissue insensi­
tivity. In most cases of this type of DM, the cause is unknown. Two subgroups 
of patients are currently distinguished by the absence or presence of obesity.
Ethiology
Genetic marker is unknown. Likelyhood in all:
- monozygotic twins over 40 years of age
- gene on chromosome 2 encoding a cysteine protease calpain-10
- monogenes form (MODY, see below)
-polygenes form
Pathogenesis
No HLA relationship has been iudentified, and autoimmune me­
chanism are not operative
Genetics influence is much more powerfull in type 2 DM, in con­
trast to the situation with DM type 1
А-cells population is increased
Associated with increased hepatic prodaction of glucose, resistance 
to the action of insulin and impaired insulin secretion
Insulin resistance may be due to any one of the three general caus­
es: an abnormal insulin molecule, an excessive amout of circulating antagonists, 
and target defect.
Defects in the receptors in the receptors present in target tissues is 
generally at the post-receptor level
Reduced utilization of glucose by peripheral tissues results in post­
prandial hyperglycaemia
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In the early stages, glucose tolerance remains normal despite insulin 
resistance. This is due to compensatory increase in insulin secretion by B-cells. 
As insulin resistance and compensatory hyperinsulinemia progress, the B-cells 
become unable to sustain this hypercecretion.This results in impaired glucose 
tolerance and later frank DM. Ultimately, В-cell failure develops.
Over-eating, especially when combined with obesity and underac­
tivity, is asssosiated with the development of DM type 2.
In women who are genetically predisposed, pregnancy may be as­
sociated with the development of hyperglycaemia. It may or may not disappear 
following pregnancy. Repeated pregnancies may increase the likelihood of de­
veloping permanent diabetes, particually in obese women.
Deposition of amyloid in pancreatic islets which is accompanied by 
atrophy of islet epithelial cells
Risk factors (diabetogenic) of DM Type 2 and Etiology
- age
- Obesity, especially abdominal-visceral obesity; standardized tables of 
waist-to-hip ratio indicate that ratios of “greater then 0.9 in M and “greater then 
0,8” in women
- Family history
- Sedentary lifestyle
->BP
- Women, who have delivered large babies >4,1 kg, have had polyhy- 
dramnions, preeclampsia or unexplained fetal losses
Exogenous factors
Prevalence depends on:
- Age -increasing
- Residence (urban/rural) - urbanization increasing
- Obesity -increasing wordwide
- Food composition -high fat content -fast food
- Physical activity -industrialization reduces physical activity
Tree Main Mechanisms of the pathogenesis of DM type 2:
1. Linkage reduction of pancreatic B-cells.
Hyperplasia of pancreatic В cell is often present and probably accounts 
for the fasting hyperinsulinism and exaggerated insulin and proinsulin responses 
to glucose and other stimuli seen early in the disease. After several years’ dura­
tion of DM, chronic deposition of amyloid in the islets may combine with inhe­
rited genetic abnormality to progressively impair В cell function.
2. Insulin resistance
Deficiency caused by:
genetic factors 
overweigh 
seddntary lifestyle.
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Increased insulin resistance in target tissues, likely due to:
- receptor abnormality
- post-receptor abnormality.
The mechanisms underlying the insulin resistance are poorly understood. 
Insulin resistance deficiency caused by: genetic factors, overweigh, sedentary 
lifestyle. Obesity is generally associated with abdominal distribution of fat, pro­
ducing an abnormally high waist-to-hip-ratio. The abdominal-visceral obesity, 
due to accumulation of fat in the omental and mesenteric regions, correlates with 
insulin resistance; subcutaneous abdominal fat seems to have less of an associa­
tion with insulin insensitivity. Several adipokines ( leptin, adiponectin, tumor 
necrosis factor-@, resistin),secreted by fat cells, can affect insulin action in ob­
esity .Leptin and adiponectin ,seem to increase sensitivity to insulin,presumably 
by increasing hepatic responsiveness. FNO-@ and resistin interfere with insulin 
action on glucose metabolism and have been reported to be elevated in obese an­
imal models. Mutation or abnormal levels of this adipokines may contribute to 
the development of insulin resistance. Correction of the lifestyle and overweight 
can prevent or re vers hyperglycemia.
3. Acquired glucose toxicity.
Hyperglycemia per se can impair insulin action by causing accumulation 
of hexosamines in muscle and fat tissue and inhibits glucose transport. Correc­
tion of hyperglycemia revers this acquired insulin resistance.
CLINICS of DM Type 2
• asymptomatic initially
• polyuria
• thirst
. weekness
. chronic skin infection
. generalised pruritus and chronic candidal vulvovaginitis in women
. occult disease: CVD, neuropathy, poor vision
Ceneral Characterictic of DM Type 2
- Onset usually after age 40 years
- Genetically-linked
- Non-H LA-associated
- Greater heritability than Typel
- Typically overweigh
- Relative insulin deficiency
- Abnormal insulin secretion
- Insulin resistance
- Increased hepatic gluconeogenesis
- Pharmacological therapy: combination of oral hypoglycemic agents
- Not prone to ketoacidosis but prone to hyperosmolar coma
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Patients with type 2 DM may or may not preset with characteristic fea­
tures.
Among subgroup of patients with nonobese type 2 DM< the majority are 
idiopathic. A variety of etiologic genetic abnormalities have been documented in 
a subset of this patients who have recently been reclassified within a group des­
ignated “other specific types”.
3. Laboratory Findings o f the Disorders of Glucose et ab- 
olism
Pre-diabetes: Impaired Fasting Glucose ( IFG) and Impaired Glucose 
Tolerance (IGT)
IFG and IGT have been officially termed "pre-diabetes." Both categories 
are associated with an increased risk of developing type 2 DM and cardiovascu­
lar disease.
Terminology and Diagnosis
Blood testing procedures
a) Normoglycemia. A normal fasting plasma glucose level is less 
than 6,1 mmol/L (110 mg/DL) and normal 2hr PPG levels are less than 7,75 
mmol/L (140 mg/dL).
b) Blood glucose levels above the normal level but below the criterion 
established for DM indicate impaired glucose homeostasis. Persons with fasting 
plasma glucose levels ranging from 6.1 to 7.0 mmol/L (110 -126 mg/dL) are 
said to have impaired fasting glucose, while those with a 2hrs PPG level be­
tween 7,75 to 11,1 mmol/1 (140 -200mg/dL) are said impaired glucose tolerance. 
Diagnosis based on:
c) Impaired Glucose Tolerance (IGT).
- Fasting (preprandial) glucose 6.1-6,9mmol/l and after 2 hrs OGTT >7,8 
but<l 1,1 mmol/1.
- 1 -5% per year developing DM 
50-80% revert to normal (IGT)
Weight loss may improve glucose tolerance 
Associated with progressive greater risk of developing macrovascu- 
lar complications.
d) Impaired Fasting Glycemia (IFG)
Fasting -  glucose>5.6 mmol/1 and after 2 hrs < 7,8mmol/l.
Hyperglycemia not sufficient to meet the diagnostic criteria for diabetes is 
categorized as either IFG or impaired glucose tolerance (IGT), depending on 
whether it is identified through a FPG or an OGTT:
- IFG = FPG 5.6 mmol/1 (100 mg/dl) to 6.9 mmol/1 (125 mg/dl)
- IGT = 2hrs plasma glucose 7.8 mmol/1 (140 mg/dl) to 11.0 mmol/1 (199 
mg/dl).
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Screen for pre-diabetes
• individuals ;45 years of age, with a BM11; 25 kg/m2(repeat testing 
should be carried out at 3-year intervals).
• individuals <45 years of age and are overweight if they have anoth­
er risk factor for diabetes (repeat testing should be carried out at 3-year inter­
vals):
• hypertensive>=140/90mm Hg
• HDL cholesterol >0,9mmol/L and/or Tg >=2,83 mmol/L
• history of IGT or 1FG on prior testing
• Screen for pre-diabetes and diabetes in high-risk, asymptomatic, un­
diagnosed adults and children within the health care setting.
To screen for diabetes/pre-diabetes, either an FPG test or 2-hOGTT (75-g 
glucose load) or both are appropriate. An OGTT may be considered in patients 
with 1FG to better define the risk of diabetes.
Treatment for pre-diabetes
• Individuals at high risk for developing diabetes need to participat­
ing in regular physical activity.
• Patients with IGT should be given counseling on weight loss as well 
as instruction for increasing physical activity. In addition, some physicians ad­
vocate the use Metformin (Glucophage), to prevent/delay the onset of overt 
DM.
• Patients with IFG should be given counseling on weight loss as well 
as instruction for increasing physical activity.
• Follow-up counseling appears important for success.
• Monitoring for the development of diabetes in those with pre­
diabetes should be performed every 1-2 years.
Diagnoses of Diabetes Mellitus (WHO, 1999)
Glucose connection
• Fasting -  whole blood > 6,1 mmol/l (120mg/dl), plasma >7,0 mmol/l 
(140mg/dl)
• 2hr’s. after consuming 75 gm glucose orally (OGTT) -  whole blood 
>11,1 mmol/l (180mg/dl), plasma>200(mg/dl)
For the occasional patient, measurement of islet cell, glutamic acid decar­
boxylase (GAD65), insulin antibodies, and ICA512 antibodies can help distin­
guish between DM type 1 and DM type 2 diabetes. At attempt should be made 
to characterize the diabetes as type 1 or type 2, based on the clinical features 
present and on whether or not ketonuria accompanies the glucosuria.
The fasting blood glucose test is the preferred way to diagnose DM.
- a plasma glucose levels < 6,1 mmol/L (1 lOmg/dL) , in FPG and a 2hrs 
post-load value < 7,8mmol/L (140 mg/dL).
-2 hrs.OGTT 75gr glucose < 7.8 mmol/l.
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If the overnight FPG >11,1 mmol/l (126 mg/dL) on two or more tests 
on different days the diagnosis of DM is made. If the FPG is 11.1 mmol/L or 
higher on more than one occasion, further evaluation of the patient with a glu­
cose challenge is unnecessary.
A random blood glucose test can also be used to diagnose DM.
Random blood samples (if taken shortly after eating or drinking) may be 
used to test for DM when symptoms are present: > 11,1 mmol/l (200 mg/dl) or 
higher indicates DM, but it most be reconfirmed on another day with a FPG or 
an oral glucose tolerance test.
Oral Glucose Tolerance Test (OGTT).
OGTT is a gold standart for making the diagnosis o f type 2 DM and
GDM.
For proper evaluation of the test, the individuals should be normally ac­
tive (not lying down) and free from acute illness. Medicaitions that may impair 
glucose tolerance include diuretics, contraceptive drugs, glucocorticoids, niacin, 
and penytoin. For 3 days before the test, the person should have eaten a diet high 
in carbohydrates (100 -200 grams per day). The morning of the test, the person 
should not smoke or drink coffee.
With an OGTT, the person fasts overnight (at least 8 but not more tan 16 
hrs).Then first, the FPG is tested. After this test, the person receives 75 grams of 
glucose (100 grams for pregnant women) dissolved in 300 mL of waterBlood 
samples are taken at specific intervals to measure the blood glucose. The classic 
OGTT measures blood glucose levels 5 times over a period of 3 hrs. Nowadays, 
physicians simply get a baseline blood sample followed by a sample 2 hrs after 
drinking the glucose solution.
Evaluating the results of the OGTT
Glucose tolerance tests may lead to one of the following diagnosis:
* Normal response:
- FPG <6.1 mmol/L (11 Omg/dL),
- 2hr’s PPG < 7,8mmol/L (140 mg/dL)
* Impaired fasting glucose:
- FPG <6.1 to7.0 mmol/l (from 1 lOmg/dL)
* Impaired glucose tolerance:
- 2hr’sPPG from 7,8 to<l l,lmmol/l (from 140 to <200mg/dL)
* Diabetes mellitus:
- FPG>=7,0mmol/L (126mg/dL) or
- 2hr’sPPG>= 1 l,lmmol/l (200mg/dL) after a 75 grams glucose load
* Gestational diabetes:
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- FPG lOOg OGTT > 5,3mmol/L(95mg/dL), and lhrs glucose level > 10,6 
mmol/Ц  180 mgdL), 2hrs >=8,9mmol/L (160mg/dL) or a 3 hrs > 140 mg/dL 
(7,8mmol/L).
Urinanalysis
- Glucosuria.
A specific and convenient method to detect glucosuria is the paper strip 
impregnated with glucose oxidase and chromogen system (Clinistix, Diastix), 
which is sensitive to as little as 0.1% glucose in urine. Diagnostic paper strip ap­
plied to the urinary stream, and differing color responses of the indicator strip 
reflect glucose concentration. Estimation of glucosuria is used to monitor treat­
ment in patient with DM, but is not recommended for routine diagnosis DM.
Differential diagnosis of glucosuria
1. When glucosuria is found, it shoud be determined whether it is sec­
ondary to hyperglycaemia or renal glucosuria. Glucosutia occurs when blood 
glucose level exceeds the renal glucose threshold of 10 mmol/1 (180 mg/dL).
2. Renal glucosuria
Non-diabetic melituria occurs in a number of conditions, the most impor­
tant being renal glucosuria and alimentary (lag storage) glucosuria.
Diagnosis of renal glucosuria is based on the Marble’s criteria.
Glucosuria is absence of hyperglycaemia.
Constant glucosuria with little fluctuation related to diet 
Normal oral glucose tolerance test.
Identification of urinary reducing substance as glucose.
Normal storage and utilization of carbohydrates.
3. Alimentary (lag storage) glucosuria
There is a transient abnormal rise in blood glucose level following a meal, 
and the concentration exceeds the normal renal threshold. During this time glu­
cose spills into the urine. This may occur in the following conditions:
Following gastric surgery with rapid gastric empting time.
Some normal people.
Hyperthyroidism 
Hepatic diseases
Ketonuria.
A specific method to detect of ketone bodies is the paper strip (Clinistix, 
Diastix) by nitroprusside tests. Ketostix can be directly applied to the urinary 
stream and estimate of ketonuria. Estimation of ketonuria is recommended for 
ketoasidosis presenting.
Glycated hemoglobin (also known as glycohemoglobin, glycosylated 
hemoglobin or HbAlc).
Measurements of HbAlc have commonly been used to monitor the gly- 
cemic control of persons already diagnosed with DM. Measurements of this he­
moglobin aid in the evaluation of the stable linkage of glucose to minor hemog­
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lobin components. It is prodused by nonenzymatic condensation of glucose mo­
lecules with free amino groups on the globin component of hemoglobin. The 
maior form of glycohemoglobin is termed hemoglobin Ale, which normally 
comprises 4-6% of the total hemoglobin.The remaining glycohemoglobin (2-4% 
of the total) consist of phosphorylated glucose or fructose and are termed he­
moglobin A la and hemoglobin Alb.Some laboratories measure the sum of these 
tree glycohemoglobin and report it as hemoglobin A l, but more laboratories are 
converting to the more intricate but highly specific HbAlc assay. There are now 
monoclonal innunoassays for measuring HbAlc.Machines based on this tech­
nology use capillary blood and give a result in about 10 minutes. Glycohemog- 
lobins circulate within red blood cells whose life span lasts up to 120 days, they 
generally reflect the state of glycemia over the preceding 8-12 weeks. Glycated 
hemoglobin reflects the state of glycemic control for the preceding 3-to-4 moths. 
Measurement should be made in patients with either type of DM at 3-to-4 month 
intervals.
ADA recommends an HbAlc <7%, other groups currently recommends 
an HbAlc < 6,5%.It shoul be mentioned here that there are a number of condi­
tions in which an HbAlc is value may not be accurate, eg, anemia and hemoglo- 
binpathies.
Studies have shown that there is about a 10% decrease in relative risk for 
microvascular disease for every 1% reduction in HbAlc.So, if a patient starts off 
with an HbAlc of 10.7 and drops to 8,2 , thought there not yet at goal, they have 
managed to decrease their risk of microvascular complications by about 
20%.The closer to normal the HbAlc, the lower the absolute risk for microvas­
cular complications.
HbAl (%) HbAlc (%) Mean blood glucose (mmol/L)
6,0 5,0 4,4
7,2 6,0 6,3
8,4 7,0 8,2
9,0 7,5 9,1
10,2 8,5 11,0
11,4 9,5 12,8
12,0 10,0 13,7
13,2 11,0 15,6
Serum fructosamine.
Serum fructosamine is formed by nonenzymatic glycosylation of serum 
proteins (predominantly albumin). Serum albumin has a much shorter half-life 
than hemoglobin. Serum fructosamine reflects the state of glycemic control for 
only the preceding 2 weeks. Normal valyes vary in relation to the serum albumin 
concentration and are 1.5 -2.4 mmol/L, when the serum albumin level is 5g/dL. 
Reduction in serum albumin will lower the srum fructosamine value, eg, hepatic 
disease or nephritic state.
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4. Other Specific types of Diabetes Mellitus.
A. Maturity-onset diabetes of the young (MODY).
Six types of MODY have been described.
- autosomal dominant inheritance
- onset of 25 years or younger
- nonobese
- non-insulin-dependent diabetes
- hyperglycemia is due to impaired glucose-induced secretion of insulin
- need low doses of oral hypoglycemic agents or diet only.
B. Diabetes due to mutant insulins.
- Very rare
- nonobese
- heterozygous and possessed one normal insulin gene
- family history
- middle age.
C. Diabetes due to mutant insulin receptor
- extreme insulin resistance
- associated with acantosis nigricans
- leprechaun- like phenotype.
D. Diabetes associated with a mutation of mitochondrial DNA
- mutation of mitochondrial DNA that impairs the transfer of leucine or 
lysine into mitochondrial proteins
- 2/3 of patients hearing loss
- 2/3 of patients have a smaller proportion
- 1/3 have a syndrome of myopathy, encephalopathy, lactic acidosis, 
stroke-like episodes
- mild form of diabetes
J. Insulin Resistance Syndrome &Syndrome X & Metabolic Syn­
drome
25% of the general nondiabetic population have insulin resistance of a 
magnitude similar to that seen in type 2 DM. These individuals are at much 
higher risk of developing type 2 DM.
- Visceral obesity
- increase triglycerides (TG)
- lover high-density lipoproteins (HDL)
- small, dense, low-density lipoproteins (LDP)
- higher BP
- hyperuricemia
- protrombotic state with increased levels of plasminogen activator inhibitor 
type 1 (PAI-1)
- risk cerebrovascular and cardiac mortality and morbidity
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- need of long-acting insulins ana sulfonylureas (promote sustained hyper- 
insilinism), insulin-sparing drugs (metformin or a thiazolidinedione]
- need not only correct hyperglycemia but also BP and dislipidemia (niacin)
Latent autoimmune diabetes of adulthood -  LADA
Certain unrecognized patients with a milder expression of type 1 diabetes 
initially retain enough В cell function to avoid ketosis but later in life develop 
increasing dependency of insulin therapy as their В cell mass diminishes, 
indicate 15% patients “of type 2DM” 
age 35 -45 years 
no obesity
insulin dependence manifested after 1 -6 years from onset DM 
first resistance to hypoglycemic drugs 
prone to ketoacidosis 
1CA, anti -GAD present 
low C-peptide
Idiopathic type 1 diabetes mellitus (type IB)
no evidence of pancreatic В cell autoimmunity to explain their 
hyperglycemia and ketoacidosis
5. Gestational Diabetes Mellitus (GDM).
DM can occur temporarily during pregnancy. Significant hormonal 
changes during pregnancy can lead to blood glucose elevation in genetically 
predisposed individuals. Women which have develop type 1 DM during preg­
nancy and women with undiagnosed asymptomatic type 2 DM that is discovered 
during pregnancy are classified with GDM. Women with DM before pregnancy 
are said to have “pregestational DM” and are not included in this group. Howev­
er, most women classified with GDM have normal glucose homeostasis during 
the first half of the pregnancy and develop a relative insulin deficiency during 
the last half of the pregnancy, leading to hyperglycemia. The hyperglycemia re­
solves in most women after delivery but places them at increaseid risk of devel­
oping type 2 DM later in life. 25 -50% of women with GDM will eventually de­
velop DM later in life.
Risk factors of GDM 
age>25 
glycosuria
strong family history of diabetes 
obesity
member of high-risk ethnic group 
previous GDM
previous macrosomic baby >4 kg
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Screening for GDM
• Screen for diabetes in pregnancy using risk factor analysis and, if 
appropriate, use of an OGTT.
• Women with GDM should be screened for diabetes 6-12 weeks 
postpartum and should be followed up with subsequent screening for the devel­
opment of diabetes or pre-diabetes.
• Any pregnant woman should be screened between 24 and 28 weeks
• 50g glucose challenge test, measuring glucose 1 hrs later
• If abnormal (7,8mmol/L;140mg/dL), then 75g OGTT should be
done
- if any two of the following tree values are met or exceeded, a diagnosis 
of GDM is established:
- FPG > 5,3mmol/L(95mg/dL), and Ihrs glucose level > 10,6 mmol/L(180 
mgdL), 2hrs>=8,9mmol/L(160mg/dL).
Testing should follow one of two approaches:
• One-step approach: perform a diagnostic 100-g OGTT
• Two-step approach: perform an initial screening by measuring the 
plasma or serum glucose concentration 1 h after a 50-g oral glucose load (glu­
cose challenge test) and perform a diagnostic 100-g OGTT on that subset of 
women exceeding the glucose threshold value on the glucose challenge test. 
When the two-step approach is used, a glucose threshold value >140 mg/dl iden­
tifies -80% of women with GDM, and the yield is further increased to 90% by 
using a cutoff of >130 mg/dl.
Diagnostic criteria for the 100-g GOTT are as follows: >95 mg/dl fasting, 
>180 mg/dl at 1 hrs >155 mg/dl at 2 hrs and >140 mg/dl at3 hrs. Two or more of 
the plasma glucose values must be met or exceeded for a positive diagnosis. The 
test should be done in the morning after an overnight fast of 8-14 h. The diagno­
sis can be made using a 75-g glucose load, but that test is not as well validated 
for detection of at-risk infants or mothers as the 100-g GOTT.
Chapter II. Long term complications of Diabetes Mellitus.
Over time, DM can lead to the blindness, kidney failure, and nerve dam­
age. Diabetes is also an important factor in accelerating atherosclerosis, leading 
to strokes, coronary heart disease and blood vessel diseases. Diabetes is the third 
cause of death after heart disease and cancer.
The majority of complications involve:
the microvascular system: diabetic microangiopathy (retinopa­
thy,nephropathy, neuropathy);
- the macrovascular system: diabetic macroangiopathy- accelerated athe­
rosclerosis leading to coronary artery disease, stroke, pulmonary vascular dis­
ease;
- the nervus system: diabetic neuropathy;
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- bone and joint disease: diabetic foot;
skin disease: necrobiosis lipoidica diabeticorum 
can involve many other organs 
Aggravating factors:
poor glycemic control;
inadequate control of hypertension and cholesterol;
smoking;
high fat diet.
1. Diabetic Retinopathy
Epidemiology
- present in 50% of patients after 10 years with DM,80% in 15 years, 25 
yers and more risk of blindness
- one of the leading causes of blindness in adults 20 -74 years
- increased risk cataracts and open angle glaucoma 
Risks
- poor glycemic control (persistent hyperglycemia)
- HLA-DR types
- hyperhomocysteinemia 
Classification of Diabetic Retinopathy
1. Non-proliferative (background) Diabetic Rethynopathy
- generally no symptoms
- microaneurysms only
- milder degrees of venous loops, retinal hemorrhages
- hard exudates, (small) dot and blot hemorrhages
2. Pre-proliferative Diabetic Rethynopathy
- macula edema, venous shunts and beading
- cotton wool (soft)exudates :gray or white areas with soft, feathery edges 
indicate ischemia within retinal nerve fibers
3 . Proliferative Diabetic Rethynopathy
great risk for loss of vision 
new vessels (neovascularizationO in the eye 
fibrous scarring, vitreous hemorrhages, retinal traction, tears 
Prevention of Diabetic Retinopathy 
tight glycemic control
activity limitation for proliferative diabetic rethynopathy;avoid all 
strenuous activities, valsalva, jarring, jogging, weight lifting, high impact aero­
bics, racquet sports
frequent follow-up visits an ophthalmologist :after 5 years of type 
1 DM and immediate referral after diagnosis of type 2 DM 
Managment of Diabetic Retinopathy
Lazer Photocoagulation (eliminates neovascularization)
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- vitrectomy
Other abnormalities of the organ of vision
Iritis and iridocyclitis 
Cataract
Diseases of the uveal tract 
Glaucoma
2.Diabetic Nephropathy
The term diabetic nephropathy is a concept embracing all clinical manife­
stations of renal pathology due to diabetes mellitus, including intercapillary, 
intracapillary and intraarterial affectiona of the kidneys in the form of microan­
giopathy. Diabetes has become the most common single cause of end-stage renal 
disease (ESRD) in the world. A nodular intercapillary glomerulosclerosis know 
as the Kimmelstill-Wilson syndrome named after two authors who in 1936 de­
scribed the pathological changes in the kidneys. The syndrome is characterized 
by retinopathy, arterial hypertension, proteinuria, hyperazotaemia and edema.
Eepidemiology
- may occur as early as 5 years after onset of DM
- 20-40% of patients with type 1DM and 4 -20% with type 2DM
Risks
- Genetics
- Hypertension
- Smoking
- Hyperlipidemia
- Poor glycemic control
Histology
Starts with nodular glomerulosclerosis, then diffuse, then exudative le­
sions of the glomeruli.
In the diffuse form which is more common, there is widening of the 
glomerular basement membrane together with generalized mesangial thickening.
In the nodular form, large accumulations of PAS-positive material 
are deposited at the periphery of glomerular tufts, the Kimmelsteil- Wilson le­
sion.
In addition, there may be hyalinization of afferent and efferent arte- 
riols, “dros” in Bowman’s capsule, fibrin caps, and occlusion of glomeruli. De­
position of albumin and other proteins occurs in both glomeruli and tubules.
Classification of Diabetic Nephropathy and Clinical picture
Stage 1 (Preclinical).
0 -5 years with DM
Renal hypertrophy (size > 14 cm)
Hyperfiltration . Clomerular filtration rate > 150ml/min
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With sustained microalbuminuria (microalbuminuria =30 -300mg 
protein/24 houres or 20 -200 ug/min timed collection, or 30 -300 ug/mg creati­
nine for spot collection).
BP normal 
Stage II
Renal hypertrophy
Clomerular filtration rate > 150- 200 ml/min 
Albumin excretion < 30mg/d 
BP normal
Stage III (Incipient Nephropathy).
5 -20 years after onset of DM
Loss of glomerular filtration rate 130- 150 ml/min
normal kidneys size (12 cm)
increased albumin 30 -300 mg/d, persistent proteinuria (macroal­
buminuria)
variable hypertension 
Stage IУ (Overt Nephropathy)
Decrease renal size <10cm. 
Clomerular filtration rate< 120 ml/min 
Albumin excretion >3,5 g/1 
BP very high 
Stages V(ESRD)
atrophic kidneys , 8 cm 
Clomerular filtration rate < 20 
Albumin excretion > 3,5 3,5g/l 
BP very high
Uremia if untreated, needs dialysis 
or transplant.
Fig.23 year-old patient with diabetes meilitus 
type i: anasarka,edema at the lower extremities 
(right),hepatomegaly splenomegaly, hypogo­
nadism (Diabetic nephropathy stages V, 
ESRD).
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Prevention of Diabetic Nephropathy
tight glucose control
Mamagment of Diabetic Nephropathy
Meticulous control of diabetes can reverse microproteinuria in some
patients
In addition, angiotensin converting enzyme inhibitors can retard 
the progression of nephropathy at this stage.
Aggressive control of hypertension is mandatory as high blood 
pressure can accelerate nephropathy.
The BP should be decreased to less than 130/80 mm HG, with an 
optimal target of below 120/80 mm Hg espessially in patients with proteinuria or 
renal insufficiency.
ACE inhibitors have proved beneficial in patients with diabetic ren­
al disease and are considered preferred therapy in patient with hypertention and 
diabetes. These agent can be used if creatinine less than 3 mg/dL.
Other agents which can be used include thiazide diuretics, calcium 
channel blokers, angiotensin II receptor blocers, beta-blockers and alfa-blockers.
Low-protein diets may be beneficial, as there is some evidence 
suggesting that high-protein diets can accelerate glomerulosclerosis (0,8 
g/kg/day in macroalbuminuria and 0,6g/kg/day in overt proteinuria).
Once the azotaemic phase is reached, the management is similar to 
other forms of chronic renal failure.
Other urinary abnormalities
Persistent infection of has urinary tract has a latent course
Fungal cystitis (also commonly see chronic/recurrent vaginitis
Pyelitis
Pyelonephritis for 10-30% of patients with DM
Perinephric abscess
3. Diabetic Neuropathy
Epidemiology
- common in both type 1 and type 2DM
- due to protein glycation and polyol pathway(metabolic defect thouth to 
be due to increased sorbitol and/or decreased myoinositol
Risks
- Hypertension
- Increase LDL, decrease HDL
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-Age
- Female
- Duration of DM
Classification of Diabetic neuropathy
1. Symmetric Distal Sensorimotor Polyneuropathy 
Can be divided into 2 types:
A. A relatively asymptomatic form which is diffuse, distal, usually oc­
curring in the lower extremities with a stocking type of distribution. There is 
numbness, tingling, or pins-and-needles sensation, often worse at night. This 
type is generally progressive and irreversible.
A painful form presenting with burning or dull aching sensation, or excru­
ciating, lancinating pain. The pain is often worse at night (“restnessless 
foot”syndrome )and partially relieved by movement. Hyperasthesia may be 
marked.
The characteristic early finding in both forms are:
- Loss of ankle reflexes and distal vibration
- “Glow and stocking” polynuropathy - pain, pins-and-needle, bumining or cold
- Hyperthesia, eathesia, anesthesia can quantitate the sensory loss with 
successively rigid fleiible monofilament
- Worse at night -“restnessless foot”syndrome
- Decrease strength of intrinsic foot muscles
- Hammer/claw toe, bunion deformities, prominent metatarsal heads
- Muscle athrophy
2. Autonomic Neuropathy
a. Autonomic cardiopathy
vagal denervation, lose the normal beat-beat variability in heart
rhythms:
-o rtostatic hypotension with nocturnal hypertension
- resting tachycardia
- fixed heart rhythms
- painless ischemia
- sudden death.
b. Diabetic gastroparesis:
- impaired motility or increased secretory
- esophageal dysfunction.
c. Bowel disorders
- decreased gastrocolic reflex -  constipation
- diarrhed at night -  increased gastrocolic reflex.
d. Cutaneus disorders
- increased /decreased sudomotor (sweating) causes dry scaly skin and 
Assuring alohg with contracture and hammer toe it lead to ulcers
e. Genitourinary
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- bladder-urgency 
-vesicopathy
- incontinence
- impotence
- retrograde ejaculation
f. Secretomotor
- gustatory sweating
- nocturnal sweats without hypoglycaemia
anhidrosis
g. Vasomotor
- dependent pedal oedema
h. Pupillary
- decreased pupil size
- resistance to mydriatics
3. Asymmetric neuropathy:
a. Cranial mononeuropathy and mononeuropathy multex
- Usually involve third, sixth, or fourth cranial nerve in order of frequency
- Third nerve involvement is characteristically pupil-sparing.
b. Peripheral mononeuropathy and mononeuropathy multiplex
Manifest as carpal tunnel syndrome, foot drop or wrist drop
c. Radiculopathy is a sensory syndrome in which dysaesthesias and pain­
ful hyperaesthesia in the anatomic distribution of one or more spinal nerves.
d. Diabetic amyotrophy:
- athrophy and weakness of the muscles of thigh (especially quadriceps) 
and pelvic girdle.
- may associated with anorexia and depression 
Treatment
1. Pain of diabetic neuropathy: non-steroidal anti-inflammatory drugs, 
codeine,phenytoin,carbamazepine,amitriptyline,imipramine or gabaptetine.
2. Mononeuropathies and radiculopathies are usually self-limiting and 
do not require any specific therapy.
3. Diabetic diarrhea: diphenoxylate, loperamide or tetracyclins.
4. Ortostatic hypotension: to sleeping with the head of the bed ele­
vated, avoidance of sudden assumption of the upright position, and full-length 
elastic stocking.
Prevention and management of Diabetic neuropathy
tight glucose control
anti-depressants and anti-epileptics for painful neuropathic syn­
dromes
erythromycin and domperidone for gactroparesis 
foot care education
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Chronic hyperglycaemia is associated with an increased risk of microvas- 
cular complications, as show in the Diabetes Control and Complication Trial 
(DCCT) oFDM type 1 and the United Kingdom Prospective Diabetes Study 
(UKPDS) of DM type 2. In the DCCT, intensive therapy to maintain normal 
blood glucose levels greatly reduced the development and progression of retino- 
pothy, microalbuminuria, proneinuria, and neuro pathy over 7 years. Intensive 
therapy was not associated with increased mortality or incidence of major ma- 
crovascular events and did not decrease the quality of life, though it did increase 
the likelihood of severe hypoglycemic episodes.
In the UKPDS, more than 5000 patient with DM type 2 were followed up 
for up to 15 years. Those in the intensely treated group had a significantly lower 
rate of progression of microvascular complication than that of those receiving 
standart care. Rates of macrovascular disease were not altered except in the met­
formin-monotherapy arm, in which the risk of 1M was significantly de- 
creased.Moreover, severe hypoglycaemia occurred less often than it did in pa­
tients with DM type 1 in the DCCT.
4. Other Complications.
Skin diseases Associated with DM.
No skin change is diagnostic of diabetes, but may changes are seen with 
diabetes.
1. Scleroderma.
2. Granuloma annulare -  asymptomatic plaque over extensor joints 
that slowly heal from the center out.
3. Acanthus nigricans; skin tags (common as insulin is a growth fac­
tor).
4. Eruptive xantomas.
5. Diabetic bullae (bullosa diabeticorum).
6. Diabetic dermopathy: generalized thick skin, may have dark macu- 
lelar skin spots. Not of clinical sighificance.
7. Oral leukoplakia/ lichen planus.
8. Intensive keratinization of the feet (alabaster’s coloring).
9. Thickining of nails.
10. Ulcer.
11. Stomatitis angularis.
12. Rubeosis diabetica (rosy 
cheeks).
13. Xanthomatosis (yello­
wish nodules on the palms, soles, but­
tocks, the back surfaces of elbow 
joints).
Fig. Stomatitis angularis.
Rosy cheeks.
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Necrobiosis lipoidica diabeticorum.
Occurs in 0,3% of diabetics.
Seen in young adults and middle aged in setting of DM type 1.
May have a history of preceding trauma.
Not always associated with diabetes. Consider a glucose tolerance 
test to pick up 20% non-overt diabetics.
Lesion due to alteration in collagen.
Signs
Distinctive,sharply circumscribed, multicolored (yellow, red,brown 
)papule that expandsto aplaque. Mostly occurs on the anterior and lateral surfac­
es of the lower legs (shins), may occur on the face, trank and arms. Lesion slow­
ly evolves over months, lasts years. Intralesional ulcers may occur, often pain­
ful.
Very resistant to treatment
Spontaneous remission in 15%
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Fig. 26-years-old patient with Diabetes mellitus type 1. 
Necrobiosis lipoidica diabeticorum.
Fig. Necrobiosis lipoidica on the skin of shins.
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Bone and Joint disease Associated with Diabetes. “Diabetic 
Foot”.
- The term refers to foot problems caused directly by diabetes, damage to 
the nerves and blood vessels occurs in the foot, reducing the ability to feel prop­
erly.
- The insensate, poorly perfused foot is a risk for ulcers from pressure ne­
crosis or inflomation from repeated skin stress and unnoticed minor trauma. 
These can evolve into cellulitis, osteomyelitis, or nonclostridial gangrene and 
end in amputation.
- Charcot foot affects the metatarsal, tarsometatarsal, and tarsal joints, 
which are located in the forefoot and midfoot
Risk Factors and Causes
- Chronic hyperglycemia
- diabetic peripheral neuropathy
Problems can begin from any small sore or injury to the foot, most espe­
cially:
- Blisters that becomes a large sore
- A simple cut that goes untreated
- Ingrown toenails
- Small wounds from rubbing shoes or socks
Symptoms and signs
- Lack of feeling in the foot
- Dull or sharp pain in the foot
- Swelling of the foot or leg
- Redness can be a sign of infection, especially when surrounding a 
wound, or a place where the foot has been rubbed by shoes or socks
- Loss of hair on the lower leg, often with the skin becoming hard and
shiny
- Warmth in specific parts of the foot can be a sign of infection
- Fever or chills associate with a foot wound that is not healing
- Thickining of foot dorsum or ankle joint
- Osteolysis, osteosclerosis
- Osteoporosis, periostosis
- Frutures, paraosseal calcification
- Foot bones are mostly affected: metatarsals and tarsal bones.
- Diabetes is the leading cause of nontraumatic lower-extremity amputa­
tion.
Symptoms of Charcot foot
Dislocation of the joint 
Heat
Insensitivity in the foot 
Instability of the joint
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Redness 
Strong pulse
Swelling of the foot and ankle (caused by synovial fluid that leaks 
out of the jont capsle)
Subluxation (misalignment of the bones that form a joint) 
Osteomyelitis and septic arthritis may develop 
Laboratory and Investigations
X-rays or MRI to detect joint effusions, large osteophytes, frac­
tures, joint misalignment and/or dislocation, osteoporosis 
Drawing fluid from the joint
Fig. X-ray : osteolysis, osteosclerosis of tarsal bones.
T reatment
Patients with wounds, infections, or ulcers of the foot should be 
treated intensively.
Antibiotics for Gramm -, + and anaerobes I/V.
Use crutches, wheelchairs; bed rest.
Local treatment + vascular evaluation in conjunction.
Surgery may be necessary to treat severe deformities or recurring 
ulcers by reshaping structures within the foot or removing bony protrusions that 
cause ulcers
Osteoctomy used to treat Charcot foot
Amputation if gangrene
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Fig. Charcot foot.
Fig. “Diabetic foot”. Ulcer. Fig. Glycemic Dry Gangrene.
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Fig. Glycemic Gangrene.
Cardiovascular complications of diabetes.
The main cardiovascular complications of diabetes are accelerated athe­
rosclerosis, and increased platelent adhesiveness, possibly due to enhanced 
thromboxane A2 synthesis, and decreased prostacyclin synthesis.
The atherosclerosis lesions can manifest in a variety of ways:
Intermittent claudication, gangrene and impotence.
Coronary artery disease leading to ischaemic heart disease, espe­
cially silent myocardial infarctions.
Dilated cardiomyopathy ( diadetic “cardiomiopathy”). 
Cerebrovascular accident
Chapter III. Treatment of Diabetes Mellitus.
1. Insulin
2. Oral hypolycemic agents
3. Lifestyle modification
4. Diet.
1. Treatment of Diabetes Mellitus Type 1.
The target in the management of diabetes mellitus is maximum compen­
sation of the disturbed metabolic processes.
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Criteria of compensation of diabetes mellitus
(Europen NiDDM POLICY Group, 1993)
- Fasting glucose. - 6,1 mmol/1 and after meal < 8,0 mmol/1
- Aglucozuria
- HbAlc < 6.5%
- Tg < 1.7 mmol/I, Holesterol < 5,2 mmol/1
- BMI < 24 (female), < 25 (male)
- BP < 140/90mm Hg
Insulin.
Insulin is required for treatment of all patients with DM type 1 and many 
patients with DM type 2. The goals of insulin therapy are:
1. Normal grougth and development in children.
2. Normal pregnancy, delivery, and conceptus in women.
3. Mininal interference with psychological adjustment.
4. Acceptable glycaemic control, with minimal hypoglycaemia.
5. Prevention of complication.
Insulin is commercially available in concentrations of 100 U/ml. There is 
an additional U500 preparation of regular insulin.
Different types and species of insulin have different pharmacological 
properties. Insulin type and species, injection technique, insulin antibodies, site 
of injection, and individual patient response differences can all affect the onset, 
degree, and duration of insulin activity. Insulin in use may be kept at room tem­
perature to limit local irritation at the injection site, which may occur when cold 
insulin is used. Abdominal injection above umbilicus has quickest absorption 
followed by arm, thigh and hip. Intramuscular injection has faster than subcuta­
neous. Smaller doses faster than larger. Insulins available in the world are re­
combinant human or human insulin analog origin. NPH = neutral protamin Ha- 
gedom.
Indication for the insulin therapy.
1. Typel DM.
2. Diabetic coma/precomatoes states, ketoacodosis.
3. Type 2 DM with complication nephropathy, hepatic insuffisiance
4. Type 2 DM: first/secondary resistance for the oral hypoglycemic 
agents.
5. Diabetes during pregnancy.
6. Post-renal transplantation diabetic patients
Temporary prescription for the insulin therapy
1. Concomitant diseases
2. Surgical intervention/injury
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Insulin Adm inistration
- Subcutaneous injections
- Continuous subcutaneous insulin pump - CCII
- intra venus injection (regular insulin only)
- doses adjusted for individual patients needs to meet glycemic control
Insulin Preparations
Insulin preparation can be classified:
Based on source as bovine, porcine, and human insulins.
Based on time course of action as rapid, intermediate, and long act­
ing insulins.
Based on strength as 40 U/mL, and 100 U/mL.
Newer insulin analogues.
Human Insulin
Human insulin differs from porcine insulin by one amino acid residue 
and from bovine insulin by tree amino acid residues. The changes in the amino 
acid residues of these three insulins are given in Table.
Amino 
acid position
A8 A10 B30
Human Threonine Isoleucine Threonine
Porcine Threonine Isoleucine Alanine
Bovine Alanine Valine Alanine
Two types of human insulins.
1. Semisythetic human insulin. This is an enzymatically modified 
pork insulin. The monocomponent porcine insulin is enzymatically dealaninated 
from the B30 position which is then replaced by threonine to make the structure 
identical to human insulin.
2. Recombinant DNA biosynthetics.
Characteristics of Insulins According Its Times Action.
1. Rapid-acting Insulins Analogs: (Humalog, Novolog, Apidra). Hu­
man analogs. Give before 20 minutes before the meal subcutaneously above 
umbilicus. Tree - four injections daily or more if it need. When intravenous in­
sulin is needed for hyperglycemic emergences, the rapid-acting insulin analogs 
have no advantage over regular human insulin, which is instantly converted to 
the monomeric form when given intravenously.
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Insulin Humalog (lispro) is an insulin analog produced by recombi­
nant technology utilizing a non-pathogenic strain of E.coli, wherein two amino 
acids near the carboxyl terminal of the В chain have been reversed in position: 
Proline at position B28 has been moved to B29 and lysine has been moved from 
B29 to B28.
Insulin Novolog (aspart) is a single substitution of praline by aspartic 
acid at position B28.
Insulin Apidra (glulisine) differs from human insulin in that the amino 
acid asparagines at position B3 is replased by lysine and the lysine in position 
B29 by glutamic acid. These changes result in these three analogs having less 
tendency to form hexamers, in contrast to human insulin. When injected subcu­
taneously, the analogs quicly dissociate into monomers and are absorbed very 
rapidly, reaching peak serum values in as soon as 1 hour - in contrast to regular 
numan insulin, whose hexamers require considerably more time to dissociate 
and become absorbed. The amino acid changes in these analogs do not interfere 
with their binding to the insulin receptor, with the circulating halfOlife, or with 
their immunogenicity, which are all identical with those of human regular insu­
lin.
The rapid-acting analogs used in insulin pups.
2. Short-acting Regular Insulins (R). Human. Slowly being replaced 
Humalog. Give before the meal subcutaneously above umbilicus, intramuscular 
or intravenous.
It is crystalline zinc insulin whose useful in treatment of diabetic ketoaci­
dosis and during the perioperative management of insulin-requiring diabetics or 
during acute infections.
For marked insulin-resistant persons who would otherwise require 
large volumes of insulin solution a U500 preparation of human regular insulin is 
available. Since a U500 preparation syringe is not available, a U100 insulin sy­
ringe or tuberculin syringe is used to measure doses. The phisian should careful­
ly note dosages in both units and volume to avoid overdosage.
3. Long-acting (Basal) Insulins: ( N/NPH,L /Lente, Humulin N). Hu­
man. Be given subcutaneous by arm, thigh and hip but not intravenous. Two in- 
jeactions daily.
It is intermediate-acting neutral protamine Hagedom (NPH) insulin -  
NPH (neutral protamine Hagedome or isophane) insulin whose onset of action is 
delayed by combining 2 parts soluble crystallane zinc insulin with 1 part prota­
mine zinc insulin. This produces equivalent amounts of insulin and protamine, 
so that neither is present in an uncomplexed form (“isiphane”).
Lente Insulin :a mixture of large and small crystals, has a large variation 
in absorbtion.
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1. Ultra Long-acting (Basal) Insulins: (U or Ultralente, Lantus, 
Levemir). Human. Be given subcutaneous by arm, thigh and hip but not intra­
venous.
Ultralente is groups of large crystals to give it a slow dissolution into the 
blood, however its rate of absorption is very variable depending on the tempera­
ture, blood supply and hormone levels, thus avoid in women.
Lantus (insulin glargine) -  is an insulin analog in which the asparagines 
at position 21 of the A chain of the human insulin molecule is replaced by gly­
cine and two arginines are added to the carboxyl terminal of the В chain. The 
arginines raise the isoelectric point of the molecule closer to neutral, maiking it 
more soluble in an acidic environment. Given as a single injection at bedtime to 
type 1 DM. Cannot be mixed with the other human insulins because o f its acidic 
pH. Not recommended in pregnancy.
Levemir (insulin detemir) -  is an insulin analog in which the tyrosine at 
the position 30 of the В chain has been removed and a 14-C fatty acid chain (te- 
tradecanoic acid) is attached to the lysine at position 29 by acylation. The fatty 
acid chain makes the molecule more lipophilic than native insulin and the addi­
tion of zinc stabilizes the molecule and leads to formation of hexamers. After 
inlection, self-association at the injection site and albumon binding in the circu­
lation via the fatty acid side chain, leads to slower distribution to peripherial tar­
get tissues and prolonged duration of action. Given once or twice daily .There is 
a vast excess of albumin binding sites available in plasma per insulin detemir 
molecule, it is unlikely that hypoalbuminemic states will affect the ratio of 
bound to free insulin detemir.
The longer-acting insulin analogs cannot be mixed with either regular 
insulin or the rapid-acting insulin analogs.
5. Premixed (NPH/Regular) Insulins: Humalog 75/25 -  Human /U100, 
onset 10-30 min, peak 1-3 hours, duration of action 18 -22 hours. Humulin 
50/50: human, onset 30 -60 min, peak 2-4 hours, duration of the action 16 -22 
hours.
Stable premixed insulins are available as a convenience to patients who 
have difficulty mixing insulin because of visual problems or impairment of ma­
nual dexterity. Premixed insulins not recommended for Type 1 DM as does not 
allow enough flexibility. Premixed preparations of insulin lispro and NPH insu­
lins are unstable because of exchange of insulin lispro with the human insulin in 
the protamine complex. Consequently, the soluble component becomes over 
time a mixture of regular and insulin lispro at varying ratios. In an attempt to 
remedy this, an intermediate insulin composed of isiphane complexes of prota­
mine with insulin lispro was developed called NPL (neutral protamine lispro). 
This insulin has the same duration of action as NPH insulin.
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Table. K inetics o f the Insulins
Insulin Duration Onset
(hours)
Peak
(hours)
Usual Effec­
tive Duration 
of Action
Humalog Very short 5-10 min 30 -40 min 2-3
Novolog 10 -30 min 40 -50 min 3 - 5
Apidra 5- 15 min 1 -  1,5 3-4
Human Regu- short Vi-1 2 6-8
lar
Human long 2-4 6-7 14-20
NPH/Lente
Ultralente/ ultralong 4-5 18-28
Lantus 1,5 Flat ~24
Levemir 1 Flat 17
C om m ercial insulin preparations
1. Rapid-acting human insulin analogs 
Insulin lispro (Humalog, Lilly)
Insulin aspart (Novolog, Novo Nordisk)
Insulin glulisine (Apidra, Sanofi Aventis)
2. Short -acting regular insulin 
Regular insulin (Lilly, Novo Nordisk)
3. Intermediate- acting insulins 
NPH insulin (Lilly, Novo Nordisk)
4. Premixed insulins
70% NPH/30% regular (70/30 insulin -  Lilly, Novo Nordisk)
50% NPH/50% regular (50/50 insulin -  Lilly)
70%NPL/30% insulin lispro (Humalog Mix 75/25 -  Lilly)
50% NPL/50% insulin lispro (Humalog Mix 50/50 -  Lilly)
70% insulin aspart protamine /30% insulin aspart (Novolog Mix 
70/30 -  Novo Nordisk)
5. Long- acting human insulin analogs 
Insulin glargine (Lantus, Sanofi Aventis)
Insulin detemir (Levemir, Novo Nordisk).
Insulin Theraphy
Starting dose an adult DM1 patients on insulin = 0, 5 -0, 6 U/kg/daily 
(weight x 0,5U). A single dose of insulin usually does not exceed 30-40 U. It 
should be kept in mind that the physiological demands in insulin are 40 -  
60U/24 h.
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Different insulin regimen
1. Regular short acting insulin . Adjusting dose based on premeal hyper­
glycemia, anticipated meal size and physical activity. 1U used for every 15g of 
carbohydrates in the meal. If carbohydrates count not possible, estimate by using 
~ prebreakfast /prelunch/ presupper ratio 3 :2:1 and then modified by postmeal 
blood glucose and added to the sliding scale.
2. Multiple Daily Injection Program (Basal- bolus therapy) -  multiple in­
jections of insulin in conjunction with self-blood glucose monitoring. If near­
normalization of blood glucose is attempted, at least three or four measurements 
of capillary blood glucose and tree or four insulin injections are necessary.
- NPH as basal insulin :- best to initiate at 0,3 U/kg/d total insulin dose 
starting at a twice daily NPH-regular dose: 2/3 given 20 -30 min prebreakfast 
and remaining 1 : 3 presupper:- NPH/Regular ratio is 2 :1 prebreakfast and 1:1 
presupper
- Insulin glargin as a basal insulin: 1 injection bedtime to provide 24-hour 
coverage usually, but sometimes it needs to be given twice a day/and rapid- 
acting insulin analogs premeal
3. “Sliding Scale Insulin” -  Variable Insulin Dose Schedule
- patient takes fixed doses of intermediate-acting insulin but varies doses 
of rapid-acting insulin based on blood glucose reading at time of dose
- use baseline R dose when in blood glucose target range: add or subtract 
units when above or below target
- allows patient to make corrections to avoid long periods of hyper- or hy­
poglycemia
4. Insulin pump therapy by portable battery-operated pump
- dosage based on providing 50% of the estimated insulin dose as basal 
and intermittent boluses prior to meal
- the meal bolus would depend on the carbonhydrate content of the meal 
and the premeal blood glucose value
- 1U per 15g of carbohydrate +1U for 50mg/dL of blood glucose above a 
target value
- farther adjustments to basal and bolus dosages would depend on the re­
sults of blood glucose monitoring
A combination of rapid-acting insulin analogs and long-acting insulin 
analogs allows for more physiologic insulin replacement.
5. Travel and Insulin Regimen. If large change in time zones (8 -10 hours) 
and staying only 1-3 days keep on regimen at home as not enough time for body 
to even adjust. Day is lengthened-, day of departure take normal AM dose, wait 
10-12 hours to take normal PM dose with a snack/meal. After 6 hours check 
blood glucose, if <11 mmol/L wait until next AM to give next dose. IF >11 
mmol/L take 1/3 of normal AM dose now. On first day at destination reset 
watch to local time and take normal doses. Day is shortened: day of departure
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take normal AM, then PM doses. On first day of destination take 2/3 of normal 
AM dose, after 10 hours, re-check blood glucose before supper. If < 11 mmol/L 
take normal PM dose. If > 200mmol/L take remaining 1/3 of morning dose 
along with PM dose. On second day at destination take normal AM dose and re­
set watch to local time, take normal evening dose before supper.
Complications of Insulin Therapy
Hypoglycaemia
Local allergic reactions at the injection site including local incting, 
erythematous and indurated lesions, and discrete subcutaneous nodules.
Fat atrophy or fat hypertrophy may develop at the injeation sires. 
Fat atrophy is usually due to impurities in the insulin preparation. Fat hypertro­
phy is attributed to the local lipogenic effects of the injected insulin.
Therapeutic problems and its therapy
Somogyi syndrome.
Patients with DM Type 1 is determining the proper adjustment of insu­
lin dose when the prebreakfast blood glucose level is high. 3 AM hypoglycemia 
leads to a surge of counterinsulary hormones to produce high blood glucose lev­
el by 7 AM.
3AM hypoglycemia leads to rebound hyperglycemia in 7AM, from 
excessive PM NPH
Avoid by periodically check 3AM blood glucose: if increased bed­
time +increased dinner regular or decreased evening snack;if bedtime blood glu­
cose normal, but increased 3AM, then increased bedtime NPH by 2U;if de­
creased 3 AM, then decreased bedtime NPH by 2U
Be treated by eliminating the dose of intermediate insulin at dinner­
time and giving it at a lower dosage at bedtime or by supplying more food at 
bedtime
“Dawn phenomenon”
Present in a patients with type 1 diabetes
Reduced tissue sensitivity to insulin between 5 AM and 8AM can 
aggravate the hyperglycemia (in absence of Somogyi)
Diagnosis of the cause of prebreakfast hyperglycemia can be facili­
tated by self-monitoring of blood glucose at 3 AM in addition to the usual bed­
time and 7AM measurements
The dosage of intermediate insulin can be divided between dinner­
time and bedtime, must increased PM NPH
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M ethods o f insulin administration
1. Insulin syringes.
Plastic disposable syringes are available in 1-ml, 0.5-ml,and 0,3-ml 
sizes. Two lengths of needles are available short (8mm) and long (12,7mm). 
Long needles are preferable in obese patients to reduce variability of insulin ab­
sorption. Ultrafine needles as small as 31 gauge reduce the pain of injections. 
“Disposable” syringes may be reused until blunting of the needle occurs (3- 5 
injections).Sterility adequate to avoid infection with reuse appears to maintained 
by recapping syringes between uses. Cleansing the needle with alcohol may not 
be desirable since it can dissolve the silicone coating and can increase the pain 
of skin puncturing.
2. Insulin pen injector devices (Novo Nordisk, Sanofi Aventis, Becton 
Dicknson).
- eliminate the need for carring an insulin bottle and syringes during the 
day
- gently mix the suspension before each use
- easy-to-use, convenient and accurate
- helps improve compliance, less dosage errors in arthritis, vision or poor 
motor coordination, or children
Cartridges of regular insulin, NPH insulin, insulin aspart, insulin glar- 
gin and 70% NPH30% regular insulin are available for reusable pens. Thirty-one 
gauge needles (5,6 and 8mm long) for these pens make injections painless.
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3. Insulin pumps (Medronic Mini-Med, Animas, Deltec Cozmo, Dise- 
tronic H-Tron -  vlOO insulin) -  continuous subcutaneous insulin infusion - 
CSII therapy
- prime candidate for the insulin pump : pregnant diabetic .patient with 
irregular work schedules
- external, battery-operated pump continuously delivers basal dose of rap- 
id-acting insulin through small subcutaneous catheter
- basal insulin infusion should maintain constant blood glucose between
meals.
- at meals, patient programs pump to deliver extra insulin bolus
- basal dose may be increased or decreased based on activity, sleep etc.
- can be disconnected, allowing the patient to remove the pump tempora­
rily
- advantages: more flexible lifestyle
- disadvantages: very expensive, increased risk of ketoacidosis if pump 
disconnected
2. Inhaled insulin (Exubera).
A novel method for delivering preprandial powdered form of insulin by 
inhalation. Inhaled insulin is administrated 10 minutes prior to meal using a 
combination of 1 and 3 mg unit doses; 1 mg of inhaled insulin is equivalent to 3 
unit subcutaneous insulin injection.This insulin preparation is contraindicated in 
patients who smoke and who have discontinued smoking for less than 6 months. 
Pulmonary function tests has recommended every year.
5b
Site of injection
the abdomen with the exception of a circle with a 2-inch radius 
around the navel and rotate sites within that region; recommended for subcuta­
neous injections of short-acting insulins
thighs: anterior and lateral aspects - subcutaneous
upper arms - subcutaneous
flanks and upper buttocks -subcutaneous
intramuscular injection recommended for DKA or dehydration but 
not for routine injections (faster onset)
only regular insulin intravenously
rotation sites of injection -  avoid lipoatrophy or lipohypertrophy
Technique Portable Insulin Pen Devises. The needle is inserted subcu­
taneous and the plunger is depressed via a button to deliver dose. Slightly longer 
injection time compared to traditional syringe as need to keep needle in place 5 
sec after plunger is completely depressed, 
have a disposable needle
cartridges can be kept at room temperature for up to 30 days 
Two types (Min/max/increments):
1. Prefilled (disposable): Humalog, Humulin (each pen contains 300U 
of R, NPH, 70/30) 3ml -  (1/60/1). Novolin Prefilled (R, NPH,70/30) 1,5 ml -  
(2/58/2).
2. Reusable (replaceable cartridge): potential for loss of sterility. Can de­
liver as little as 0,5U with short 30g needles. B-D Pen Classic, 1.5 ml -  
(1/30/1). Autopen AN3000 - (1/16/1)&AN3100 - (2/32/2). NovaPen 1.5 ml -  
(1/40/1). Disetronic Pen 3,15 m l-(1/80/1)
Technique Insulin Infusion Pumps. Insert subcutaneous Teflon cannula 
or 26-27-g stainless steel needle into abdomen or buttocks, change every 3-5 
days. For regular of Lispro insulin 'A is used as basal infusion over 24 hours, the 
rest is bolus insulin for meals, snacks using 1U/10-15 g of carbohydrates.
Inhaled Insulin
can take right before 1st bite of meal 
faster onset than subcutaneous 
Not yet approved
Blood Glucose M onitoring (Self-M anagement train­
ing)
Self-monitoring and recording of blood glucose is now standard
management
Blood glucose monitoring is useful for monitoring patient’s long­
term diabetes control
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Goals :НЬА1С should be no higher than 1% above the upper limit 
of the normal range for any particular laboratory
Initially monitor blood glucose 4 times a day, before each meal. 
Follow closely when make changes
Once on stable dose can monitor twice a day 4 days/week (8 finger 
sticks). Follow closely when make changes
When blood glucose stable check every day in rotating fashion: 
AM, next day lunch, then dinner, then every night before bedtime 
Once under control, patient can check 1 - 2 times/week 
some patients may learn to self titrate their doses; Is affected so 
markedly by daily fluctuations in environmental stress, exercise, diet, infections
The Average Home Blood Glucose meter (Glucometer)
One Touch Fast Take: uses blood from arm, less painful, uses 40% less 
blood (1,5 uL of blood or 2,5 uL) and automatically drags blood drop to test 
strip on contact. Results in 15 sec, store 150, gives the 14 day average.
GlucoWatch Biographer: automatic, up to 3 reading/hour for 12 hours, 
alarm sounds if out of set ranges.Uses ionophoresis that has the enzyme glucose 
oxidase as a biosensor, then measures electrons from oxidation. Improved quali­
ty of life as less finger-sticks.
Mini-Med makes a continuous glucose monitoring system as well. La- 
sette: uses laser to puncture for testing, less painful.
Glucometer Dex: stripless, uses disposable cartridge good for 10 tests.
AtLast System; creates a small break in the arm or thigh using a custom- 
made lancet.
Microlet Vaculance: helps draw-up blood after skin in lanced in thigh, 
abdomen or palm so long as meter does not reguire a “hanging drop”
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D iabetic Diet
Today there is no “diabetic” diet. The medical nutritional therapy for 
people with diabetes should be individualized, with consideration given to usual 
eating habits and other lifestyle factors.
Balanced diet
protein -15% of dai ly calories
fat -20% calories (saturated < 10%, polyunsaturated < 10%) of dai­
ly calories
carbohydrates -65 % of daily calories
preferred distribution of calories 2/10 breakfast, 3/10 lunch, 4/10 
supper, 1/10 bedtime snack
50g of dietary fiber each day
Eat lots of whole grains, vegetables, beans and fruits as 40-50% of 
daily calories
Carbohydrate counting - 15 :1 rule. Ш of rapid-acting insulin
needed for each 15 grams of carbohydrate taken in. Every 15g carbohydrate 
consumed with meal requires Ш of rapid-acting insulin administered just before 
eating the meal is particaulary important in insulin-requiring diabetics
Glycemic index; a ranking of carbohydrates according to their ef­
fect on blood-sugar levels.
Sugar substitutes (nonnutritive sweeter)
Table. 15 grams of Carbohydrates
Bread/Starch
Group
Fruit Group Milk Group Candy/junk Food
1 slice of 
bread, 1/3 cup of 
cooked rice, 3/4 
cup of unswee­
tened cereal, 1/2 
cup of sweetened 
cereal, 1/2 cup of 
com or peas or 'A 
a cup of pasta
Small appie/other 
piece of fruit,
1/2 cup of fruit 
juice,
2 tablespoon of 
raisins,
1-1/4 cup of 
strawberries
1 cup of any milk, 
% cup of regular 
fruit yogurt,
1 cup of aspar­
tame sweetened 
yogurt
Nart candy (six 
lifesavers),l/2 cup 
of ice 
cream/frozen yo­
gurt, V* cup of 
sherbet, 1 table- 
soop honey or 
jam, 2 sugar pack­
ets or 1 tablespoon 
of sugar, 9 jelly 
beans3 graham 
crackers or two 
small cookies
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Table. Glycemic Index
Glycemic Load + gram carbohydrates in serving x Glycemic Index
Baguette = 136 Pasta = 71
Baked potato = 121 Chocolate = 70
While bread = 100 All-Bran/Dry beans = 60
Grape-nuts = 96 Apple = 54
White rice 81 Carrots 49
Wild rice = 81 Lends = 40
Wild rice = 78 Peanuts = 21
Refined carbohydrates such as sugar, bread, spaghetti, macaroni, bagels, 
crackers, cookies and rice. Refined carbohydrates have glycemic indices close to 
those of refined sugars. Whole grains are absorbed at a significantly slower rate, 
therefore do not drive up HbAlC as high.
Dietary Management of Diabetes Mellitus: Stepped care.
This involves the estimation of the total daily caloric requirement of the 
individual patient. This must be estimated after considering a number of varia­
ble factors like as age, sex, actual weight, desirable weight, activity, and occupa­
tion of the patient.
First step.
Total daily caloric requirement can be calculated as:
Sedentary individuals 30 Kcal/kg/day.
Moderately active individual 35 Kcal/kg/day.
Heavity active individuals 40 Kcal/kg/day.
Second step.
This involves allocation of the calories in a proper proportion to carbohy­
drate, protein and fat. The recommended proportion of calories to be derived 
from each of them:
Carbohydrate 50-60%
Protein 10-20%
Saturated fat < 10% (<7% if LDL is elevated)
Polyunsaturated fat <10%
Monounsaturated fat 10-15%.
A few more important factors need be considered at this stage. They are: 
Minimal protein requirement for a good nutritious diet is about 0,9
g/kg/day.
Carbohydrates should be taken in the form of starches and other 
complex sugars. Rapidly absorbed simple sugars like glucose should generally
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be avoided. Use of caloric sweeteners including sucrose is acceptable in many 
patients.
Fish oils cantaining omega 3 fatty acids have been reported to be 
beneficial, as antiatherogenic.
High-fiber diet is beneficial as it has an antiatherogenic effect me­
diated through lowering of blood lipids.
Third step.
This involves distribution of the calories throughout the day. This is parti­
caulary important in insulin-requiring diabetics, to avoid hypoglycaemia. Differ­
ent distributions may be required for different lifestyles.
A typical pattern of distribution of calories is:
20% of the total calories for breakfast.
35% of the total calories for lunch.
30% of the total calories for dinner.
15% of the total calories for late-evening feed.
2. Treatment of Diabetes Mellitus Type 2.
Lifestyle modification
In well-controlled studies that included a lifestyle intervention arm, sub­
stantial efforts were necessary to achieve only modest changes in weight and ex­
ercise, but those changes were sufficient to achieve an important reduction in the 
incidence of diabetes. In the Finnish Diabetes Prevention Study, weight loss av­
eraged 9.2 lb at 1 year, 7.7 lb after 2 years, and 4.6 lb after 5 years; "moderate 
exercise," such as brisk walking, for 30 min/day was suggested. In the Finnish 
study, there was a direct relationship between adherence with the lifestyle inter­
vention and the reduced incidence of diabetes. In the DPP , the lifestyle group 
lost -12 lb at 2 years and 9 lb at 3 years (mean weight loss for the study duration 
was -12 lb or 6% of initial body weight). In both of these studies, most of the 
participants were obese (BMI >30 kg/m2). A low-fat (<25% fat) intake was rec­
ommended; if reducing fat did not produce weight loss to goal, calorie restriction 
was also recommended. Participants weighing 120-174 lb (54-78 kg) at baseline 
were instructed to follow a 1,200-kcal/daydiet (33 g fat), those 175-219 lb (79- 
99 kg) were instructed to follow a 1,500-kcal/day diet (42 g fat), those 220-249 
lb (100-113 kg) were instructed to follow an 1,800-kcal/day diet (50 g fat), and 
those >250 lb (114 kg) were instructed to follow a 2,000-kcal/day diet (55 g fat).
Oral drugs fur treating hyperglycemia
Medications for type 2 diabetes are designed to:
1. Drugs that stimulate insulin secretion(insulin secretagogue). : sulfony- 
lureas and meglitinide.
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2. Drugs that alter insulin action ( insulin sintetaizer): Metformin and 
Thiazolidinediones.
3. Drugs that principally affect absorption of glucose (digestion modifi­
ers): acarbose and miglitol.
4. Combination edications: Glucovance.
Design of Oral Glycemics 
Medications
1. Drugs that stimulate insulin secretion (insulin secretagogue). Pre­
meal Medication.
Second generation of sulfonylureas: glyburide and glipizide.
Third generation of sulfonylureas: glimeperide.
Table. Sulfonylureas (second and third generation sulfonylureas). Long 
acting drugs. ___________ ___________ _____________ ____________
Pharmacological
Name
Commercial
Name
Tablet Size Daily Dose Duration of 
Action
Glyburide DiaBeta,
Micronase
1,25; 2,5, 
and 5 mg
1,25 -  20 mg 
as single dose 
or in 2 divided 
doses
Up to24 hours
Glipizide Glucotrol 5 and 10 mg 2,5 -  40 mg as 
a single dose 
or in 2 divided 
doses on an 
empty stomach
6 -1 2  hours
Glucotrol
XL
5 and 10 
mg
Up to 20 or 30 
mg daily as a 
single dose
Up to24 hours
Glimepiride Amaryl 1,2 and 4 
JDS________
1 - 4  mg Up to 24 
hours
56
Action
Sulfonylureas primarily lower blood glucose levels by increasing the re­
lease of insulin from the pancreas. Specific receptors on the surface of pancrea­
tic В-cells bind sulfonylureas in the rank order of their insulintropic potency. 
Activation of this receptors closes potassium channels, blocks К channels, re­
sulting it depolarization of the В-cell and increase exocytosis of stored insulin.
• Use in patients with residual В-cell function
• Well absorbed
• Work well in combination with Acarbose, Metformin, Troglitazone
Side-effects:
• Hypoglycemia
• Weight gain
• Exfoliative dermatitis
• hepatitis
Table. Meglitinides - short acting drugs. Pre-meal- medication .
Pharmacological
Name
Commercial
Name
Tablet Size Daily Dose Duration 
of Action
Repaglinide Prandin 0,5, 1, and 2 
mg
4 mg in two 
divided doses 
given 15 mi­
nutes before 
breakfast and 
dinner
3 hours
Nateglinide Starlix 60 mg and 
120 mg
60 or 120 mg 3 
times a day be­
fore meals
1,5 hours
Primary effect is hepatic glucose output, “Insulin Pill”, no renal adjust­
ment needed. A meglitinide derived from benzoic acid, its acts similar to an ex­
tremely short-acting sulfonurea but less insulin increase thus less weight gain 
and fewer hypoglycemic episodes.
Action
new class of drugs unlike sulfonureas that bind to receptors on the 
insulin producing cells,
meglitinides work through a separate potassium based channel on 
the cell surface allowing for Ca infux
given before a meal it reduces the postprandial hyperglycemia 
may cause hypoglycemia but less frequent than the hypoglycemia 
seen with sulfonylurea agents
works well with Metformin
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very good for young,healthy active patients who eat at unpredicta­
ble times
safe in sulfaureas allergy
titrate cautiously if elderly with renal or hepatic dysfunction
2. Drags that alter insulin action. Insulin sensitizer.
These increase sensitivity of insulin by decreasing hepatic gluconeogene- 
sis (primary effects) and increasing peripheral insulin sensitivity (secondary ef­
fects). They do not increase insulin levels or weight gain. Alone, they do not 
cause hypoglycemia.
Table. Biguanides. Pre-meal -medications.
Pharmacological
Name
Commercial
Name
Tablet Size Daily
Dose
Duration of 
Action
Metformin Glucophage 500,850
and
lOOOmg
-2,5 g; one 
ablet with 
neals 2 or 3 
imes daily
7 - 1 2
hours
Extended-release
metformin
Glucophage
XR
500 mg 500 -  2000 
ng once a 
lay
Up to24 
hours
Action
• Increase glucose utilization in muscle, intestine, fat
• Decrease hepatic glucose output by 30%
• Won’t cause hypoglycemia’s requires insulin to work and does not 
stimulate its release
• Decreases Tg by 50%,total and LDL with slight increase HDL.
Titration of Metformin (ADA, 2009).
• Begin with low-dose Metformin (500mg) taken one or twice per 
day with meals (breakfast and/or dinner) or 850 mg once per day.
• After 5-7 days, if gastrointestinal side effects have not occurred, 
advance dose to 850, or 500 mg tablets, twice per day (before breakfast and/or 
dinner).
• If gastrointestinal side apper as doses advanced, decrease to previos 
lower dose and try to advance the dose at a later time.
• The maximum effective dose can be up to 1,000 mg per day but is 
often 850 mg twice per day. Modestly greater effectiveness has been observed 
with doses up to about 2,500 mg/day. Gastrointestinal side effects may limit the 
dose that can be used.
• Based on cost considerations, genetic metformin is the first choice 
of therapy. A longer-acting formulation is available in some countries and can 
be given once per day.
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Side-effects
• Diarrhea
• Metallic taste, nausea,anorexia
• Decrease В-12 and folate absorbtion
• Mild inhibition of lactate metabolism
Table. Thiazolidinediones ( TZDs or “Glitazones”) .
Pharmacological/
Commercial
Name
Tablet Size Daily Dose Duration of Ac­
tion
Rosiglitazone 2,4 , and 8 mg 4 8 mg daily ( can
(Avandia) be divided) Up to 24 hours
Pioglitazone (Ac- 
tos)
15,30, and 45 mg 15 -45 mg daily Up to 24 hours
Action
• Decreases resistance to insulin by at cell membrance (PPAR- 
gamma receptor) by altering nuclear transcription in muscle (90%0 (“muscle 
drug”) and liver (10%). The major metabolic defect ( insulin resistance) in DM2 
is in the muscle.
• No increase hypoglycemia as requires insulin to be presenr.
• Increase fertility (ovulation if anovulatory),.
• Additition contraception in anovulatory premenopausal women
• Good for obesity and insulin resistant in combination with insulin 
or sulfonureas
• Insulin sparing like Metformin.
Side-effects:
• Increased cholecterol.
• Weight gane
• Anemia
• Edema (fluid retention)
•
3. Drugs that principally affect absorption of glucose (digestion mod­
ifiers).
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Table. Alfa-glucosidase inhibitors. Pre-meal medications.
Pharmacological/ 
Commercial Name
Tablet Size Daily Dose Duration of Ac­
tion
Acarbose (Precose)
50 and 100 mg 75 -  300 mg in 3 4 hours
Miglitol (Glyset)
25, 50, and 100 mg
divided doses with 
first bite of food
75- 300 mg in 3 di- 4 hours
vided doses with 
first bite of food
Action
• In small bowel to delay the breakdown of ingested carbohydrates
• Decrease postprandial glucose 50% and fasting 15%
• No hypoglycemia
• Good for children
• Not absorbed
• No systemic side-effects
• Synergistic with sulfonureas
• Good if mild liver or renal impairment 
Side-effects
• Abdominal pain
• Diarrhea
• Terminal flatulence from colonic breakdowns of carbohydrates.
4. Combination medications.
Glucovance = Metformone+Glyburide (l,25/250;2,5/500;5/500 mg). 
Avandamet= Rosiglitazone+metformin (l/500;2/500;4/500mg).
• Can be used for initial therapy.
Design. Oral Glycemics according meal
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Design. Oral Glycemics according mechanism action
Table. Oral antidiabetic drugs that stimulate insulin secretion.
Drug Tablet size Daily dose Duration of ac­
tion
SYLFONYLUREAS 1,25-20 mg as Up to 24 hours
Glyburide (Micro- 1,25 mg; 2,5 mg; single dose or in
nase,Diabeta) 5mg 2 divided doses
Gllipizide (Glucotrol)
5 and 10 mg
2,5 -40 mg as 
single dose or in 
2 divided doses
6 -1 2  hours
on empty sto­
mach
Glucotrol XL
5 and 10 mg Up to 20 or 30 
mg daily as a
Up to 24 hours
Glimeperide (Amaril)
1,2 and 4 mg
single dose 
1 -  4 mg as sin­
gle dose
Up to 24 hours
MEGLINIDE 4 mg in two di- 3 hours
ANALOGS vided doses giv-
Repaglinide (Pran- 0,5mg,lmg, and er 15 minutes
din) 2 mg before breakfast 
and dinner
d-
PHENYLALANINE
DERIVATIVE
Nateglinide (Starlix) 60 mg and 120 60 or 120 mg 3 1,5 hours
mg times a day be­
fore meals
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Table. Oral antidiabetic drugs that are insulin-sparing.
BIGUANIDES
Metformin (Glucophage) 500, 850, and 1 -  2,5 g; one 7 -1 2  hours
1000 mg tablet with 
meals 2 or 3
Extended-release Metformin 
(Glucophage XR) 500 mg
times daily
Up to 24 hours
500 -  2000 mg 
once a day
THYAZOLIDINEDIONES
Rosiglitazone (Avandia) 2, 4 , and 8 4 8 mg daily (
mg can be divided) Up to 24 hours
Pioglitazone (Actos)
15, 30, and 45 
mg
15 -45 mg dai­
ly
Up to 24 hours
ALFA-GLUCOSIDASE
INHIBITORS
Acarbose (Precose) 50 and 100 75 -  300 mg in 4 hours
mg 3 divided doses 
with first bite 
of food
Miglitol (Glyset)
25, 50, and 75- 300 mg in
4 hours
100 mg 3 divided doses 
with first bite 
of food
Table.Combination oral antidiabetic drugs.
Glyburide/Metformin
(Glucovance)
1,25 mg/250 
mg
2,5 mg/500 
mg
5 mg/500 mg
Maximum daily 
dose of 20 mg 
glyburide/2000 
mg metformin
See individual 
drugs
Rosiglitazone/metformin
(Avandamet)
1 mg/500 mg
2 mg/500 mg 
4 mg/500 mg
filaximum daily 
dose of 8 mg ro- 
siglitazone/2000 
mg metformin
See individual 
drugs
62
Injeccted antihyperglycemic medications for use in patients with DM 
type 2
New medications that effect glycemic control.
1. Amylin agonists - Symlin (pramlintide).
Symlin (pramlintide) is the first in a new class of injected antihypergly­
cemic medications for use in patients with DM type 2 or DM type 1 treated with 
insulin.
• Synthetic analog of human amylin (neuroendoctine hormone syn­
thesized from pancreatic В-cells that contributes to glucose control during the 
postprandial period)
• When used with insulin,this compound can help improved glycemic 
control
• Cannot be realized with insulin alone
Action
• Redused postprandial glucouse peaks
• Reduces glucouse fluctuations throughout the day
• Enhances satiety leading to potential weight loss
• Lowers mealtime insulin requirements
Indication
• DM type 2,as an adjunct treatment in patients who use mealtime in­
sulin therapy( regular insulin or rapid-acting insulin analogs) and have failed to 
achieve desired glucose control despite optimal insulin therapy, with or without 
a concurrent sulfonylurea agent and/or metformin
• DM typel, as an adjunct treatment in patients who use mealtime 
insulin therapy and have failed to achieve desired glucose control despite optim­
al insulin therapy.
Administration
• Taken just prior to meals, tree time a day subcutaneus (injection
form).
2. Glucagon-like peptide-1 agonists (GLP-1)- Byetta (exenatide).
Byetta is the first in a new class of a drugs for the treatment of DM type2 
called incretin mimetic.If s origins ia an interesting place- the Gila monster’s sa­
liva. This small lizard noted it could go a long time wiyhout eating. This sub­
stance found in it’s saliva that slowed stomach empting, thus making the lizard 
feel fuller longer. This substance similar in nature to a gut hormone found in 
humans GLP-1.
GLP-1 a naturally occurring peptide produced by the 1-cells of the small 
intestine, potentiates glucose-stimulated insulin secretion .Exenatide has homol­
ogy with die human GLP-1 sequence but has longer circulating half-life. It binds
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avidly to the GLP-1 receptor on the pancreatic В-cell and augments glucose- 
mediated insulin secretion.
Action
• To have many effects on glucose regulation as GLP-1
• Mimics the body’s natural physiology for self-regulating blood sug­
ar
• Enhance glucose-dependent insulin secretion by B-cells
• Suppresses inappropriately elevated glucagon secretion
• Slow gastric empting.
Side effects
• Nausea, vomiting, diarrhea
Administration
• Two time a day subcutaneous 5 meg bid within 1 hour in morning 
and evening (injection form).
• Is approve for use with sulfonylurea, metformin, and/or a TZD.
Treatment Approach Diabetes Mellitus Type 2:
Stepped care.
Choice of specific antihyperglycemic agents is predicated on their effec­
tiveness in lowering glucose, extraglycemic effects that may reduce long-term 
complications, safety profiles, tolerability, ease of use, and expence.
Step l.If fasting glycemia < 160 mg/dL start with nutritition, lifestayle 
modification, smoking cessation, exercise, self monitoring glucose, aspirin every 
day, vitamin E 400 IU/d to decrease oxidative stress, decries BP to <130/80.
Step 2.1f not at target after 2-4 month or initial fasting glycemia is >160 
mg/dL add on combination of oral hypoglycemic.
Step 3.Add a 3 rd oral glycemics agent.
Step 4. Add insulin.
Step 5. If HbAlC still hugh, stop orals and intensify insulin by giving 
NPH before breakfast and every night before bedtime + regular or Lizpro before 
meals or 70/30 before breakfast and dinner.
Step 6. Add Metformin or Troglitazone to insulin therapy.
Poorly controlled diabetes mellitus type 2 -  use 3-4 oral agents of differ­
ent classes. May need to add NPH insulin every night before bed time.
Treatment Approach Diabetes Mellitus Type 2 the Overweight pa­
tients.
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• Diet and exercise
. + Metformin or @-Glucosidase or TZd’s to treat insulin resistance
• + Sulfonylurea
• + every night before bedtime NPH insulin
• +NPH or Lente before bedtime.
Consider Orlistat.
Treatment Approach Diabetes Mellitus Adult Patient 20-30 years old
Screen for DM Type 1 with stimulated C-peptide measurement:
• If low-DM  Type 1, high-DM  type 2
• If 20-30years old with high C-peptide -  diet, exercise, weight loss.
• If fasting glucose > 180 start medicines.
. Thin, youger adult patients or if low C-peptide is more likely to 
have a В-cell defect and will respond better to Sulfonylureas or Repaglinide or 
Insulin as the initial treatment.
Insulin therapy Diabetes Mellitus Type 2.
Start insulin if:
• fail 3 month nutritional and exercise therapy and oral drugs not 
working,
• ketosis
• imminent surgery,
• gestational
• renal damage.
Starting insulin dose 0,5 -0,6 units/kg/day: 2/3 atn(70%NPH,30%R), 1/3 
pm (50 -50) also start Metformin at 500 mg*7d then twice a day. Dose should 
cover expected carbohydrates intake (1U per 10-15 g carbohydrates).
• Athletes may only need 0,5 U/kg
• Females may need 0,7 U/kg during the peak hormonal time of their
cycle, 0,8U/kg during the 2nd trimester, and 0,9 -1 U/kg during 3rd trimester
• Up to 2U/kg may be need if very sick or during puberty. A child in 
DKA with an infection during puberty may need 4 U/kg.
Starting NPH or intermediate acting: weight in kg /4 = dose in units at 10 
pm.
Start 70/30 at weight in kg/2 = dose in units.
Algorithm of Insulin Therapy for DM Type 2 (ADA, 2009).
1. Start with bedtime intermediate-acting insulin or bedtime or morn­
ing NPH (can initiate with 10 U or 0,2 U/kg.
2. Check fasting glucose (fingerstic) usually daily and increase dose, 
typically by 2 U every 3 days until fasting levels are consistently in target range
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(3,9 -  7,2 mmol/L -70-130  mg/dL).Can increase dose in larger increments, e.g. 
by 4U every 3 days, if fasting glucose is > 10 mmol/L (180 mg/dL).
3. If hypoglycaemia occurs, or fasting glucose level < 3,9 mmol/L (70 
mg/dL), reduce bedtime dose by 4 U or 10% - whichever is gteater.
4. If HBAlc>7% after 2-3 months and if fasting blood glucose is in 
target range (3.9 -7,2 mmol/L -70 -130 mg/dL), check blood glucose before 
lunch, dinner and bed. Depending on blood glucose results, add second injection 
as below. Can usually begin with 4 U and adjust by 2 U every 3 days until blood 
glucose is in range:
a) Pre-lunch blood glucose out of range add R-insulin at breakfast
b) Pre-dinner blood glucose out of range add NPH-insulin at breakfast 
or R-insulin at lunch
c) Pre-bed blood glucose out of range add R-insulin at dinner
5. If not HBAlc>7% after 2-3 months -  continue regimen and check 
HBAlc every 3 month, if HBAlc >7% after 3 months recheck pre-meal .blood 
glucose levels and if out of range, may need to add another injection. If HBAlc 
continues to be out of range, check 2 hour postprandial levels and adjust pre- 
prandial R-insulin.
Control levels:
• Fasting blood glycemia -65-126 mg/dL
• 2 hour postmeal -  180mg/dL, 2-4 am -60 -80 mg/dL
. Hbalc < 7%.
• If poorly control and patient on oral glycemics: add every night be­
fore bedtime NPH 0,1 units /body weight or single dose of 70/30 before dinner 
while continue oral medicines. As less weght gain than am NPH.
Chapter TV. The Comatose States in Diabetes Mellitus.
Definition
“Coma” is derived from Greek “Koma” meaning deep sleep. Coma has 
been defined as absence of any psychologically understandable response to ex­
ternal stimuli or inner need.
Signs of Coma
1. Altered physiological function.
2. Raised intracranial tension.
3. Herniations syndromes.
1. Altered physiological function.
In comatose patient five parameters altered which are assessed.
A. State of consciousness: This is a level of the individual awareness 
and the responsiveness of his mind to himself, the environment and the impres­
sions made by his senses. Various terms used in the past to define different de­
grees of coma are:
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a) Coma: There is a complete loss of consciousness from which the 
patient cannot be aroused by painful stimuli, all reflexes are lost including cor­
neal, light cough, swallowing, etc.
Evaluation of Severity of Coma
( Edinburgh Classification).
Grade 0. Fully conscious.
Grade 1. Drowsy, but responds to verbal commands.
Grade 2. Unconscious, but responds to minimal pain stimulus.
Grade 3. Unconscious, but responds to strong pain stimulus.
Grade 4. Unconscious with no response pain.
b) Stupor. This is a state of partial loss of response to the environment. 
The patient is difficult to arouse and though he can be briefly aroused, it is slow 
and inadequate. The patient is otherwise not aware of his environment and falls 
back into the stuporous state.
c) Hypersomnia or lethargy: Thia is morbid drowsiness or prolonged 
sleep from which the patient can be aroused or awakened. He appeareas to be in 
complete possession of his senses but goes back to sleep as soon as the stimula­
tion is remived.
d) Syncope: this is traisient, partial or complete suspension of con­
sciousness with impaired circulation and respiration, pallor, perspiration and 
cold skin.
e) Fugue state: This is a disturbance of consciousness, lasting hours or 
days, in which the patient performs purposeful acts, but later, consciously fails 
to remember actions out during that period.
f) Confusion. This is a mild lowering of the level of consciousness. 
This is impaired, capacity to think clearly and with customary rapidity, and to 
perceive, to respond to and remember guestions or directions.
g) Delirium. This is characterized by confusion, disorded perception 
and loss of attention. This is marked disorientation in time, excitement and 
hyperkinesias.
B. Respiratory patterns: Comatose patients often have characteristic 
pattern depending upon the site of lesion and its etiology.
a) Hyperventilation: This is present with hypoxia, acidosis, salicylate 
poisoning, severe psychogenic causes.
b) Hypoventilation; This is present with respiratory failure, sedative- 
narcotic overdosage and braine-stem compression.
c) Cheyne-Stokes respiration: This is characterized by alternate pe­
riods of hyperpnea and apnea. It is present with bilateral cerebral hemisphere 
dysfunction as in hypertensive or metabolic diseases. It also occurs with im­
pending transtentoprial herniation.
d) Central Neurogenic Hyperventilation: This is characterized by a 
sustained repid, regular and deep hyperpnea. It is seen in lesions of Ascending
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Reticular Activating System and often suggests transtentorial herniation with 
mid-brain compression.
e) Apneustic breathing: This is characterized by apause at full inspira­
tion indicating lesion of lower pons.
f) Ataxic or cluster breathing: This is characterized by irregularly ir­
regular breathing pattern and is seen with compression of medulla oblongata.
C. Pupils: Equal and normally reactive pupils suggest that the oculo­
motor nerve and the upper brain-stem are intact. Full and conjugate eye move­
ments suggest that midbrain and pontine tegmentum are intact.
a) Pupillary reaction helps to differentiate structural from metabolic 
causes of coma. Pupillary pathways are relatively resistant to metabolic insult 
and hence in metabolic disorders, pupils are reactive to light. Absence of light 
reflex suggests structural lesion, asphyxia, hypothermia and drugs.
b) Fixed and dilated pupils suggest instillation of mydriatic drops or 
direct trauma to the orbit or oculomotor nerve.
c) Hippus: This is spontaneous, rhythmic constriction and dilatation of 
pupils which suggest mid-brain damage.
d) Irregular pupils: 1-2 mm irregularity may be normally present or 
may occur with early oculomotor nerve palsy, trauma or mydriatic eye drops.
D. Eye movements and Ocular reflexes:
a) Conjugate gaze to one side suggests ipsilateral frontal lobe lesion or 
contralateral pontine lesion.
b) Sundowm dewiation is seen with mid-brain compression.
c) Ocular bobbing occurs with primary pontine hemorrhage.
d) Horizontal eye roving is seen with mild metabolic coma.
e) DolF’s eye movements or oculocephalic reflex: On vertical or hori­
zontal rotation of the head, conjugate deviation of the eyeballs occur on the op­
posite side if brainstem is intact. If brainstem is intact. If brainstem is damaged 
the eyes follow the direction of the head rotation. In hypoglycemia and hepatic 
encephalopathy this response is brisk. However, as the metabolic coma 
progresses, the abnormal response eventually ensues. This reflex must not be at­
tempted if there is doubt about trauma to the cervical spine.
f) Caloric response or oculovestibular reflex: After the external audi­
tory canal is cleared of wax, the patient is put in supine position with head ele­
vated to 30o and the external canal is then irrigated with cold water. Thia will 
result in horizontal nystagmus with fast component to the opposite side if vesti­
bule-oculomotor brainstem pathways are intact. In metabolic or structural 
brainstem lesion, there is dysconjugate ocular movement.
g) Citio-spinal reflex: A noxious stimulus over the skin of the neck, 
face or upper trunk causes bilateral papillary dilatation if the sympathetic path­
ways are intact.
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h) Comeal reflex: On touching the cornea with a wisp of cotton, there 
is blinking of both the eyelids if fifth and seventh cranial nerves are intact. This 
reflex is absent early in posterior fossa or brainstem lesion.
E. Motor response: Distinct motor response can occur in various le­
vels and types of coma. Application of noxious stimuli leads to varios postures:
a) Decorticate posture: Flexion of any or all the limbs suggests lesion in 
the descending motor pathways above rostal mid-brain.
b) Decorticate posture: Extension of the limbs suggests lesion in the mid­
brain and upper pons due to herniation or toxic or metabolic disorder.
c) Triple flexion; Decerebrate upper extremities with lower limb flexion is 
triple flexion response which results from the spinal reflex secondary to dam­
aged descending motor tracts.
d) Cortical response: When there is lesion of the cerebral hemispheres, 
several motor and behavioral patterns, similar to those of a normal infant func­
tioning at the thalamic level appear. They are bilateral symmetrical such as 
sucking, snorting, grasping, motor perseveration and gegenhalten (increased 
muscle tone to passive movements).
F. Raised intracranial pressure (ICP).
The normal ICP is 2-15 mm of Hg. It is raised with any space-occupying 
lesion in the brain. The symptoms and signs of raised ICP are headache, vomit­
ing, papilledema, bradycardia, hypertension, Cheynes-Stokes respiration, yawn­
ing and hiccupping.
F. Herniation syndromes.
G. There are two herniation syndromes-uncal and transtentorial which 
can rapidly cause irreversible brain-stem damage if untreated at an early stage. 
A third type infratentorial herniation is not common.
a) Uncal herniation: This results from an expanding intracranial lesion 
in the temporal lobe or lateral cranial vault. Uncus and the hippocampal gyrus 
compresses the adjacent midbrain the oculomotor nerve and the posterior nerve 
and the posterior cerebral artery. Initially there is ipsilateral papillary dilatation 
with contralateral hemiplegia. Later, there is is decorticate and decerebrate post­
uring and loss of ocular reflexes. As the pons in compressed, the corneal reflex 
is lost and when medulla is involved there may be apnea, hypotension and car­
diac arrest
b) Transtantorial or central herniation: This is associated with lesions 
in frontal, parietal or temporal lobes. Diencephalon or midbrain is displaced.
c) Infratentorial: The signs and symptoms are due to herniation of the 
cerebellum and mesencephalon upward through the transtentorial notch, ob­
structing CSF and venous return or a downward herniation through the foramen 
magnum causing fatal cardio-respiratory failure.
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l.Diabetic Hypoglycemia.
Medical conditions that limit the body’s glucose reserve, lengthen the 
time insulin stays in the body, or that increase sensitivity to insulin. Occurs most 
often in insulin-treated diabetics, usually due to problems with matching insulin 
dose to estimated blood glucose levels.Hypoglycemia is a dangerous comopica- 
tion, and in the short time run more serios than hyperhlycemia. Prolonged hy- 
poglyucemia may cause permanent brain damage.
Less commonly, hypoglycemia occurs in non-diabetics persons (alcohol 
intoxication, insulin-secreting tumors, oral hypoglycemic drugs, pentamidine).
“Re-explain” Renal failure, Exogenous, Pituitary, Liver failure, Alco­
hol, Insulinoma/Infection, Neoplasm
Ethiology (Risk in Diabetics):
Insulin excess (intensive therapy, dosing errors, erratic absorption 
due to lipohypertrophy)
Medicines(sulfonamides, sulfonylureas, beta-blockers)
Not enough carbohydrate
Too much glucose use by the body
Unusual physical exertion
Pathogenesis
Protection against hypoglycaemia is normally provided by two mechan­
isms as plasma glucose concentration falls:
1. Cessation of insulin release.
2. Secretion of counter-regulatory hormones.
The 4 counter-regulatory hormones are glucagon, catecholamines (epine- 
frin and norepinefrine), cortisol and growth hormone. They counter hypoglyce­
mia by increasing hepatic glucose prodactiion and decreasing glucose utilization 
by non-hepatic tissues. Glucagon is the primary counter-regulatory hormone, 
while catecholamines serve as the major backup. Cortisol and growth hormone 
do not function acutely, but come into play sustained hypoglycemia.
3. Diabetic patients are vulnerable to hypoglycaemia due to two reasons:
- insulin excess
- counter-regulatory failure. In the early stages inself, DM Type 1 patients 
lose the capacity to increase glucagone release in response to hypoglycaemia. 
Many patients also lose the capacity to release cathecholamines in response to 
hypoglycaemia, as a result of diabetic autonomic neuropathy.
Symptoms and signs:
Hypoglycemia may be:
Mild
Severe
Proper comatose state
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Symptoms and signs of the mild hypoglycemia
•  Anxiety, Hunger
•  Irritability restlessness
•  Trouble concentrating
•  Dizziness
•  diplopia, blurred vision
•  Sweating
•  Tremor
•  Palpitation
•  Skin moist
•  Respiration, body temperature normal 
Laboratory
•  Fasting blood glucose <2,8 mmol/1 ( les then 40 mg%) and <2,2 
mmol/1 after meal
•  Glucose absent in urine, no acetone
Treatment of the mild hypoglycemia
•  By eating or drinking carbohydrates;
•  orange juice, tea
•  sugar candies
•  glucose tablets
Symptoms and signs of severe hypoglycemia
•  personality changes, mood changes
•  trizm
•  Muscle rigidity, exaggerated tendon reflexes, tonic and clonic 
spasms
•  Pupils dilated 
Treatment severe hypoglycemia
•  Glucagon -1 mg im/iv/sc (onset 5-20 min)
•  Glucose - 40% - 20 -40 ml i/v
Deep hypoglycemic comatose state
•  Consciousness is fully lost
•  Hypotention or hypertention,arrhythmia
•  areflexia, lowered body temperature,
•  adynamia, cessation of sweating and convulsions
•  Oedema of the brain and lungs
•  Cerebrocirculatory disorders, hemiplegia
•  Death
Treatment of hypoglycemic coma
•  40% Glucose i/v strem 40-100 ml
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•  Hydrocortisone150-200 mg i/v, i/m or prednisolon 30 -90 mg i/v
•  Adrenaline 0,1% -0,5 -1 ml s/c,i/v
•  Mannitol 15 -20% 0,5 -lg/kg i/v,Magnezium sulphate 25%-5 -10ml
i/v
Prognosis
•  Favourable when diagnosis/treatment are timely
•  Fatal outcome when treatment are absence
Complications in hypoglycemic coma
•  Edema of the brain and lungs
•  Cerebrocirculatory disorders
•  Myocardial infarction
Insult and hemiplegia
Somagui phenomenon (posthypoglycaemia hyperglycaemia)
Refers to rebound hyperglycaemia following an episode of hypog- 
lycaemia, due to counter-regulatory hormone release.
Manifests as morning fasting hyperglycaemia, in response to unre­
cognized nocturnal hypoglycaemia
The significance of the Somagui phenomenon is that the correction 
of the morning hyperglycaemia depends on reducing, and not increasing the 
evening dose of intermediate-acting insulin.
Clues to the presense of Somagui phenomenon
The classical clinical picture is one of the worsening diabetic control in 
the presense of increasing insulin doses and is manifested especially by fasting 
hyperglycaemia.
a) excessive hunger and weight gain occurring in the context of worsening 
hyperglycaemia
b) subtle clinical signs of nocturnal hypoglycaemia, such as mild noctur­
nal sweating, morning headacheas, and hyportermia
c) Wide fluctuations in the plasma glucose and urine glucose occurring 
over short time intervals, and not related to meals
d) Can be confirmed by documenting hypoglycaemia at 3AM and hyper­
glycaemia in the fasting state
e) The ultimate criterion for the diagnosis is improvement in diabetic con­
trol after a decrease in the insulin dose
The Dawn Phenomenon
Closely related to the Somagui phenomenon in that there is fasting 
hyperglycaemia, but no hypoglycaemia during the night
The mechanism of the dawm phenomenon is thought to be noctur­
nal surge of growth hormone release or increased clearance of insulin in the 
mornings
-can be confirmed and differentiated from the Somagui phenome­
non by documenting at 3 AM and in the morning
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The significance of the dawn phenomenon is that, the correction of 
the fasting hyperglycaemia depends on increasing, and not decreasing the insu­
lin.
2. Diabetic Ketoacidosis.
It is acute complication of the diabetes mellitus which characterized by 
hyperglycemia, dehydration, acidosis, ketonemia, ketonuria
Ethiology
-Too little/no insulin injected
-Too much carbohydrate intake
- Fevers
•  Infections
•  Heart attacks
•  stress
•  Medicines: thiazide water pills
•  corticosteroids
•  birth control pills
•  protease inhibitors
Pathogenesis
Diabetic ketoacidosis results from insulin deficiency and glucagon excess. 
Hyperglycaemia resulting in a hyperosmolar state, which induces an osmotic 
leading to volume depletion and dehydration. Activation of lipolysis in adipose 
tissue, resulting in release of increased amounts of free fatty acids into a plasma, 
which are taken up by the liver.Accelerated hepatic gluconeogenesis and im­
paired peripheral utilization of glucose, both resulting in severe hyperglycaemia. 
This hyperglycaemia induces an osmotic dieresis leading to volume depletion 
and dehydration. Activation ketogenic process resulting in ketosis and metabolic 
acidosis. The mechanism is complex and invololves the following sequences: 
the exess glucagon causes a resetting of the hepatic metabolism of fre fatty ac­
ids. This is achieved throuth an increased activity of the enzyme, carnitine acyl- 
transferase. The result is that hepatic mitochondria convert free fatty acids to ke­
tone bodies which accumulate in the body fluids. The ketone bodies mainly in­
clude acrtoacetic acid and beta-hydroxybutyrie acid, but to minor amount, ace­
tone also.They are responsible for the acidotic state. These acids dissociate 
completely, releasing hydrogen ions into the body fluids with a resultant fall in 
pH. The fall in pH is countered by the buffers, especially bicarbonate, which is 
used up.
Pathogenesis of DKA - Summary
•  Insulin deficiency combined with increased counter-regulatory 
hormones
•  Unrestricted hepatic glucose production -  extreme hyperglycemia
•  Lipolisis - free fatty acids -  ketoacids -  acidosis
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•  Osmotic diuresis causes dehydration and electrolyte abnormalities 
Ketoacidotic coma degree
•  Mild - stage DKA I
•  Manifested -  DKAII
•  Severe -  DKA III
•  Coma proper -  DKA IY
Symptoms and signs:
•  Confusion or drowsiness
•  Nausea/ vomiting
•  Fruity smelling breath -acetone odor
•  Rapid, deep breathing -  Kussmaul respiration’s
•  diffuse abdominal pain
•  Increased thirst/urination
•  dehydration 
DKA I
•  Sharp weakness
•  Lassitude
•  Somnolence
•  Vomiting
•  Headache, dizziness
•  Abdominal pain - ’’pseudoperitonites”
DKA II and DKA П1
•  Sopor (deep pathological sleep)
•  Pain sensation, swallowing, pupillary and corneal reflexes are pre­
served
DKA IY (proper coma)
•  Consciousness is fully lost, diminished muscle tonus
•  Respiration is gasping, deep with prolonged inspiration and brief 
expiration (Kussmaul’s respiration) with ffutty (aceton) smelling breath
•  pink, pale, dry, cold, inelastic skin
•  eyeball hypotension
•  Pupils constricted
•  Collapse, arrythmia 
Oliguria, anuria
Laboratory Findings
•  Hyperglycemia 20 to > 30 mmol/1
•  PH 7.2 -  6.8, ketonemia
•  Decreased Na, K, Cl, НСОЗ
•  Glucosuria, acetonuria, proteinuria, cylindruria, microhaematuria
•  neutrophilic leucocytosis, accelerated ESR
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ECG -signs of the hypokaliemia such as:
•  Segment ST dearease
•  low T wave
•  QRST complex elongeed
•  Patological U >T (2:1) V1 -  V2
•  Fibrillation, exstrasystole 
Diagnosis criteria for DKA:
1. Blood glucose > 250 mg/dL, arterial pH < 7,3, serum bicarbonate < 
15 mEq/L and moderate degree of ketonemia and/or ketonuria.
2. The anion gap of > 12 mEq/L is usually present.
3. Assesment of ketonemia and/or ketonuria is usually performed by 
nitroprusside test which provides srmiquantitave assay of acetoacetate and ace­
tone levels. Tis assay underestimates the severity of ketoacidosis as it does not 
recognize the presence of beta-hydroxybutyric acid, the main ketoacid in DKA.
Treatment
•  Rehydration 1-2 L 0,9%NaCI in Is1 1-2 hr (15cc/kg/hr) and 0,5 -1L 
per hour ( 2-9-2hr).
•  Insulin infusion:10 -20U(0,15U/kg) bolus, then 0,1 U/kg infusion 
(add 500U insulin to 1L 0,9%NaCl for concentration of 0,5U/ml)
•  When blood glucose <15mmol/l add 5% glucose and reduce insulin 
infusion by 1/2
•  Avoid hypokaliemia
•  K+ lost from cells due to insulin deficiency and general catabolic 
state
•  Blood levels do not reflect total body losses which may be 400 - 
500mEq
•  K+ falls during treatment due to rehydratation and insulin ac- 
tion(drives K+ into cells)
•  Replace as KCL
•  When K<3mEq/L add 40mEq/L
•  When K<4 -4,5mEq/L add 10 -20mEq/L
•  When К is 3 -4 add 30mEq/L
•  When К is 5-6 add<10mEq/l
•  If pH<6,9 give 1 OOmol in 4000 ml H20 at 200 ml/hr
•  IfPh6,9 -7 give 50mmol (200mlbicarb in H20 at 200ml/hr)
•  Mannitol 15% -20% 0,5 -1 g/kg (treatment cerebral edema) 
Prognosis in ketoacidotic coma
•  Most favourable if coma not more 6 hr
•  Is poor in according of myocardial infarction or cerebrocirculatory 
disturbances
•  Fatal outcome without treatment
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Complications of diabetic ketoacidosis
Acute gastric dilatation or erosive gastritis 
Cerebral oedema.
Hyperkalaemia.
Hypoglyucaemia.
Infections.
Insulin resistance.
Myocardial infarction.
Vascular thtombosis Somagui phenomenon.
3. Hyperglycaemic Hyperosmolar State.
This is a syndrome characterized by extreme dehydration resulting from 
sustained hyperglycaemic dieresis under circumstances in which the patient is 
unable to drink sufficient water. The biochemical hallmark of the syndrome is 
extreme hyperglycaemia in the absence of significant ketoacidosis.
Usually complication of DM type 2 
High mortality rate, of more than 50%
Ethiology
•  Profaund dehydration resulting from hyperglycemia
•  Precipitating events: infection, stroke, myocardial infarction, trau­
ma
•  Drugs :glucocorticoids, immunosuppressives, diuretics
•  Medical procedures -  dialysis
•  Reduced fluid intake, especially in elderly, bedridden patients
•  Bleeding
•  Acute pancreatitis 
Pathogenesis
•  Extreme hyperglycemia
•  Hyperosmolality
•  Volume depletion and CNS signs 
Laboratory
•  High serum osmolality >350mOsm/L
•  Blood glucouse >30 to 55 mmol/L( range 600 -  2,400 mg/dL)
•  Urine negative for ketones, high urine glucose
•  Prerenal azotaemia with elevation of blood urea nitrogen and crea­
tinine
•  A mild metabolic acidosis with marginal decrease in plasma bicar­
bonate (<10 mmol/L) indicates lactic acidosis
•  Hyponatriemia, hyperchloremia, hyperazotmia
•  Leucocytosis, high haemoglobin
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Symptoms and signs
•  Coma develops in periods - 2hour to 1 -2 days
•  Rapid dehydration
•  Dry mucous and skin, eyeball tonus diminished
•  Pupils constricted
•  Hypotension, colanse, tachycardia, arrhythmia
•  Tachypnoea without acetone odor
•  Oliguria, anuria
•  CNS signs: bilateral,spontaneous nystagmus, muscular hypertonus, 
epileptoid fits, transient hemiplegia
•  Venos and arterial trombosis 
Treatment
•  Rehydration with 0,45% NaCl
•  Insulin infusion 0,1 U/kg/hr
•  Cerebral edema may result if osmolality is treated too aggressively 
Heparin 5000 -10 000 U i/v
4. Hyperlactacidaemic coma.
Lactic acidosis occurs when lactic acid is produced at accelerated rates, 
due to anaerobic metabolism in skeletal muscles and other tissues. 
Ethiology
•  Very rare occurrence
•  Hypoxia of any genesisxardiac and respiratory failure, anaemia, 
shock, hemorrahges
•  Drugs: biguanides, salicylates
•  Renal or hepatic insufficiency 
Pathogenesis
•  Develops acutely during a few hour
•  Excess production of lactic acid
•  Pyruvic acid is accumulated and converted into lactic acid
•  Activated the processes of anaerobic glycolysis 
Laboratory
•  Mild hyperglicaemia <20mmol/l, negative ketonaemia
•  Mild glucosuria, negative ketonuria
•  Increased blood ratio lactic/pyruvate
•  Diagnosis is confirmed by alow arterial pH (<7,2), increased anion 
gap, decreased plasma bicarbonate, and a high concentration (>5,0 
mmol/L) of lactic acid in the blood.
Symptoms and signs
•  Nausea, vomiting
•  Somnolence, delirium, loss of consciosness
•  Kusmaul’s respiration without acetone odor
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•  Low body temperature
•  Hypotension, collanse
•  Motor anxiety
•  anuria 
Treatment
•  To neutralize and remove the excess of lactic acid:2,5% sodium bi­
carbonate -336mml/hr(100mmol/hr i/v drip
•  Oxygen
•  Insulin i/v drip 6-8U in 500ml -5% Glucouse
•  Plasma, substituting solutions i/v
•  Hydocortisone 250 -500mg i/v
•  Haemodialysis in severe cases(ineffective therapy, anuria)
Prognosis
•  Doubtful
•  Mortality 50%
Chapter V. Insulinoma.
Insulinoma is a pancreatic insulin secreting tumor:
Median age is 50 years old, but 23 years old if have MEN-1.
Most are solitary, spherical, size varies from 2 mm to 10 sm, very 
rarely to 15 sm.
10% multiple, 10% malignant, 10% MEN-1 related.
If malignant, matastases spread into the liver.
Located in the tail, head, and body of the pancreas 
Sometimes are located extra pancreatically :in the duodenal wall, 
splenic hilum 
Pathogenesis
Dificient supply of the brain with glucose and oxygen leads to stimulation 
of the sympathetic nervus system and subsequent increase of catecholamains in 
the blood. Reduced oxidation processes and disorders of all types of metabolism 
in the brain are as a result of hypoglycaemia lead to the loss of normal tonus by 
the walls of the cerebral vessels. The last circumstance is the cause of vascular 
dilatation and increased permeability not only under the effect of catechola- 
maines, but also as a consequence of theaugmented flow of blood to the brain 
because of the constriction of the peripheral vessels. Dilatation of the vessels 
and the increase of their permeability lead to development of cerebral oedema, 
deceleration of the rate of blood flow, and the formation of thrombi with subse­
quent development of atrophic and degenerative changes in the brain. Histologi­
cal examination of the brain revels diffuse changes in the nerve cells: petechiae, 
haemorrage.
Symptoms and signs
Attack of hypoglycaemia occuk suddenly
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In the morning: diplopia, blurred vision, palpitation, sweating, 
weakness, confusion, amnesia, hunger or nausea.
Face is flushed, the skin moist, profuse sweating 
Increased muscular tonus, tendon and periosteal reflexes, convul­
sions, Babinski”s sign +, Rossolimo’s sign +.
Pupils wide 
Deep coma
The period of excitation is replaced by loss of consciousness :
Areflexia
Fall in body temperature 
Bradicardia, shallow breatning.
During latent period between hypoglycaemic attacks patient complain of 
loss of memory, impaired mental working capacity, apathy, sometimes muscular 
pain, weigth gain 
Laboratory
Range of glucouse 0.55 -  1,1 mmol/L (52-10 mg/dL) or lower in 
hypoglucaemic attack.
Immunoreactive insulin increased,C-peptide and proinsulin in­
creased.
Fasting glycaemia <1.65 mmol/1 (30 mg/dL),blood glucose testing 
on a fasting stomach and during 24 hours with the patient reciving ba diet 
ordinarly prescribed.
Plasma sulfonyreas test 
MRI/CT confirm.
Treatment
-Surgery
Prognosis
Favorable if surgery treatment.
If radical treatment is not applied, the prognosis is poor 
Letal outcome may occur during a hypoglycaemia coma.
Chapter VI. Diseases of the Thyroid Gland.
Anatomy of the Thyroid Gland
Thyroid gland is located in the neck, below Adam’s apple, in front of 
windpipe, with two connecting lobes and isthmus and is well supplied with 
blood vessels, the right lobe is often bigger than the left. The isthmus is located 
in the region of the 2nd to 4th tracheal rings. In an adult the thyroid gland weight 
about 15-20g and after 50 years it diminishes.
Histology of Thyroid gland
The thyroid gland consist of follicles, the cavity of its is filled with visc­
ous colloid, a product of the epithelial cells of the follicles. Colloid consists of
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thyroglobulin. The intrafollicular islets in the stroma between follicles. These 
islets serve as a source for the new of Hides.
The thyroid gland contains of the 3 types of the epithelial cells 
by the fine-needle biopsy :
A-cell -  folliculare epitelium
■ В-cell (Ashkinazi’s cell, onkocytes)
■ C -cell produced calcitonin 
Thyroid gland secreted:
- T4-thyroxin,
- T3 -triiodothyronine;
- calcitonin 
Biochemistry
Free T4 and free T3 represent the hormonally active fraction 
The remainder is hormonally inactive, mainly bound to T4 binding 
globulin (TBG) and albumin
T3 is more biologically active then T4
Some T4 is converted to T3 in peripheral tissues by 5’-dejodinase 
Metabolized by most tissues; metabolites reach liver are excreted in
bile
Regulation of the Thyroid Gland:
Extrathyroid
Stimulation by the pituitary gland -  TSH, epinephrine, prostaglandins
When the levels of T4 and T3 fall, the pituitary secretes more TSH. When 
T4 and T3 levels rise, the pituitary secretea less TSH.
Intrathyroid (autoregulation) of Thyroid Gland:
■ Response to iodide-with increasing iodide supply, inhibition of 
iodide organification decreasing T3 and T4 synthesis (Wolf-Chaikoff effect)
■ Varying thyroid sensitivity to TSH in responce to iodide availability
■ Increased ratio of T3 to t4 in iodide deficiency 
Thyroid hormones effects:
■ Circulation and cardiac rate (force and output)
■ Central nervous system function
■ Appetite, blood fat and sugar levels, regulation of fat
■ Energy levels, carbons and protein metabolism
■ Bowel function
■ Body temperature
■ Growth and skeletal development
■ Muscle tone and agility
■ Speed of metabolism
Thyroid hormones are therefore essential for life, growth and develop­
ment
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Terminology and Classification of the Thyroid gland disord­
ers
Thyroid disorders include:
1. Goitre (generalized enlargment of the thyroid gland that does not 
result from inflammatory or neoplastic processes): diffiise toxic goiter, diffrise 
non-toxic goiter, nodule or multinodules goitre
2. Hyperthyroidism (where the thyroid releases too much hormone 
and the body’s metabolism goes too fast)
3. Hypothyroidism (where the thyroid releases too little hormone so 
the body’s metabolism goes too slowly): hypothyroidism&myxedema
4. Thyroiditis (inflammation of thyroid gland by specific agents or 
autoimmune processis): Hashimoto’s thyroiditis, subacute thyroiditis, post- 
partion thyroiditis
5. Thyroid Nodules and swellings: benign and malignancy. May be 
adenoma, colloid nodule, cyst, primary thyroid malignancy, metastatic neoplasm
Ethyology
Common following signs: 
genetic predisposition 
autoimmune reactions
outside factors such as: iodine and microelements deficiency, radi­
ation, virus infection, stress
Diagnosis
a. Physical examination: palpation of the thyroid gland
b. Laboratory findings,
c. Ultrasound
d. Fine needle biopsy
e. Iodine thyroid scan
a. Physical examination
Goitre may be:
- diffuse (thyromegaly), nodular, multinodular, diffrise-nodular
- Euthyroid, hypothyroid, hyperthyroid .
Thyroid hormones act like chemical messengers and deliver instruc­
tions to various tissues and target organs via the bloodstream and clinical symp­
toms may be different. But approximatly 40% diagnosis of the thyroid gland 
diseases can make diagnosis with clinical examination.
“Portrait’s” diagnosis of the patients with thyroid gland dis­
order function
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Hyperthyroidism Hypothyroidism
CNS Young-looking, anxiety, nervous­
ness and/panic attacks, make a lot 
of rapid unnessary movements and 
verbose, absence concentration, 
easily upset, insomnia, feel hotter 
than those around them, sweeting, 
trembling of the hands and a hard 
muscle weakness
Old-looking, sluggish­
ness, indecisiveness, 
slowness of thought 
processes(brain fog), 
poor memory and con­
centration, feeling cold 
even on warm day, fa­
tigue, exhaustion and 
low energy, slow ref­
lexes, deepening, 
hoarse voice
Facial expres­
sion
An angry frightened look, staring 
gaze
Poor mimic, swelling 
of face and feet
Skin, hair, 
weight
Warm, thin, transparent, velvet, 
moist, lose weight
Thick, dry, coarse, pale, 
skin rashes, brittle hair 
and nails, hair loss, 
alopecia thining eye­
brows, overweight
Thyroid gland Diffuse or multinodular goitre, 
soft, mobile, not fused with the 
underlying tissues
Enlarged thyroid gland 
or diminished
CVS Palpitations, fast pulse, arrithmia, 
increased systolic blood pressure, 
chest pain
Slow, weak pulse, bra- 
dicardia, increased di­
astolic and decrease 
systolic blood pr.
GDT Increased appetite but weight lost, 
diarrhoea
chronic constipation
Sexual distur­
bances
Menstrual cycle disturbances or 
scant mensis, infertility, impo- 
nence in man, reduced libido
Menstrual cycle distur­
bances or scant mensis, 
infertility, imponence 
in man, reduced libido
Temperature Normal or subfebril Low basal temperature
b. Laboratory findings and investigation
Immunoassay techniques for diagnosing thyroid disorders measure the
amount of circulating hormones in the blood very accurately. 
Table. Thyroid Function Test. _______________
Hormone Range
TSH 0,30 -5,00mIU/L
Free T4 11 -  23pmol/L
Free T3 3,5 -  6,7 pmol/L
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The TSH level is a good indicator of thyroid function and is considered 
the most important hormone to be initially tested. It is the first hormone assessed 
when suspecting a thyroid disorder.
- hypothyroidism: TSH level decreased, T3 and T4 decrease;
- hyperthyroidism: TSH level LOW, T3 and T4 increase.
If the TSH levels are not low, then other tests must be run:
Thyroid antibody test
Thyroid constituents Range
Antibody against thyroid thyroglobulin Less then 40 ME/ml
Antibody against thyroperoxidase Less then 35 ME/ml
Miscellaneous Tests
- Thyroid antibodies: antithyroglobulin antibodies, microsomal antibodies 
increased in Hashimotoe’s thyroiditis
- TSH receptor antibodies: thyroid stimulating immunoglobulin (TS1) or
TSAb increased in Graves disease
Accurate and widely available blood tests can confirm or rule out the di­
agnosis quite easily within a day or two. Other special tests are occasionally use 
to distinguish among the varios causes of hyperthyroidism
c. Ultrasound
Ultrasound may be used for:
- surveillance, localization of thyroid gland and lymphatic nodules
- quantitation of thyroid gland : normal volume in female -  18ml, normal
volume in mail -  24ml;
- quantitation of residual recurrent tumor;.
d. Fine -Needle Thyroid Biopsy.
Aspiration of thyroid tissue with a 25-gauge (fine needle) is helpful in the 
diagnosis of thyroid disorders, especially nodular lesions. Small nonpalpable 
(less then 10 mm) nodules are detected in half of “normal” thyroids and are rare­
ly malignant
- to guide fine-needle aspiration biopsy of clinically suspicious thyroid 
nodules and nodes
e. Iodine Thyroid Scan
Will show if the cause is a single nodule (“hot” nodule) or the whole
gland.
Because the thyroid gland normally takes up iodine in order to make thy­
roid hormones, measuring how much radioactive iodine or technetium is cap­
tured by the gland can be a very useful way to measure its function. The dose of 
radiation with this test is very small and has no side effects. Such radioactive
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thyroid scan and uptake tests are often essential to know what treatment should 
be used in a patient with hyperthyroidism.
1. Non-toxic goiter.
Non-toxic endemic goitre
is generalized enlargement of the thyroid gland in a euthyroid indi­
vidual .
does not result from inflammatory or neoplastic processes in per­
sons .
dwelling in areas of iodine deficiency (approximately 115 coun­
tries).
5% of the world’s population have goiters.
Endemic in the regions of the world with low-iodine diets: in­
creased rate of congenital hypothyroidism and cretinism
- Most adults endemic goitre are found to be euthyroid; however, some 
are hypothyroid or hyperthyroid
- may become multinodular and grow to great size
- high rate of congenital hypothyroidism and cretinism
Sporadic non-toxic goitre - in which only the individual is affected in 
persons living outside the areas of iodine deficiency.
Classification of the Goitre (WHO, 1994)
■ Grade 0- the thyroid unpalpable and invisible
■ Grade 1 -palpable, not visible in normal position of the neck; the 
thickiened mass moves up during swalloving
■ Grade 2 - neck swelling, visible when the neck is in normal position
Risk factors
Appearance of a goitre is more likely during:
■ adolescence,
■ pregnancy and lactation
■ goitrogens:thiocynates(cabbage, turnip, soy, cassava)
■ drugs: iodine, lithium, para-aminosalicylic acid because of icreased 
thyroid hormone requirements
Risk factors for sporadic goiter
1. Family history
2. diet
3. age over 40 years
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4. gender (w>m)
Ethiology and Pathogenesis
■ Iodine deficiency or excess
■ Goitrogens: brassica vegetables (cassava, sorghum, millet, maize)
■ Drugs: iodine, lithium, para-aminosalisylic acid
■ Any disorder of hormone synthesis with compensatory growth
■ Periphereal resistance to thyroid hormone
■ Early stages: goiter is usually diffuse. Later stages: multinodular 
nontoxic goiter with nodule, cyst formation and areas of ischemia, hemorrage , 
and fibrosis
Fig.Non-toxic goiter in 41 years-old women.
Complications
- Compression of neck structures, causing stridor, dysphagia, pain, 
hoarseness
- attempts to shrink such goiters with iodine supplements or thyroxine are 
usually unsuccessful and may cause thyrotoxicosis
- since noduler goiters tends to become autonomous over time
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- Multinodular goiter may become autonomous leading to toxic multino­
dular goiter and thyrotoxicosis
Diagnosis and laboratory
- Physical examination: palpation of the thyroid gland and lymphatic no­
dules
- TSH normal or slightly increase, T4 normal, antithyroid anibodies in 
low titres or undetectable, thyroglobulin elevated
- Ultrasound scan
- Fine needle biopsy if nodules are present, different with malignancy
- Radioactive iodine scan
Treatment
Treatment depends on the underlying cause:
■ Remove goitrogens
■ Suppression with L-T4 may be effective in any TSH-depended goi­
tre
■ Goitre caused by iodine deficiency - Iodine-therapy : KJ, “Eu- 
thyrox”. Prevention -  the introduction of iodinerich foods into the diet(seafood 
and iodised salt). Iodine supplementation 20 mg/kg salt. The minimum dietary 
requirement for iodine is about 50 mg daily, with optimal iodine intake being 
150- 300 mg daily. Iodine sufficiency is assessed my measurement of urinary 
iodine excretion, the taget being more than 100 mg of iodide per gram of creati­
nine.
■ Hyperthyroidism -  is managed with drugs that slow the activity of 
the thyroid or surgically removed
■ Hypothyroidism -  by lifelong hormone replacement T4 therapy
■ Adults with large multinodular goiter may require thyroidectomy 
for cosmesiss, compressive symptoms, or hyrotoxicosis
2.Hyperthyroidism & Thyrotoxicosis
The term refers two main categories:
Hyperthyroidism due to excessive glandular synthesis of thyroid hor­
mone and thyrotoxicosis/hyperthyroidism due to exogenous intake of thyroid 
hormone or inflammatory process or ectopic production of thyroid hormone
Thyrotoxicosis are a series of clinical disorders associated with in­
crease circulating levels of free thyroxine or triiodothyronine.
The various causes include the following a clinical diagnosis:
A. Graves’ Disease .
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B. Toxic Nodular Goitre.
C. Toxic Nodule.
D. Thyroiditis a) classical subacute thyroiditis b)silent thyroiditis ^post­
partum thyroiditis
E. McCune-Albrigth Syndrome.
F. Jod Basedow (Jodine-induced)
G. Extra-thyroidal Sources of Thyroid Hormone a)endogenous (struma 
ovariae< ovarian teratoma metastases from follicular carcinoma) b) exogenous 
(drugs)
H. Excessive Thyroid Stimulation a) pituitary thyrotrophoma b) pituitary 
thyroid hormone receptor resistance) > hCG (e.g. molar pregnancy)
3. Graves’ Disease.
Know as diffuse toxic goitre in Russia.
Know as Basedow’s in Europe.
Know as Grave’s in USA.
Definition.
Diffuse toxic goitre is an autoimmune endocrine disease with conge­
nital defect of the immune control system.
Characterized by an increase in synthesis and release of thyroid 
hormones.
The thyroid gland is typically diffuse enlarged in 98% of young fe­
males, associated with exophthalmos).
in the elderly, toxic multi-nodular thyroid goiter is a close 2nd.
Iis encountered everywhere, peaks in 4th decade of the ages, 
much more common in women than in men (8:1).
Caused by a mixture of genetics and environment.
General Considerations
■ autoimmune disease
■ thyromegaly or goiter
■ excess production of thyroid hormone
■ Decreased TSH, increased T4, free T4 and free T4 index
■ increased TS1 or TSAb
■ family history,may be associate with other autoimmune disorders in 
family (DM 1 .alopecia areata, myasthenia gravis )
■ age 30- 40y.o , F>M (8:1)
■ Association with HLA-B8/HLA-DR3.
■ Associated with DM Type 1, Addisons, vitiligo, pernicious anemia, 
alopecia areata, celiac disease, myasthenia gravis.
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Determines factors
■ The neouro-endocrine incitement (pregnancy, lactation, climax)
■ Psychic trauma, craniocerebral trauma
■ Excessive insolation
■ The intake of large doses of iodine
■ Acute and chronic infections
Etiology and Pathogenesis.
The pathogenesis of the hyperthyroidism due to thyroid stimulating IgG 
(TSH-R AB, antithyroglobulin, antimicrosomal Ab’s) that bind to the TSH re­
ceptor in thyroid cell membranes which increase secretion of thyroxine and trii­
odothyronine by thyroid. No direct correlation between serum concentration of 
Ab’s and serum thyroid hormones.
■ Autoimmune disorder due to a defect in T-suppressor cells
■ B-lymphocytes produce thyroid stimulating immunoglobulins di­
rected against TSH receptor that mediate thyroid stimulation.
Clinical Features
There are actually three distinct parts of Graves’ disease:
1. Hyperthyroidism : overactivity of the thyroid gland .
2. Ophtalmopathy : autoimmune inflammation of the tissues 
around the eyes causing swelling .
3. Pretibial myxedema : thickening of the skin over the lower
legs .
In the degree of severity hyperthyroidism is classified as mild, moderate 
and severe.
Symptoms and Signs
■ Merzerburg’s triad : diffuse , symmetric, soft, smooth , nontender 
goitre, Ophthalmopathy/exophthalmos, tachicardia
■ Dalrimpl’s syptom: stare, sparkl glare glance, exophtalmos
■ Graefes’ sign : is lagging of the upper lid behind the globe when the 
person fixes his gaze on some slowly descending object; as a result, a white strip 
of the sclera is seen between the upper lid and the iris.
■ Kochers’ sign: is explained by the increased retraction of the upper 
lid, due to which a white strip of sclera appears between the upper eyelid and iris 
when the patient fixes his gaze on an object moving up.
■ “Thyrotoxic heart”: severe tachycardia/atrial fibrillation, enlarge­
ment of the heart or dilated cardiomyopathy, heart failure.
■ Ophtalmopathy: proptosis (exophtalmos) , lid lag ,lid retraction , 
diplopia (double vision), characterictic stare , conjnctival injection
■ Dermopathy: pretibial myxedema peau d’orange-like thicken­
ing and redness at anterolateral shin due to lymphocytic infiltrate
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■ Onycholysis, acropathy(elephant skin), swelling and clubbing in 
extremities (improves with topical glucocorticoid with nocturnal plastic occlu­
sive dressing)
Most people with Graves’ disease have no obviose eye involvement. Their 
eyes may feel irritated or they may look like they are staring. About one of 20 
people with Graves’ disease will suffer more severe eye problem, which can in­
clude bulging of the eyes, severe inflammation, double vision, or blurred vision. 
If these serious problems are not recognized and treated, they can permanently 
damage the eyes and even cause blindness. Thyroid and eye involvement in 
Graves’ disease generally run a parallel course with eye problems revolving 
slowly after hyperthyroidism is controlled.
Fig. Dalrimpl’s syptom: stare, sparkl glare glance, exophtalmos
Fig. Graefes’ sign (left) and Kochers' sign (right).
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Fig .Pretibial mixedema
Diagnosis
■ Physical examination
■ Suppressed TSH
■ Increased T4, free T4 and free T4 index
Treatment
- Medical therapy (“antithyroid” or “thyrostatics drugs”)
- Radioactive 131J therapy
- subtotal thyroidectomy
Drugs
Thiourea drugs:
- methimazole, propylthioracil, iodide agents.
Action
- inhibit thyroid hormone synthesis
Methimazol: orally in initial doses of 30 -60mg once a day duration 3-6 
weeks, orbital radiation: surgical decompression and as the free thyroxine level 
becomes normal (5-10 mg orally once a day or 5-10 mg methymazol + 50 mkg 
levothiroxine orally once a day, 1-2 years).
Indication
- young adults
- patients with mild thyrotoxicosis
- small goiters
- fear of isotopes
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- preparing hyperthyroid patients for surgery and elderly patients for ra­
dioactive iodide treatment
Side-effects and complications
- pruritus, allergic dermatitis
- nausea, dyspepsia
- agranulocytosis (control white blood count and stop methymazol- 
therapy)
- sore throat and febrile illness,
- onset is generally abrupt
- posttreatment primary hypothyroidism
- high rate of recurrent hyperthyroidism (about 50%, patients with thyro- 
peroxidase and thyroglobulin antibodies remain high after 2 years of therapy)
Propylthiouracil in initial doses of 100 -150mg daily in four divided dos­
es duration 3 - 4  weeks. The dosage is generally reduced as a manifestation of 
heperthyroidism resolve and as the free thyroxine level becomes normal (50 - 
100 mg orally once a day +50 mkg levothiroxine orally once a day, 1-2 years).
Side-effects and complications
- arthritis
- lupus erythematosus
- aplastic anemia, thrombocytopenia, hypoprothrombinemia
- acute hepatitis
- Such complications as acute hepatitis and agranulocytosis/ aplastic ane­
mia, thrombocytopenia, hypoprothrombinemia is administration with predni­
sone treatment.
Iodide contrast agents:
iopanoic acid (Telepaque), ipodate sodium (Bilivist, Oragrafin). Lu- 
gol’s solution (10 drops 3 times daily orally).
Treatment periods of 8 - 10 months, but efficacy tends to wane 
with time.
Action
- inhibit peripheral 5’-monodeiodination of thyroxine, thereby blocking 
its conversion to active T3.
Indication
- severe thyrotoxicosis
-thyrotoxic “storm”
- thyroxine overdosage
- subacute thyroiditis
- amiodarone-induced thyrotoxicosis
- intolerant to thioureas
- newborns with thyrotoxicosis
Symptomatic treatment
Beta-blockers
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Propranolol -10 -80mg
- orally a day under the pulse and BP control. Initial doses lOmg orally 
and increased progressively until an adequate response is achieved.
- Athenolol 50 - lOOmg orally a day.
- Methoprolol 50 -  150mg orally a day.
It effectively relives the tachycardia, tremor, anxity, diaphoresis, periodic 
parslysis. Propranolol is available in a long-acting formulation that provides 
more consistent relief.
Treatment of Ophthalmopathy:
- Prednisone 60- 80 mg orally a day for 3-4 weeks or retroorbital injec­
tion 1 time a day. The dosage is generally reduced as a manifestation of ophtal- 
mopathy
- Orbital radiation
- Surgical decompression
Therapeutic option:
- severe cases of ophtalmopathy;
- Note that propilthiouracil or methimazole may worsen ophthalmopathy. 
Cessation of the smoke. Smoking increasees the risk of having a flare in
ophtalmopathy following 131J treatment and also reduces the effectiveness of 
prednisone treatment.
Treatment of cardiac complication (“thyrotoxic heart”)
- Digoxin is treated atrial fibrillation and heart failure
- Diuretics i/v (furosemid)
- beta-blockers (propranolol,) -80 120 mg orally a day
- Standart antianginal therapy, if angina pectoris present
- Anticoagulation therapy for prevent arterial thromboembolism in thyro­
toxicosis-induced atrial fibrillation ( 0,325mg aspirin orally tonight)
Radioactive Iodine (1 3 1J) Therapy 
Indication
■ Non effective medical therapy
■ Elderly patients
■ Patients with coronary disease
Radioactive iodine therapy not be given to pregnant women 
Complication
- hypothyroidism: L-T4 lifelong therapy with measurements of free T4 
and TSH when indicated.
Thyroid surgery: subtotal thyroidectomy 
Indication
■ Toxic nodular goiter
■ Pregnant women
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■ Significant chance of malignancy
■ Very large goitre
Complications
- hypothyroidism: L-T4 lifelong therapy with measurements of free T4 
and TSH when indicated.
4.Thyrotoxic crisis (“storm”)
Definition
This disorder is an extreme form of thyrotoxicosis.
■ It is a severe state of uncontrolled hyperthyroidism
■ Occur with stressfull illness, infection, trauma, surgery in hyper­
thyroid patient, radioactive iodine administration
Clinics
■ Hyperthyroidism
■ Vomiting, diarrhea, dehidration
■ Very high fever, often with dry skin
■ Severe tachycardia, arrithmia, congestive heart failure, pulmanary
edema
■ Mental status changes ranging from delirium to coma
Laboratory
■ Increased T3,T4,undetectable TSH
■ +/_- anemia, leukocytosis, hypercalcemia
Treatment
Initiate promt therapy, don’t wait for confirmation from laboratory find­
ings
■ Thiourea drugs: propylthiouracil 150-250 mg every 6 hours, or me- 
thimazole, 15-25 mg every 6 hours.Ipodate sodium (500mg/d orally if begun 1 
hours after the first dose of thiourea
■ Iodine to inhibit release of thyroid hormone :iodine is given 1 hours 
later as Lugol’s solution (10 drops 3 times daily orally) or as sodium iodine (lg 
intravenously slowly).
■ Hydrocorttisone to block peripheral conversion and to lower body 
temperature:50mg every 6 hours
■ Propranolol 0,5-2 mg intravenously every 4 hours or 20 -120 mg 
orally every 6 hours
■ Aspirin is avoided since it displaces T4 from thyroid-binding globu­
lin, raising free T3 serum levels
■ Fluid and electrolyte maintenance, vasopressors as indicated
93
Definitive treatment with 131J or surgery is delayed until the patient is eu­
thyroid.
5. Other less Common Causes of Hyperthyroidism
l.Toxic Nodule
- may be single or multiple nodules
- autonomous thyroid hormone production, may arise from a nodule in a 
multinodular goitre
- occurs in a elderly patients
- not associated with infiltrative ophthalmopathy or dermopathy.
- thyroid function tests mandatory; TSH-R - Ab negative 
-most small thyroid nodules are asymptomatic 
-Scanning techniques: uptake of 123J, ultrasonogram
- be treated : propanolol, surgery or radioactive iodine therapy
2. Subacute Thyroiditis (DeQuervain’s Thyroiditis) (see below)
3. Struma Ovarii
- thyroid tissue is contained in about 3% dermoid tumors and teratomas.
- increase intraabdominal J131 uptake
- surgery treatment
4. Pituitary tumor (TSH Hypersecretion by the pituitary)
- caused by a pituitary adenoma or pituitary hyperplasia (know as “non- 
neoplastic inappropriate secretion of thyrotropin)
Fig. Toxic Nodule
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- TSH increase/or normal
- treatment to bromocriptine or octreotide /transfenoidal surgery or radia­
tion therapy
5. Hashimoto’s thyroiditis (see below)
6. Pregnancy and trophoblastic tumors
- occur in 5 -9% of women in the first 6 months after delivery
- may occur during the first 4 months of pregnancy
- transient hyperthyroidism results from the release of stored thyroid hor­
mone following damage to the thyroid by thyroperoxidase antibodies whose IgG 
subclasses activate the complement cascade
- high serum level of HCG may cause sufficient teceptor activation to 
cause thyrotoxicosis
- eventually return to euthyroid state, 1/3 remain hypothyroid
- treated by propranolol during the hyperthyroid phase, followed by thy­
roxine during hypothyroidism
6. Hypothyroidism & myxedema.
Definition.
Hypothyroid is the syndrome of relative or absolutely insufficiency of 
thyroid hormones by thyroid glands with complete loss of its action on the target 
organs. In the degree of severity hypothyroid is classified as mild, moderate and 
severe. Unrecognizing hypothyroid severe states is striking myxedema (“muc­
ous edema”).
Classification
Hypothyroidism may be due to primary disease of the thyroid gland it­
self or lack of pituitary TSH, congenital or acquired:
1. Primary (thyrogenic):
- post-surgical thyroidectomy or post-ablative 131J;
- autoimmune -Hachimoto’s thyroidites;
- iodine deficiency - congenital
2. Secondary (pituitary):
- insufficiency of pituitary TSH
3. Tertiary (hypothalamic):
- decreased TRH from hypothalamus
4. Peripheral tissue resistance to thyroid hormone
5.
Determienes factors, ethioiogy and pathogenesis
1. Age >50 years old
2. Hashimoto’s thyroiditis
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3. Autoimmune diseases
4. Iodide deficiency
5. Genetic thyroid enzyme defects
6. Drug goitrogenes : lithium, iodide, propilthyiouracil/methimazole,
phenylbutazone, sulfonamides, amiodarone, interferon-alfa, interleukin-2.
7. Food goitrogenes in iodidedeficient areas
8. Infiltrating diseases (cancer, sarcoidosis) due to peripheral resis­
tance to thyroid hormones
9. Hypothyroid phase in subacute viral thyroiditis following initial 
hyperthyroidism
10. Neck radiation therapy
11. Thyroidectomy
The fluid retention seen in myxedema is caused by the interstitial accumu­
lation of hydrophilic mucopolysaccharides, which leads to lymphedema. Hypo- 
natriemia is due to impaired renal tubular sodium reabsorption due to reductions 
in Na+ -K+ ATpase. Cellular proteins are also affected in myxedema.
Epidemiology
■ 2-3% of general population
ш F>M 10:1
Clinical Features
■ Slowing of mental and physical performance, slow speech, memo­
ry loss, lethargy, delayed return of deep tendon reflexes
■ Cold intolerance, hypothermia
■ Cool, dry, rough, pilling skin, yellow (carotenemic) skin color
■ Puffiness of face, per orbital edema, peripheral edema
■ Hoarseness, enlarged tongue and lips
■ Hair dry and coarse, eyebrows thinned (lateral 1/3)
■ Constipation , meteorism, hypo/achlorhydria
■ Weight change (“not true obesity”) due to pleural effusion , perito­
neal effusion cavities (intestinal edema), peripheral edemoes
■ “Myxedema heart”: cardiac enlargement, pericardial effusion , bra- 
dicardia, generalized atherosclerosis, diastolic hypertension, heart sounds dull, 
systolic murmur at the apex of the heart
■ Anemia, hyponatremia
■ Menorrahagia/ amenorrea, galactorrhea, infertility, decrease libido
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Fig. Hypothyroidism (myxedema) in a 46 years-old patient :puffiness 
of face, per orbital edema, peripheral edema ,hair dry and coarse, eyebrows 
thinned .
Fig. 50 years -old patient with hypothyroisis.Enlargment of a tongue. 
Laboratory Findings
■ T4 and radioiodine uptake low. Serum T3 is not good test 
Й TSH increased
■ Subclinical hypothyroidism:
- if TSH >10 mU/L check anthythyroid antibodies and start therapy
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- if TSH 5-10 mU/L + goitre -  check antibodies, if negative re-check in 1 
-6 months; if positive start thyroxine therapy
■ Titers of antibodies against thyroperoxidase and thyroglobin high in 
Hashimoto’s thyroiditis
■ ECG; small voltage of waves, bradicardia, decreased S-T interval 
below the base line, elongation P-Q
■ Pituitary enlargement due to hyperplasia of TSH-secreting cells by 
CT or X-ray
■ Increase serum cholesterol, liver enzymes, creatine kinase, hypona- 
triemia, hypoglycemia
Treatment
1. Levothyroxine (L- T4): (dose range usually 0.05 - 0.2mg/kg/day) 
under the monitor TSH is in the middle of its normal range. Brand preparations 
of levothyroxine in the world appear to be bioequivalent to each other and cer­
tain genetics (Euthyrox, Levoxine, Levothroid). Take on empty stomach.
- Initial doses elderly : 12,5 -  25 ug/ day ; with cardiac problems start 
12,5 ug/day and increase gradually
- Initial doses age 30 -60 : 75 -100 ug/day
- Lifelong therapy
Side-effects
- tachycardia, arrhythmias
- tremor, anxity
- diarrhea, cramps
Contraindication
- acute infarct myocardial, thyrotoxicosis
2. T4 + T3 combination (Liothyronine, Liotrix) ratio of 10:1. This 
combination has been improve mood and neurophysiologic function compared 
to T4 alone.
3. Liothyronine (Cytomel) 25 ug twice a day. Synthetic T3,short half 
life, lots of peaks and valleys throughout the day.
4. Liotrix (Thyrolar) : 20 mg/daily. Combination of synthetic T4 
(1 OOmg) + T3 (25 ug)
Complications of hypothyroidism
1. Increase susceptibility to infection
2. Megacoion in long-standing hypothyroidism
3. “Myxedema coma”
4. “Myxedema madness” -organic phychoses with paranoid delusions
5. Infertility
6. Hypoventilation, hypoxia, hypercapnia
7. Hypotention.
98
7. Hypothyroid (myxedema) coma.
Definition
Most severe complication of hypothyroidism. It is a rare syndrome usually 
seen in an elderly female with longstanding hypothyroidism.
Determienes factors
1. Longstanding unrecognized hypothyroidism
2. Severe infections (pneumonia)
3. Surgery,
4. Stroke
5. Trauma, castrointestinal bleed
6. Drugs : narcotics, sedatives, diuretics
7. Cold exposure, hypotermia
Clinics
■ Hypothyroidizm, stupor, hypoventilation, hypothermia, bradicardia, 
hypertention
■ Decreased T3 and T4, increased TSH, decreased glucose
■ Check ACTH and cortisol for evidence of adrenal insufficiency
Treatment
■ Cortiosteroids (due to the possibility of concomitant adrenal insuf­
ficiency) lOOmg bolus, folloved by 50 mgi/v D
■ L-T4 0,2 -  0,5 mg (400ug) i/v loading dose, then 0,1 mg (100 ug) 
i/v or BID untill oral therapy tolerated
■ Correct hypoventilation (intubation)
■ T3 1 OOmg i/v daily then 25mg BID
■ Fluid and electrolyte correction.
8. Hashimoto’s thyroiditis
Definition
Hashimoto’s thyroiditis or autoimmune thyroiditis is an autoaggressive 
with lymphoid and plasmocytic infiltration of thyroid gland by thyroid antigens.
Patients develop hyperthyroidism as a result of release of stored thyroid 
hormone during severe Hashimotoe’s thyroiditis.
Two variants of Hashimoto’s Thyroiditis :
1. Goitrous: presents with a euthyroid /or hypothyroid goiter.
2. Atrophic: hypothyroid state and atrophic gland 
Ethiology and Pathogenesis
■ Genetic predisposition/associated with HLA В8/ HLA DR3
■ More common in female of middle age, F : M = 17 :1
■ Defect in clone of T-suppressors leads to cell-mediated destruction 
of thyroid follicles
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■ B-lymphocytes produce antithyroglobulin and anthythyro perox­
idase (anti-TPO or antimicrosomal antibody)
■ Hypothyroidism or a euthyroid state, increased TSH compensatory; 
followed by decreased free T4 and eventually decreased free T3
■ Antimicrosomal and anti-thyroglobulin antibodies
Clinical picture
- Develop gradually
- No complaints or weakness may be present
- In severe cases attended by thyrotoxicosis
- Goitrous form usually presents with a rubbery goiter and euthyroidism, 
then hypothyroidism becomes evident
- If thyroid very firm and enlarged, patient complain of pressure of the 
neck and sometimes difficalty in swalloving (compression symptoms)
- Thyroid gland not painful, mobile
- Atrophic variant patient are hypothyroid from start
- Associated with thyroid lymphoma
Laboratory finding
- TFT reveals hypothyroidism, or a euthyroid state with a compensatory 
increase in TSH; followed by decreased free T4 and eventually decreased freeT3
- Antimicrosomal and anti-thyroglobulin antibodies
Treatment
■ Treated according thyroid status
■ If hypothyroid, replace with L-thyroxine 1,6 -1,8 mkg/kg/daily , 
start by initial dose 25 mkg orally daily
■ If euthyroid, also treat with L-thyroxine if significant anti-thyroid 
antibody present.
9.Subacute thyroiditis.
Definition.
Subacute thyroiditis is acute inflammation of the thyroid, probably viral in 
origin, characterized by giant cells and lymphocytes.
Ethiology and Pathogenesis
■ Viral infection (epidemic parotitis, meals, rubella, grip,etc)
■ Often preceded by upper respiratory tract infection (URTI)
■ F:M =7:1, ages 30-50
■ Disruption of thyroid follicles by inflammatory process results in 
the release of stored hormone
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Clinical picture and laboratory finding
■ Pain worse to turn heard, swallow, may radiate to ear, jaw or chest
■ Hyperthyroidism is followed by hypothyroidism
■ Symptoms mimic a manic episode such as that the diagnosis missed
■ Thyroid gland enlarged and tender
Two forms of subacute thyroiditis:
1. Painful tender thyroid (“DeQuervain’s’Thyroiditis); 
* Acute onset with fever, pain in the neck with the turn of the head, swallow­
ing, cough; pane radiates to jaw, occiput, ears.
2. Painless untender (‘Silent”) thyroid; symptoms mimic
■ thyrotoxicosis stage duration 1 -2 months
■ During thyrotoxicosis thyroid radioiodine uptake is low
■ Lab: WBC elevated without leukosytosis, < ESR, <thyroglobulin, 
<or> TSH,< T4,T3
T reatment
- Prednisone 30 -60mg/daily with a gradual reduction by 5 to 2,5 mg 
every 10 days under the WBC control
- Symptomatic treatment: beta-blockers (propranolol,) -10 -80mg 
orally a day under the pulse and BP control. Initial doses lOmg orally and in­
creased progressively until an adequate response is achieved. - Athenolol 50 - 
lOOmg orally a day. - Methoprolol 50 -  ISOmg orally a day.
- Ipodate sodium or iopanoic acid 500mg orally daily promptly corrects 
elevated T3, continue for 15 -60 days until free T4 normalize
- ASA can be used for painful form (increases peripheral conversion) for 
3-5 months
- If symptomatically hypothyroid may treat short-term with thyroxine
10. Thyroid nodules and thyroid cancer.
Thyroid nodules
Nodular (irregular) goitre is a common term which refer all formation 
which more then 10 mm in a volume detectible by palpation or other visual me­
thods. It is clearly defind discrete mass, separated from the thyroid parenchyma.
Ethiology
iodine deficiency
family history of goitre
F:M = 7:2 ; suspicious -19%, malignant -4%
If less then 1,5 cm volume of nodules usually benign
Classification
101
benign tumors: follicular adenoma (adenoma may produce thyro­
toxicosis)
thyroid cancer
hyperplastic area in a multinodular goiter
cystic nodule : true thyroid cyst, area of cystic degeneration in a 
multinodular goiter. Less then 4 cm with serous fluid usually benign.
thyroid incidentalomas: nodules not palpable on examination, but 
detected on imaging study for another purpose (size <lcm volume)
Clinics
small thyroid nodules asymptomatic
large nodular goiter become a cosmetic embarrassment, caused dis­
comfort, dysphagia, hoarseness
Pemberton’s sign: large substemal goiters caused superior vena ca­
va syndrome (facial erythema and jugular vein distention that progress to cyano­
sis, facial edema when both arms are kept raised over the head)
Diagnosis
fine needle aspiration (FNA): read by an experienced cytopatholo- 
gist (benign or malignant). Two or more biopsies may be obtained, 
thyroid function test 
ultrasound investigation
thyroid scan : minimal 131J uptake into nodule is “cold” nodules. 
15 -20% of its are maligmant.; very low malignant potential if warm or “hot” 
(significant 131J uptake into nodule).
High index of suspicion
firm, fixed with cervical nodes higher>2 cm 
hoarseness, vocal cord paralysis, enlarged lymph nodes 
young adults 
men
increase growth higher>0,5 cm per 6 months by ultrasound 
solitary (single or dominant) 
therapeutic radiation of head, neck, or chest 
ultrasound signs: irregular margins, intranodular vascular spots, mi­
crocalcification
cyst with bloody fluid or if reaccumulates
Treatment
1. Medical therapy.
2. Surgery
3. Ultrasound guided ethanol injection
4. Radioiodine 131J
5. Photocauterization
1. Medical therapy: Levothyroxine treatrnent(“suppressive Levo- 
thyroxine treatment”)
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Indication
TSH increase /normal - “suppression” 0,05 -0,1 mg daily x 6
months
TSH low (indication of autonomus thyroid secretion)- L-T4 inef­
fective and liable to cause clinical thyrotoxicosis , L-T4 should be not admini­
strated.
Most suitable for younger for larger nodules >2 cm 
Side-effects
small loss of bone density
Patients at risk for osteoporosis are advised to have periodic therapy for 
osteoporosis.
Contraindication
thyroid incidentalomas (nonpalpable thyroid nodules)
cyst
small nodules less 1cm
certain cardiovascular disorders (angina pectoris, arrhythmia)
2. Surgery 
Indication
if growing nodule 
compressive symptoms 
if “cold” nodule and high clinical suspicion 
microfollicular adenoma if non-autonomas 
macrofollicular nodule 
large retrosternal goitre
3. Ultrasound guided ethanol injection 
Indication
autonomous nodule
cystic nodule; cystic nodules yielding serous fluif are usually be­
nign, but fluid should be submitted for cytology 
macrofollicular nodule 
toxic nodule
2. Radioiodine 131J therapy 
Indication
- autonomus nodule
- toxic nodule
- multinodulat toxic goitre
The great majority of thyroid nodules are benign. Conversion to a malig­
nant nodule is rare. Patients with small nonpalpable thyroid nodules are at very 
low risr for malignancy, and even those are malignant have a minor effect on 
morbidity and mortality.
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Multinodular goires tend to persist or grow slowly.The prognosis for pa­
tients with thyroid nodules that prove to be malignant is determined by cytology
All patients with benign irregular goitre need to be followed by regular 
periodic palpation of the thyroid gland (one time 3 months), ultrasound exami­
nation (one time 6 months), and rebiopsied one time a year or if growth nodule 
occurs.
Thyroid cancer
Thyroid cancer is diagnosed about 40 per million population. Most thyro­
id cancers remain microscopic and indolent. Those cancers that do become ag­
gressive often have mutations in the p53 tumor suppressor gene or the ras and 
gsp oncogenes.
Determines factors 
increases in age 
F:M=3:1
External x-ray treatment to the neck/head during childhood 
Childhood exposure to radioactive isotopes of iodine in nuclear fal­
lout (Chernobyl accident, Nagasaki accident) 
familial (3%)
associated with multiple hamartomas of the skin and mucous
membranes
associated with breast cancer or adenomatous poliposis coli
Classification
Thyroid cancer is either parafollicular (medullary) or follicular (papillary, 
follicular, anaplastic). Most present with a thyroid mass and cervical lymphade- 
nopathy.
1. Papillary carcinoma is the most common thyroid malignancy.
Remember the P’s (R.Silver, J.Shin, 2002): -
- Papillary: well-differentiated
- Popular : the most common thyroid malignancy: seen more commonly 
in younger patients, associated with radiation exposure
- Psammoma: multicentric, some follicular components histologicaly
- Palpable nodes and usually metastasizes to regional lymph nodes first
- Positive Prognosis: lifespan not affected if confined to one lobe and <
2cm
- Positive 131 I uptake
2. Follicular carcinoma
Remember the “F’s (R.Silver, J.Shin, 2002) :
- Female
Follicular :more aggressive then papillary
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Far away metastases : angioinvasive, spreading to lung, bones, dis­
tant sites without lymph node involvementHurtle cell cancer is aggressive va­
riant of this cancer with frequent pulmonary metastases 
FNA biopsy not diagnostic 
Favourable prognosis
3. Anaplastic carcinoma, 
old age
rapidly progressive 
poor prognosis
4. Medullary carcinoma.
Remember the M”S (R.Silver, J.Shin, 2002):
Medullary: worse prognosis than papillary or follicular cancer 
Men -  associated with multiple endocrine neoplasia (MEN) Ha or 
lib, high familial aggregation
aMyloid; may produce calcitonin, ACTH, serotonin, prostaglan­
dins, kallikrein, bradikinin (these substances can be used as tumor markers) 
Median node dissection
5. Lymfoma.
seen in the context of a nodule or an enlarging goitr in a patient 
with Hashimoto’s thyroiditis 
Diagnosis 
FNA
Treatment: surgery, radiation, chemotherapy 
Surgery
1. Total thyroidectomy
2. Subtotalthyroidectomy for adults under age 45 who have a single tumor 
less then 1 cm in diameter
2. Nodal dissection 
Complication
1. Airway problems
2. Hypoparathyroidism: tetany
3. Recurrent laryngeal nerve damage
4. Hypothyroidism 
Adjuvant therapy
1. Thyroxine is prescribed in dose of 0,05 -  0,1 mg daily immediately 
postoperatively (suppressed TSH ) long-term treat.
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Chapter VII. Diseases of the Parathyroid Gland.
Anatomy
The parathyroid glands are small endocrine glands.
Lie closely to the posterior surface of the thyroid
Usually represented by two pairs.
The superior pair is located on the borderline between the superior 
and median thirds of the thyroid at the level of the cricoids cartilage.
The inferior pair is located at the inferior pole of the thyroid.
In some cases may be located in the tissue of the thyroid, the thy­
mus.
Sizes 0,6 x 0,3 x 0,15 cm, weight is about 0,05 -0,3g.
Secreted parathormone (PTH)
Effects of the parathormone
Regulated the constant content of phosphorus-calcium metabolism 
together with thyrocalcitonin, a hormone of the thyroid gland.
Under the influence of the parathormone the blood calcium content 
rises, and under the effect of the thyrocalcitonin diminishes.
Regulation
Is mainly autoregulating and depends on the content of calcium in
the blood.
ACTH, glucocorticoids,the growth hormone,'T4, andro­
gens,oestrogens, vitamin D also participate in the regulation of phosphorus- 
calcium metabolism. Unlike the parathormone ,this hormones produce a hypo- 
calcaemic effect.
Vitamin D intensifies the absorbtion of calcium and phosphorus in 
the intestine and also augments the reabsorption of phosphorus in the kidney.
Role of Calcium
It reduces the excitability of the peripheral nervous system and 
permeability of cell membranes.
Is plastic material for the formation of bone tissue. The amount of 
calcium in the bone tissue amounts to about 95-99% of its contain in the body.
It participates in regulating blood coagulation.
The daily requirement of calcium in adults is 0,5- l,0g.
The total content of calcium in the blood -s  2,4 -2,9 mmol/L (9,6 - 
11,6 mg/dL).
The total content of phosphorus in the blood is 3,2 -4,8 mmol/L (10
-15 mg/dL).
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Definition
Hyperpathyroidism is caused by hyperproduction of the parathormone 
(PTH) and characterized by pathological changes first of all in the bones and 
kidneys.
Epidemiology
-Age 20 -50 years old
- w > m
Ethiology
-A single or multiple adenomas or hyperplasia of the parathyroid glands.
- The causes of the formation of adenomas remain unknown.
Pathogenesis
Overproduction of PTH has a direct effect on the bones
Increased activity of osteoclasts which discharge citric acid
Local acidosis causes mobilization of phosphate and calcium from 
the bones and their passage into the blood.
Impoverishment of bone tissue in calcium and phosphate causes its 
cystic reorganization, replacement of destroyed bone tissue with fibrous tissue, 
osteomalacia, ffractures of the bones.
PTH inhibits the reabsorption of phosphorus in the renal tubules, 
which results in its intensified excreation in the urine and low concentration in 
the blood.
Compensatory flow of inorganic phosphorus compounds from the 
bones into the blood.
By inhibiting the secretion of calcium by the kidneys excess PTH 
induces hypercalcaemia.
Promotes nephrocalcinosis and nephrocalculosis.
Hypercalcaemia and hupercalciuria inhibit ADH, which results in 
polyuria with eventual polydipsia.
Classification
1. Primary Hyperpathyroidism (Recklinghausen’s disease):
- Autonomous secretion of PTH by parathyroid.
- Serum calcium and PTH are raised.
- Causes -  single adenoma, multiple adenoma, nodular hyperplasia and 
carcinoma.
Primary hyperpathyroidism secondary to a parathyroid adenoma may be a 
part of multiple endocrine neoplasia syndrome :
MEN1 (Werner’s syndrome): tumors of pituitary, pancreas and parathyro­
id glands. Other abnormalities seen include Zollinger-Ellison syndrome.
MEN2A: phaeochromocytoma,medullary carcinoma of thyroid as well as 
hyperpathyroidism.
1. Hyperparathyroidism.
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MEN2B has additional multiple neuromas but hyperpathyroidism is not 
present
2. Secondary Hyperpathyroidism
- Parathyroid hyperplasia with increased PTH secretion in an attempt to 
compensate for prolonged hypocalcaemia.
- Serum calcium is low, PTH raised.
- Causes -  chronic renal failure, malabsorption, osteomalacia and rickets.
3. Tertiary Hyperpathyroidism
- Adenoma formation and autonomous PTH secretion occurring in cases 
of secondary hyperparathyroism.
- Serum calcium and PTH are raised.
Symptoms and signs 
Non-specific symptoms
Anorexia, nausea, vomiting, constipation 
Peptic ulceration
Hypertension, tachycardia, arrithmia 
Myopathy
Weight loss, weakness, lassitude and tiredness 
Drowsiness, poor concentration, depression, memory loss.
Skeletal manifestations:
Bone pane, fractures and deformity due to osteitis fibrosa and ostei­
tis fibrosa cystic.
Localised bone swelling, especially of the mandible.
Denerative arthritis and attacks of acute pseudogout, especially of the 
knee joints, due to chondrocalcinosis affecting the menisci 
Renal manifestation
Polyuria and polydipsia 
Recurrent calculus formation
Deposition of calcium salts in the renal parenchyma -  nephrocalci-
nosis
Impairment of renal function with uraemia, hypokalaemia, hyper- 
uricaemia, hyperchloraemic acidosis and dilute urine.
Calcification of arterial walls and soft tissues of hand 
Corneal calcification, best seen by slit-lamp examination 
Laboratory finding
Raised serum calcium and raised PTH.
Serum phosphate low 
Raised serum chloride
Serum alkaline phosphatase may be raised depending on the degree 
of bone involvement 
ECG
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Shortened QT interval 
Cardiac arrhythmias 
X-Ray examination
Nephrocalcinosis
Demineralisation and subperiostal eosions of phalanges, most 
marked on the radial side of middle phalanx.
Resorption of the terminal phalanges.
Diffuse osteoporosis of long tubular bones, cranium. Cysts are lo­
cated near epiphises of long tubular bones
“Peper-pot” appearance of the skull on lateral view.
Soft tissue calcification
DEXA (dual-energy X-ray absorptiometry) and CT scan reduced 
bone density.
Visual diagnostics for localization of the tumor 
Ultrasonography
Selective neck vein catheterization with PTH measurements 
CT scanning and subtraction imaging 
Treatment
Ademoma is treated by surgical removal
Hyperplasia is treated by removal of all four glands and transplanta­
tion of some of the excised tissue to the forearm.
Prognosis
In operative treatment is usually favourable.
Without operative treatment patients with primary hyperparathy­
roidism become invalids and die from mounting cachexia and renal failure.
2.Hypercalcaemic Crisis
Definition
Hypercalcaemic crisis is acute calcium intoxication of the body asso­
ciated with hyperproduction of 3EP to lead to rapid and abrupt rise in the blood 
calcium to critical values -  3,5 -  4,25 mmol/L.
Seen in elderly patients with primary hyperparathyroidism.
The pathogenesis is not clear enough.
Clinical picture
Develops abruptly but sometimes gradually 
Temperature rises to 40oC 
Anorexia, thirst, nausea, vomiting
Abdominal spastic pain that can simulate acute appendicitis, can be 
attended by gastric haemorrhage, acute pancreatitis, ulcer perforation 
Muscular weakness, pain in the joints and muscles 
Somnolence, pyrexia and altered conscious level
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Renal form of hypercalcaemic crisis is characterized by the clinical 
picture typical for acute renal insufficiency or uraemic coma 
Dehydration 
Hypotention, collapse 
Leucocytosis, accelerated ESR, anaemia 
Proteinuria
ECG may show AV block, prolonged PR interval and QRS, bundle 
branch blocks and shortened QT interval.
Laboratory Findings
hypercalcaemia is considered mild if the total serum calcium level 
is between 2,6 -  3 mmol/1 (10,5 -  12 mg/dL )
hypercalcaemia is considered severe if the total serum calcium level 
is above 14 mg/dL 
T reatment
In mild hypercalcaemia < 12mg/dL simple oral hydration along 
with increased salt intake is sufficient.4-6 litres of 0,9% saline I/V over 24 
hours.
Diuretics : furosemide 40 -160 mg/day or ethacrynic acid 50 -200 
mg/day -  after correction of volume.
Forced diueresis with 4-6 litres of I/V fluid per day and furosemide 
2 hourly.Sodium, potassium and magnesium
Salmon calcitonin 200 -400 IU subcutanrusly 8 hourly for 24 hours. 
Mithramycin 25 mcg/kg I/V over 6 hours for 3-8 days.
Neutral phosphate (0,1 M) 500 mL 1/V over 6-8 hours. 
Corticocteroids : Prednisolone 5-15 mg 6 hourly orally or hydrocor­
tisone 50-100 mg I/V , hourly.
Bisphosphonates : oral phosphate 250 mg 6 hourly.
Indomethacin 25 mg 6 hourly orally.
Haemodialysis with a low-Ca bath 
Prognosis
Depends on timely diagnosis and treatment 
Mortality reaches 65%.
3. Hypoparathyroidism.
Definition
Hypoparathyroidism or tetany is caused by insufficient production of 
PTH and is characterized :
The common clinical manifestation is tetany.
Serum calcium is low (hypocalcaemia) and serum phosphate high. 
Ethiology
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The disease may be caused by:
The accidental removal of the parathyroid glands in resection of the
thyroid.
Inflammatory processes in parathyroid glands (tuberculosis, amy­
loidosis, measles).
Trauma.
Congenital insufficiency.
Autoimmune processes.
Malignant metastases
Radioactive iodine therapy used in the management of toxic goitre 
Pathogenesis 
PTH deficiency leads:
To the reduced passage of calcium from the bone tissue into the
blood.
Increased phosphorus reabsorption in the proximal parts of the renal
tubules.
To cause hypocalcaemia and hyperphosphatemia.
Hypocalcaemia gives rise to the imbalance between the ions of so­
dium and potassium, calcium, magnesium, which, in its turn, sharply stimulates 
neuromascular excitation.
Classification
Postoperative hypoparathyroidism.
Congenital hypoparathyroidism.
Idiopathic hypoparathyroidism.
Pseudohypoparathyroidism (resistance to PTH).
Symptoms and signs
According to the clinical course, acute, chronic and subclinical forms of 
hypoparathyroidism are distinguished.
Chronic form of hypoparathyroidism .
In congenital or idiopatic hypoparathyroidism.
In spring and autumn.
Cold hands and feet.
Numbness’ gooseflesh, parastesia and feeling of spasms.
Painful tonic spasms which affect symmetrical groups of muscles 
and are selective character.
Trophic disorders: brittle and reedy nails, defects of the teeth, ca­
ries.
Cataract, focal or total baldness, early appearance of grey hair. 
Episodes of migraine, angiana pectoris bronchial asthma.
Illnesses of the genitor-urinary system .
Il l
Diagnostic tests
Chvostek’s sign is manifested by tapping the facial nerve in front of 
the tragus of the conha auriculae with a finger or percussion hammer.This sign 
may be of the I,II,III degree. Chvostek II and Chvostek III are usually detected 
in the latent form of the disease.
Chvostek I imuscle contraction of the entire region innrvated by the 
facial nerve is characteristic of obvious tetany.
Chvostek II: muscular contraction occurs in the region of the wing 
of the nose and the comer of the mouth.
Chvostek III: contraction of just the muscle of the comer of the
mouth.
Trousseau’s twitching is detected by applying a rubber tourniquet 
or rubber cuff compressing the patient’s arm till the pulse disappears for two to 
tree minutes.
Schlesinger’s sign is demonstrated by the rapid passive flexing of 
the patient’s leg at the hip joint when it is extended at the knee joint.In latent te­
tany the extensor muscles of the hip contract convulsively with extreme supina­
tion of the foot.
Erb’s sign: contraction of the muscles of the limbs under the effect 
of galvanic current even of the small intensity.
Laboratory
Hypocalcaemia, hyperphosphataemia
ECG lengthening of the Q-T wave 
Treatment
In the acute phase, calcium chloride 10% - 20 ml W  slow.
Substitution therapy is provided by alfacalcidol or calcitriol, both at 
a dose of 0,25 -2 mg/day.
4. Tetany crisis. (Acute form).
The bout of spasms may last from several minutes to several hours, some­
times several times a day or week.
Causes
Infections 
Psychic trauma 
Overcooling or overheating 
Symptoms and signs
Consciousness may be present or lost in severe cases
“Fish’s mouth”, a sardonic smile
Trismus -spasms of the masticatory muscles of the jaw.
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“Accoucheeur’s hand” -  a characteristic position of the hand .The 
fingers are flexed and bent to the palm slightly, the thumb is flexed, the hand 
bent at the wrist joint.
In spasm of the muscles of the lower extremities the thighs and 
shins are stretched out, the feet turned inward, the toes flexed.
Opistothonus; spasm of the muscles of the back causes the trunk to 
be bowed foreward.
Sharp disorders of respiration: result of the convulsive contractions 
of the intercostals muscles, muscles of the abdomen and diaphragm.
Laryngospasm, which can leads to asphyxia and fatal outcome.
Pyloric spasm, diarrehoea, polyuria
Tachicardia
Hypertention
Acute psychosis
Brain oedema, extrapyramidal symptoms.
diagnostic tests
Chvostek’s sign is manifested by tapping the facial nerve in front of 
the tragus of the conha auriculae with a finger or percussion hammer.This sign 
may be of the I, II, III degree. Chvostek II and Chvostek III are usually detected 
in the latent form of the disease.
Chvostek I: muscle contraction of the entire region innrvated by the 
facial nerve is characteristic of obvious tetany.
Chvostek II: muscular contraction occurs in the region of the wing 
of the nose and the comer of the mouth.
Chvostek III: contraction of just the muscle of the comer of the
mouth.
Trousseau’s twitching is detected by applying a rubber tourniquet 
or robber cuff compressing the patient’s arm till the pulse disappears for two to 
tree minutes.
Schlesinger’s sign is demonstrated by the rapid passive flexing of 
the patient’s leg at the hip joint when it is extended at the knee joint.In latent te­
tany the extensor muscles of the hip contract convulsively with extreme supina­
tion of the foot.
Erb’s sign: contraction of the muscles of the limbs under the effect 
of galvanic current even of the small intensity.
113
Fig. “  T ro u sseau ’s sy m p to m .
Laboratory
Hypocalcaemia, hyperphosphataemia 
ECG lengthening of the Q-T wave
T reatment
Slow I/V 20ml of 10% solution of calcium gluconate 
If tetany is not relieved, administration of the magnesium 
Persistent vomiting is treated with 1/V isotonic saline and potas­
sium.
In alkali excess, their withdrawal and if nessesary, ammonium chlo­
ride 2g 4 hourly will control tetany.
Prognosis
In timely and correct replacement therapy is favourable 
In the occurrence of laryngospasm is very serious : death from asphyxia
Chapter VIII. Diseases o f the Adrenals.
Anatomy
The adrenals are a paired, vital organ of internal secretion:
■ two small structures situated one a top each kidney.
■ Weight 10 -  20 g
■ Length 40-60mm, width 20 -35mm,thickness 6-10mm 
Adrenal glands consist of two distinct regions:
■ Of a yellow outer -the adrenal cortex, which surrounds
■ and an inner layer -the adrenal medulla, which has a reddish-brown
tinge
The adrenal cortex secreted 3 classes of steroid hormons:
■ Mineralocorticoids (aldosterone) from zona glomerulosa (outermost 
layer=“salt”).
■ Glucocorticoids (cortisol) from zona fasciculate (middle 
layer=“sugar”)
■ Adnrogens (dehydroepiandrosterone sulphate, dehydroepiandroste- 
rone, androstenedione) from zona reticularis (innermost layer =“sex”).
Effects of Mineralocorticoids and Its Regulation 
Aldosterone regulates the water-salt metabolism:
■ on the kidney promoting the reabsorption of sodium ions (Na+) in 
to the blood. Water follows the salt and this helps maintain normal blood pres­
sure.
■ acts on sweat glands to reduce the loss of sodium in perspiration.
■ acts on taste cells to increase the sensitivity of the taste buds to 
sources of sodium.
The secretion of aldosterone is stimulated by:
■ a drop in the level of sodium ions in the blood.
■ a rise in the level of potassium ions in the blood.
■ angiotensin II.
■ ACTH.
Glucocorticoids effects and Its Regulation:
■ Stimulate gluconeogenesis.
■ Increase insulin resistance (diabetogenic action).
■ Increase protein catabolism.
■ Stimulate leukocytosis and lymphopenia.
■ Inhibit bone formation; stimulate bone resorption.
■ Inhibit fibroblasts, causing collagen and connective tissue loss.
■ Suprese inflammation.
■ Regulate extracellular fluid volume; promote renal solute-free water 
clearance.
Androgens effects and Its Regulation:
■ Primarily responsible for adrenarche (pubic and axillary hair).
■ in F is a major source of androgens/hypersecretion may produce a 
masculine pattern of body hair and cessation of menstruation.
■ In M excessive production can cause premature puberty.
■ Regulated by ACTH.
The adrenal medulla releases:
■ adrenaline (also called epinephrine)
■ noradrenaline (also called norepinephrine)
■ Both are derived from the amino acid tyrosine
■ Controlled by the sympathetic NS and hypothalamus 
Catecholamines effects and Its Regulation:
■ increase in the rate and strength of the heartbeat resulting in in­
creased blood pressure;
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■ blood shunted from the skin and viscera to the skeletal muscles, co­
ronary arteries, liver, and brain;
■ rise in blood sugar;
■ increased metabolic rate;
■ bronchi dilate;
■ pupils dilate;
■ hair stands on end ("gooseflesh" in humans).
■ clotting time of the blood is reduced;
■ increased ACTH secretion from the anterior lobe of the pituitary 
Adrenals Regulation
■ ACTH stimulates growth of adrenal cortex and secretion of its hor­
mones.
■ Primary control by CRH from hypothalamus.
■ Feedback inhibition by cortisol on pituitary, hypothalamus and 
CNS.
■ By sleep-wake cycle and stress.
1. Adrenal insufficiency.
Hyposecretion of the adrenal cortices hormones 
ACTH excess
Classification Adrenal Insufficiency
■ Primary (adrenal causes):
Addisson”s Disease 
Congenital
Acquired enzyme defects
■ Secondary Adrenal Insufficiency (pituitary, inadequate ACTH): 
Hypothalamic
Pituitary
Glucocorticoid therapy
■ Abrupt onset
■ Slow onset
Ethiology of the Primary abrupt onset Adrenal Insufficiency (Water- 
house-Friedrickson Syndrome)
■ Adrenal hemorrage (Waterhouse-Friedrickson Syndrome)
■ Necrosis/trombosis (sepsis, leucemia, haemophilia e.t.c.)
■ Trauma
■ Clinical presentation is acute adrenal/Addissonian crisis
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Ethiology of the Primary chronic adrenalocortical insufficiency (Ad- 
disson”s Disease).
■ Autoimmune adrenalitis (destruction of cells in the adrenal cortex)
■ Tuberculous drenalitis
■ Adrenal metastases
■ AIDS
■ Bilateral adrenalectomy
■ Drugs (ketoconazole)
Ethiology of the Pituitary Hypocorticism
■ Autoimmune hypophisitis
■ Tumor
■  Infictions
■ Trauma
■ necrosis
Symptoms and signs
Both primary and secondary chronic adrenal insufficiency characterised
by:
weakness and fatigue 
postural hypotension
- weight loss, anorexia, nausea, vomiting 
Diarrhea
Abdominal, muscle and joint pain
Syptoms and signs of Addisson’s diasease
■ Golden brown pigmentation (a dusky bronze =me!anoderma) of the 
skin and mucous membranes : palmar creases, buccal mucosa, pressure areas, 
creases, hippies, face, the folds of the palms, the dorsal surface of the hands and 
feet, postoperative cicatrices . Pigmentation marked on the open parts of the 
body: areas against which the clothes rub,the axilla and the groin, elbows, knees, 
the small of the back, skin folds, nipples of the mammary glands, the genitals.
■ Dehydration, salt craving.
■ Hypotention (systolic blood pressures under 100 mm Hg), small
heart.
■ Amenorrhea, scant axillary and pubic hair.
■ Associated with vitiligo, Hashimoto’s thyroiditis, pernicious anae­
mia, type 1 DM, primary ovarian failure and hypoparathyroidism.
■ The association of two or more of these endocrinopathies is known 
as type II polyglandular autoimmune syndrome.
■ The combination of adrenal insufficiency, hypoparathyroidism and 
chronic mucocutaneous candidiasis constitutes type I polyglandular autoimmune 
syndrome.
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Fig..Pigmentation of the skin, scant axillary hair, birth mark (left)in 
the both Caucasion patient’s. Normal color of the skin in healthy person 
(right).
Fig. Addison’s disease. Pigmentation marked on the open parts of the 
body: areas against which the clothes rub, nipples.
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Fig. Hyperpigmentation of fold on the palme skin and nails. Normal 
color of the skin of healthy person.
Fig.Hyperpigmintation in the palmar skin creases and nails.
tation of the skin (vitiligo).
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Fig. Pigmentation of the gums and buccal mucosa.
Laboratory Finding
A diagnosis of Addison’s disease is made by laboratory tests. The aim of 
these tests is first to determine whether levels of cortisol are insufficient and 
then to establish the cause.
- low cortisol
- high ACTH
- ACTH stimulation test
- CKP stimulation test
- adrenal antibodies if autoimmune ethyology
- huponatriemia, hyperkaliemia,hypoglycaemia
- Plasma rennin activity is high and plasma aldosterone levels low or 
normal
- chronic anemia
- In tuberculous adrenalitis, chest radiograph may show evidences of pul­
monary tuberculosis. CT scan and plain radiograph of abdomen may show 
adrenal calcification.
Treatment
Patient with Addison’s disease require life-long glucocorticoid and mine- 
ralocorticoid replacement therapy.
■ Cortisone acetate 25 mg per or os on getting up in the morning, and 
12,5 mg in the evening at 6 PM. Alternatively, prednisolone is given in a dose 
of 5 mg in the morning and 2,5 mg in the evening.
■ Florinef (mineralocorticoid) 0.05mg-0,2 mg per os daily
■ Increase dose of steroid in times of illness or for surgery/stress
■ Tubercuolous adrenalitis should be treated with antituberculous 
chemotherapy.
Special problems. Surgery
■ If need surgery with general anesthesia are treated with injections of 
hydrocortisone and saline on the evening before surgery and continue until the 
patient is fully awake and able to take medication by mouth.
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2.Pituitary adrenal insufficiency.
Ethiology
■ Tumor, pituitary metastases
■ Lymphocytic hypophysitis
■ Pituitary trauma/radiation
■ Long term glucocorticoid therapy 
Clinical picture
■ Usually more chronic than primary
■ Slow onset
■ Pallor, not hyperpigmentation
■ Secondary hypogonadism : amenorrhea, decreased libido, scant 
axillary and pubic hair, small testicles.
■ Secondary hypothyroidism.
■ Prepubertal growth deficit, delayed puberty.
Laboratory finding and investigations
■ X ray examination of the sella turcica : sella turcica is enlarged with 
a widened entrance and deepened fundus osteoporosis of the posterior 
wall of the sella turcica, calcinats (pituitary adenomas).
■ Low cortisol
■ Low ACTH
■ Usually normal K+
■ Pituitary adenomas by CT scan
Fig. Normal X-ray of the sella turcica.
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Fig. Pituitary adenomas by X-ray exam.
T reatment
■ Surgery (transsphenoidal resiction)
■ radiation of the tumor
■ Cortisone acetate 25 mg per or os on getting up in the morning, and 
12,5 mg in the evening at 6 PM. Alternatively, prednisolone is given in a dose 
of 5 mg in the morning and 2,5 mg in the evening.
■ Florinef (mineralocorticoid) 0.05mg-0,2 mg per os daily .
3. Acute adrenal crisis&addisonian crisis.
Acute adrenocortical insufficiency is a crisis state threatening the life of 
the patient and developing as a result of the rapid or sudden decrease in the 
functional reserves of adrenal cortex.
Causes of Addison’s disease 
Infection 
Stress.
After bilateral adrenal infarction or bilateral haemorrhage 
Adrenal haemorrhage and often death has been associated with me- 
ningococcaemia (Waterhouse-Friderichsen syndrome).
Causes of Secondary adrenal inssuficiancy 
Postpartum pituitary necrosis (Sheehans).
Necrosis of pituitary macroademoma.
Surgical trauma (transient).
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Pathogenesis
Sharp deficiency in corticosteroid hormones forms the basis of the patho­
genesis.
Clinical
Clinical features of acute adrenal deficiency result from glucocorticoid de­
ficiency, mineralocorticoid deficiency, androgen deficiency.
Loss of mineralocorticoid activity is associated with development 
of hypotension, hyponatraemia and hyperkalaemia.
The predominant manifestation of adrenal crisis is shock, but the 
patient often have nonspecific symptoms such as anorexia, nausea, vomiting, 
abdominal pain, weakness, fatigue, lethargy, confusion or coma.
Two other common symptoms are abdominal tenderness and fever.
Patients with long-standing adrenal insufficiency who present in 
crisis may be hyperpigmented and have weight loss, serum electrolyte abnor­
malities, and other manifestations of chronic adrenal insufficiency.
Treatment
If acute onsrt of hypoetension, shock and volume repletion that is unex­
plained and catecholamine resistant always consider this and treatment with ste­
roids, do not wait for laboratory confirmatory tests.
Hydrocortisone 100 mg 6 hourly and taper it over 24 to 48 hours to 
amaintenance dose once the underlying stress resolves.
Correct hypovolaemia and sodium depletion with normal saline.
Glucose solution 5% if patient is hypoglycaemic.
Prognosis
Farourable if timely treatment had been applied
If no treatment is given, death occurs in one or two days.
4. Hupercortisizm.
Hypercorticizm is a hormonal disorder caused by prolonged exposure of 
the body’s tissues to high levels of the hormone cortisol.
It is relative rare.
Age 20 to 50
Classificaion and ethiology
■ Cushing’s disease: Pituitary Cushing’s.Corticosteroid excess caused 
by an ACTH secreting pituitary adenoma
■ Cushing’s Syndrome: iatrogenic,adrenal adenoma, micro-
macronodular hyperplasia
■ ACTH-independent Cushing’s Syndrome: ectopic ACTH or ectopic 
corticotropin hormone syndrome
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■ Pseudo-Cushing’s: due to a supraphisiological doses of glucocorti­
coids drugs, pregnancy, pubertat period, obesity .
Table. Causes of Cushing’s syndrome.
ACTH dependent ACTH independent
Cushing’s disease Iatrogenic (use of corticosteroids)
Ectopic ACTH syndrome(tumor) Adrenal adenoma
Iatrogenic (ACTH therapy) Adrenal carcinima
Ectopic corticotrophin-releasing 
hormone syndrome (rare)
Micronodular carcinoma (rare)
Macronodular hyperplasia (initial 
stages)
Macronodular hyperplasia (rare)
Cushing’s disease is corticosteroid excess due to pituitary- 
dependent bilateral adrenal hyperplasia. The pituitary tumors in Cushing’s dis­
ease are usually microadenomas (< 10 mm in size) which generally do not cause 
symptoms by local mass effect.
Cushing’s syndrome of pituitary origin is more common in women.
Ectopic ACTH syndrome, usually due to small cell carcinoma of 
lung, is more common in men. Other tumors include carcinoid of Thymus, pan­
creatic carcinoma and bronchial adenoma.
Syptoms and signs
■ Weakness, headache
■ Pain in the back and limbs
■ Gonadal dysfunction: oligo/amenorrehea in women, decreased libi- 
do/impotence in a men
■ Hypertrichosis by the masculine type in F
■ Emotional lability, ffank psychosis, euphoria or depression, head­
ache and backache ,sleep disorders.
■ Acne and furuncles, dry and desquamating, with a purplish-marble 
patent skin, haemorrages
Signs
■ Weight gain.Centripetal (truncal) obesity but thin extremities, su­
praclavicular fat pads, posterior cervical fat “buffalo hump”, “moon faces”
■ Facial plethora, hirsutism in women
■ Wide purple striae around the breasts/abdomen, thights;
■ acne, easy bruising, poor wound healing
■ Hypertension.
■ Osteoporosis, pathologic fractures, a vascular necrosis.
■ Truncal obesity (Cushing’s obesity)
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Selective localization of fat on the face - ’moon face” (a rounded face), 
purplish-red, facial plethora.
■ Chest, abdomen,neck over the7th cerebral vertebra - ’’buffalo 
hump”.
■ Thin limbs . proximal myopathy
■ Hirsutism but with loss of hair on the head, downy hair prevails on 
the face
■ Masculine type in female.
■ Ginecomastia.
■ Female balding
■ Skin infections, bruising.
Fig. Cushing’s obesity:centripetal (truncal) obesity, but thin extremi­
ties. 32-years-old patient.
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Fig. “Moon face”.
Fig. Wide purple striae around the breasts, abdomen, hips.
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Fig. Multiple narrow stria in al5 years-old boy with hypothalamic 
pubertal syndrome.
Laboratory findings and investigations of Cushing’s disease
■ Cushings disease: high cortisol, urinary 17-cs and uriary 17- 
ketosteroids: slightly increased ACTH, no suppression with low dose Dexame- 
thasone.
■ Plain radiograph of the pituitary fossa may show one or more of the 
following abnormalities:
Enlargement of the sella turcica.
Erosion of clinoid processes.
Suprasellar calcification.
Double floor of the sella turcica
■ X- ray marked osteoporosis of the vertebral bodies “fish” vertebrae
■ hyperglycaemia, glucosuria, leukocytosis, hypokaliemia, hyperlipi­
demia,, nephocalcinosis.
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Fig. X-ray diagnosis: macroadenoma.Destruction of posterior wall of 
the sella turcica. Destraction of clinoid processes.
Laboratory and investigations of Cushing’s syndrom
■ Cushing’s syndrom; high cortisol, low ACTH
■ X-ray examination of adrenal (adenoma)
■ Adrenal huperplasia: normal serum ACTH, no supression with low 
dose dexamthasone, supresesses with high dose
■ ACTH secreating Tumor: increased ACTH, no suppression
T reatment
Treatment for hypercoticizm are designed to lower the high level of corti­
sol
1. Medical therapy :hypothalamic 5-HT antagonist:medical adrena­
lectomy with Ketoconazole (Nizoral), Aminoglutethimide, Bromocriptine, Me- 
tyrapone (Metopirone), which inhibit adrenal steroid biosynthesis perioperative-
iy
2. Surgery. Transsphenoidal resection of microadenoma or adrena­
lectomy.
3. Radiation therapy:stereotactic radiosurgery or gamma-knife radiation.
4. Reducing corticosteroid use.
5.Hyperaldosteronism. (Conn’s syndrome).
Definition
State of hypersecretion of the mineralocorticoid aldosterone .
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Classification
1. Primary Hyperaldosteronism is due to an abnormality in the zona 
glomerulosa.
2. Secondary Hyperaldosteronism results from the stimulation of al­
dosterone secretion by angiotensin II following activation of rennin-angiotensin 
system.
Primary Hyperaldosteronism
Ethiology
■ Aldosterone-producing adrenal adenoma (Conn”s syndrome)
■ Bilateral adrenal hyperplasia:
Idiopathic
ACTH-dependent (glucocorticoid-responsive or dexamethasone- 
suppressible). In this type of hyperaldosteronism, the secretion of aldosterone is 
under ACTH control. Therefore, treatment is by administering glucocorticoids 
which suppresses ACTH release.
Pathogenesis
Excess aldosterone produces sodium retention, potassium loss and meta­
bolic alkalosis.
Symptoms and signs
■ Fatigue.
■ Muscle weakness from hypokalaemia.
■ Parasthesias, tetany due to metabolic alcalosis.
■ Headaches.
■ Hypertension uncontrolled by standard therapy.
■ Hypokaliaemia off diuretics.
■ Polyuria, polydipsia, nocturia due to nephrogenic diabetic insipidus.
Labarotory
■ Hypokalaemia: elevated urinary potassium (>30 mEg/day during 
hypokaliaemia in inappropriate).
■ High normal Na+.
■ Metabolic alcalosis.
■ High 24 hr”s urinary or plasma aldosterone .
■ Low random plasma renin .
Diagnostic criteria:
■ Dastolic hypertention without edema.
■ Decreased renin.
■ Increased aldosterone secretion both unresponsive to increases in 
volume.
Treatment
■ Medical: spirinolactone (aldosterone antagonist) -  up to 400 
md/day.A few patient develop gynaecomatia with spirinolactone. In them, ami- 
loride 10 -40 mg/day may be substituted.
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■ Surgical: removal of adenoma is curative (unilateral adrenalecto­
my).
■ ACE inhibitors may be given for control of hypertension.
Secondary hyperaldosteronism
Results from aldosterone excess mediated throuth the rennin- 
angiotensin system.
Ethiology
■ Physiological : salt depletion from inadequate intake or excessive 
loss through kidney or gastrointestinal tract.
■ Pathological : excessive diuretic therapy, nephritic syndrome, cirr­
hosis with ascites , congestive heart failure, accelerated or malignant phase of 
hypertension, severe renal artery stenosis.
Laboratory
■ Hypokalaemia
■ Plasma aldosterone levels are elevated.
■ Plasma rennin activity is elevated.
Treatment
■ Salt depletion is treated with intravenous saline.
■ Congestive heart failure is treated with spirinolactone and ACE in­
hibitors.
■ Barterer’s syndrome is treated with spirinolactone and indometha- 
cin.
■ Malignant hypertension is treated with antihypertensive drugs.
■ Renovascular disease is treated with ACE inhibitors, but definitive 
therapy is angioplasty or surgical correction.
■ If excessive diuretic therapy is the cause (Thiazide), it should be 
substituted or supplemented with one of the potassium-sparing diuretics like spi­
rinolactone, amiloride or triamterene.
6. Pheochromocytoma.
Definition
Tumor which synthesized and release cathecholamines which leading to 
malignant hypertension
Epidemiology
■ Occur with equal frequency in males and females in any age.
■ Rare tumor arising from chromaffin cells of the sympathetic nerv­
ous system (occur anywhere from the base of the brain to the urinary bladder).
■ Most commonly a single tumor of adrenal medulla
■ 10% extra-adrenal, 10% multiple tumors, 10% malignant, 10% fa­
milial.
■ Most pheochromocytomas are noncancerous (benign) and don’t 
spread to other part of the body.
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■ Rare cause of hypertension 
Ethiology
■ Tumor cause unclear
Classification
■ Adrenalosympathetic (paroxysmal) form.
■ Stable form (stably increased arterial pressure without crises).
■ Asymptomatic form.
Symptoms and signs
■ Symptoms often paroxysmal, may be triggered by stress, exertion, 
certain foods.
■ Classic triad: ’’pounding” headache, palpitations, diaphoresis.
■ Blood pressure >260/160mm H g.
■ Postural hypotensionithis result from volume contraction.
■ Tremor, anxiety, chest or abdominal pain.
■ Tachyarrythmias.
■ Cardiomyopathy.
■ Nausea, vomiting.
■ Skin and mucous are pale, limbs cold, pupils dilated.
■ Fever.
■ Cafe au lait spots:these are patches of cutaneous pigmentation, 
which vary from 1-10 mm and occur any place on the body.Characteristic loca­
tions include the axillae and intertridinous areas (Groin). They vary from light to 
dark brown, hence the name cafe au lait.
Laboratory and investigation
■ Increased urinary catecholamines usually sufficient to confirm di­
agnosis.
■ Elevated plasma epinephrine unsuppressed by central @- 
adrenergic.
■ Hyperglycemia, hypercalcemia, erythrocytosis.
■ Positive adrenal CT scan and MRI
■ Meta-iodo-benzoguanidine uptake by tumor site during scan; useful 
to locate for surgery
Treatment
■ Surgical resection.
■ Adequate pre-operative preparation: -@-blockade pre-operation
- Doxazozine, Phentolamine , Labetalol. Peri-opetative: beta-blokade -  
propranolol.
■ Rescreen urine one month post-operatively.
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7. Pheochromocytoma’s crisis. (Hypertensive crisis).
It is acute malignant hypertention due to excessive production of 
cathecholamine by hormone active tumor.
May vary in occurrence from monthly to several times per day.
The duration may vary from seconds to hours.
Worsen with time, occurring more frequently and becoming more 
severe as the tumor grows.
Aggravatings factors 
Stress.
Exertion.
Certain foods.
Palpation of the abdomen.
Clinical signs
■ Ubrupt onset.
■ Headache.
■ Palpitations.
■ Diaphoresis.
■ Blood pressure >260/160 mm H g .
■ Epigastric and flank pain.
■ Polyuria.
Treatment
Phentolamine (Regitin) 0.05 mg I/V titrated to desired effect or Ni- 
troprusside begin infusion 0,3 -  0,5 mcg/kg/min I/V titrate to desired effect; 
Doxazozine (Cardura) 2mg per os titrate to 16 mg to titrate effect.
Complications
Stroke.
Tacchiarritmiaas.
Heart failure 
Prognosis
Curable if recognized and properly treated, but fatal if not.
Chapter IX. Diseases of the Hypothalamic-Pituitary Sys­
tem.
Pituitary Gland (Hypophisis)
Anatomy
A small endocrine gland situated in the sella turcica of the sphenoid 
bone, bridged over by diaphragm sellae.
It is related to sphenoidal aie sinuses below, optic chiasma above 
and cavernous sinuses laterally.
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The anteroposterior dimention is about 10 , it is 12 -15 mm wide 
and 5 -6 mm high. Weights about 0,7 g.
The sagittal demention of the sella turcica are about the 10-15 mm 
and vertical 8-12 mm.
Consists of two parts: the anterior lobe(adenohypophysis) and the 
posterior lobe(neurohypophisis).
Anterior Pituitary
Forms the adenohypophysis comprising 75% of the hypophysis 
Consists of basophil, eosinophol and chromophobe cells 
Anterior Pituitary Produced Six Different Hormones:
Electron microscopically 5 distinct types of cells can be identified:
■ Somatotrophs secreting Growth hormone (GH).
■ Lactotrophs secreting Leutenizing hormone (LH).
■ Lactotrophs secreting Follicle stimulating hormone (FSH).
■ Thyrotrophs secreting Thyroid stimulating hormone (TSH).
■ Corticotrophs secreting Adrenocorticotropin hormon (ACTH)
■ Lactotrophs secreting Prolactin (PRL)
Posterior Pituitary
The posterior lobe, pituitary stalk and eminentia medialis of the tuber ci- 
nereum are components of the neurohypophysis.
Posterior Pituitary Produced Hormones:
■ Oxytocin.
■ Antidiuretic hormone (ADH)= arginine vasopressin hormone.
Table. The Pituitary Hormones and its action.
Hormone Actions
Thyroid stimulating hormone (TSH) Stimulates the production of T4 
and T3
Luteinising hormone (LH),
Follicle stimulating hormone (FSH)
In males, both FSH and LH are nes- 
sesary for spermatogenesis.In 
males, FSH stimulates Sertoli cells 
to secrete androgen binding protein 
(ABP), transferring, plasminogen 
activator and inhibin.
In males, LH stimulates Leyding 
cells to produce testosterone.
In females, FSH promotes growth 
and development of ovarian fol­
licles during the follicular phase of 
menstrual cycle.
In females, the mid-cycle peak of 
LH (LH surge) induces ovulation.
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Hormone Actions
In females, both FSH and LH are 
nessesary for the development of 
corpus luteum during the luteal 
phase of menstrual cycle.
Growth Hormone (GH) Promotes growth
Prolactin (PRL) Exerts its main effects on the 
breasts, stimulating lactation
Adrenocorticotrophic Hormone 
(ACTH)
Controls cortisol release from 
adrenal cortex, and skin pigmenta­
tion
Arginine Vasopressin (AVP) -ADH Promotes reabsorption of water by 
renal tubules
Oxytocin Promotes uterine contraction and 
expression of milk from the breasts
Hypothalamus
The higher regulator of the neuro-endocrine system
It is a region of the brain located in its basal part within the limits of 
the middle cranial fossa.
There are 32 pairs of nuclei, which participate in the regulation of 
the most vital vegetative functions of the organism.: arterial pressure, vascular 
permesbility, appetite, sleep and wakefulness, psychic activity, activity of the 
peripheral endocrine glands(“target” glands).
The feedback system or “plus-minus” interaction ensures the nor­
mal production of hormones in the organism, thus maintaining the consistency 
of the internal medium and various functions of the organism.
There are releasing factors for all the tropic hormones,
Monoamines (dopamine, noradrenaline, serotonin) regulate the se­
cretion of releasing factors and their entry into the circulation. They are pro­
duced by the nerve cells located in the middle part of the hypothalamus.
Activity of the hypothalamic centres is controlled by other parts of 
the central nervus system and particularly by the cerebral cortex.
Hypothalamic Control of Pituitary
The hypothalamus and hypophysis constitute a single interconnected sys­
tem of the organism. The hypothalamus nuclei are connected with the hypophy­
sis by means of neurosecretory pathways
■ Tropic (releasing) and inhibitory factors control the release of the 
anterior pituitary gland and by direct feedback inhibition.
■ The posterior pituitary receives ADH and oxytocin from hypotha­
lamus, secreting them under CNS control.
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Table.Hypotalamic Hormones and its Action.
Hormone Action
Corticotrophin releasing factor 
(CRF), Arginine vasopressin (AVP)
Stimulating ACTH and LPH
Gonadotrophin releasing factor 
(GnRF)
Stimulating LH and FSH
Somatostatin or Somatotropin re­
lease inhibiting factor
Inhibiting GH and TSH
Thyrotrophin releasing hormone 
(TRH)
Stimulating TSH and PRL
Dopamine (D) or prolactin release 
inhibitory factor
Inhibiting PRL
1. Hypopituitarism. (Panhypopituitarism).
It is state of hyposecretion of anterior pituitary.
■ Can be caused by either hypothalamic or pituitary dysfunction.
■ Patients may have single or multiple hormonal deficiencies.
■ May be genetic or idiopatic(acquired)
Etiology of hypopituitarism
■ Invasive: generally primary tumors.
■ Infarction: e.g. Sheehan;s syndrome.
■ Infiltrative: e.g. sarcoidosis, histiocytosis .
■ Immunologic: autoimmune destruction.
■ Infections: e.g. ТВ, syphilis.
■ Injury: severe head trauma.
■ Iatrogenic: following surgery or radiation.
■ Idiopathic: familial forms, congenital midline defects.
Classification
1. Congenital hypothalamic: Deficiencies of GnRP (Kallmann’s syn­
drome), TRH, GHRH, CRF.
2. Acquired hypothalamic: craniopharyngioma, sarcoidosis, tuberculo­
sis,histiocytosis-X, radiotherapy, tumors.
3. Pituitary : pituitary adenoma, post-partum necrosis (Sheehan’s syn­
drome),surgery, autoimmune, radiotherapy, haemorrage, empty sella syndrome.
Clinical
Manifestation of hypopituitarism depending upon which specific hor­
mones are lacking and whether their deficiency is partial or comletely .
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Symptoms
■ Sexual dysfunction.
■ Weakness.
■ Loss of weght
■ Easy fatigability.
■ Lack of resistance to stress, cold, and fasting.
■ Axillary and pubic hair loss.
■ Hypotention;
■ Pituitary tumors may cause visual field defects.
■ LH deficiency: leads to loss of libido and impotence in males, and 
oligomenorrhoea or amenorrhoea in females.Later бшт males, there may be gy- 
naecomastia and decreased frequency of shaving. In both sexes, axillary and 
pubic hair becomes sparse and later absent. The skin is finer and wrinkled.
■ ACTH deficiency: leads to cortisol deficiency resulting in symp­
toms and signs of adrenal insufficiency, with skin pallor due to lack of melanin 
and normal plasma electrolytes.
Fig. Hypothalamic-pituitary 
cachexia (Simmonds’ syn­
drome) : secondary hypocor- 
ticoidism,a secondary hypo- 
thyrosis,a secondary hypogo- 
nadotrophic hypogonadism; 
an amenorrhea, an oligotro­
phy of mammary glands, ab­
sence hair of apubis and an 
axillary fossae. Secondary so­
matotropic insufficiency: an 
atrophy of muscles, anoedon- 
tus. A secondary polyfactorial 
anaemia of serious degree. 
Hypoprotein edemas. Growth 
-158 sm, weight - 26 kg.
■ TSH deficiency: leads to symptom and signs of secondary hypothy­
roidism.
■ PRL deficiency: leads to failure of lactation.
■ Ultimately, the patient goes into coma resulting from hypoglycae- 
mia, water intoxication and hypothermia.
Essentials of diagnosis
■ Fall in LH/FSH and PRL leads to sexual dysfunction; axillary and 
pubic hair loss, amenorrea or infertility in women, erectile dysfunction in men.
■ TSH deficiency leads to hypothyroidism.
■ ACTH deficiency leads to adrenal insufficiencyeasy fatigability, 
weakness, lack of the resistasnce to stress, hypotension .
■ Fall in GH, clinically not apparent.
Fig. 20 years-old women with anorexia veurosa.
Growth -  160 cm, weight - 42 kg. Normal growth of hair.
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Fig.23 years-old patient. Panhypopituitarism( tumour of a bottom of 
IV ventricle of a brain). Secondary hypocorticoidism.Cachexia. Growth - 
172 cm, weight - 45 kg.
Laboratory
■ Low free T4 with low or inappropriately normal TSH.
■ Low testosterone without elevation of LH and FSH.
■ Provocation tests may be required to assess pituitary reserve
T reatment
■ Transsphenoidal removal of pituitary tumors.
■ Radiation therapy with x-ray, gamma knife, heavy particles.
■ Lifetime hormone replacement therapy:
ACTH deficiency is treated with cortisol 20 mg in the morning and 
10 mg in the evening or prednisolone 5 mg in the morning and 2,5 mg in the 
evening.
TSH deficiency is treated with T4 0,1 -  0,15 mg daily.
Gonadotrophin deficiency is treated with sex hormone replacement, 
based on the age and sex of the patient.
2. Diabetes insipidus. Posterior Hypopituitarism.
Definition
It is state of absolute deficiency of ADH or of resistance to ADH.
Hypothalamic diabetes insipidus may be either an independent disease, or 
a symptom of certain endocrine and non-endocrine diseases. It is encountered in 
patient of all ages, but most often occur in young people from 18 to 25 years of 
age.
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Classification
1. Deficient production of ADH (hypothalamic):
- Primary diabetes insipidus: familial or idiopathic
- Secondary diabetes insipidus .
2. Deficient action of ADH : nephrogenic diabetes insipidus (“renal di­
abetes insipidus”):total or considerable insensitivity of the distal part of the kid­
ney tubules to ADH).
3. Vasopressinase-induced diabetes insipidus of pregnancy.
Ethiology
1. Primary deficiency of ADH:
Trauma
Infection
Tumor
Granulomas
Inflammatory( autoimmune hypophisitis)
Vascular 
Genetic defects 
idiopathic
2. Secondary deficiency of ADH :
Psychogenic polydipsia 
Dipcogenic polydipsia (abnormal thirst)
Iatrogenic
3. Nephrogenic diabetes insipidus:
Drugs :Lithium,amphotericin B, aminoglycosides, rifampicin
Metabolic :hypercalcaemia, hypokalaemia
Amiloidosis
Genetic
Idiopathic.
Pathogenesis
The lack of ADH leads to a reduced reabsorption of water in the distal 
segments of the convoluted tubules of the kidneys, which causes an increase in 
dieresis (polyuria). Dehydration is attended by stimulation of the “thist centre” 
in the hypothalamus resulting in thirst (polydipsia).
Clinical
Polyuria, excessive thirst and polydipsia are the cardinal manifesta­
tions
Daily urine output may reach as high as 10-15 litres.
Laboratory and investigations
The urine is clear, and o f  low specific gravity.
The osmolality is low, usually less then that polasma. However in 
primary polydipsia, plasma osmolality may be lower than urinary osmolality. 
Serum sodium is borderline high indicating water loss.
MRI of pituitary and hypothalamus
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Water deprivation test: the diagnosis of hypothalamic diabetes insi­
pidus depends on demonstrating that a rise of plasma osmolality induced by 
withholding fluids is not accompanied by a normal rise in the osmolality or spe­
cific gravity of urine. The later test is necessary to show that kidney is capable 
of concentrating the urine which it cannot do in nefrogenic diabetes insipidus.
Treatment
Desmopressin 10 -20 meg intranasally once or twice a day.
Chlorpropamide enhances the renal responsiveness to vasopressin.
Carbamazepine is an alternate drug with similar action.
Thiazide diuretics are the only effective drugs for nefrogenic di­
abetes insipidus.
Growth Hormone Disorders
GH functions:
is essential for body growth
to regulate body composition, fluid homeostasis,
glucose and lipid metabolism,
skeletal muscle and bone growth, and possibly cardiac functioning.
sleep, exercise, and stress
3. Acromegaly.
Definition
Acromegaly is an endocrine disease characterized by the disproportional 
growth of the skeleton, soft tissues, and internal organs, which as a result of the 
GH hypersecretion occurring in adult life after epihyseal clousure.
Ethiology
Pituitery tumor or diffuse hyperplasia of eosinophil cells in the an­
terior pituitary.
Rare causes: excessive growth hormone secretion from pancreatic 
islet cell tumor, or excessive secretion of growth hormone-releasing hormone 
from hypothalamic lesions, bronchial carcinoid and small cell lung carcinoma.
Pathogenesis
GH exerts much of its growth-promoting effects through the release of 
IGH-1 produced in the liver and other tissues.Hyperproduction of the GH leads 
to hypertrophy of the bones of the skeleton, joint cartilages, capsules and ten­
dons, and hyperplasia of the internal organs. GH-secreting pituitary tumors 
usually cause some degree of hypogonadism, either by cosecretion of prolactin 
or by direct pressure upon normal pituitary tissue.In the initial phase of the dis­
ease the endocrine glands (thyroid, parathyroid glands, pancreas) are hyperplasia 
and their function is increased, but at a later period of the disease hypoplasia of 
endocrine glands develops with reduction of function.
Symptoms and signs
Headaches, impairment of vision and memory, apathy, drowsiness
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Arthralgias and muscular pain
Hypertention, cardiomegaly and heart failure with a dilated left ven­
tricle.
Decreased libido and impotence.
Irregular menses or amenorrhea.
Portret’s diagnosis:
Enlargement of the superciliary arches, zygomatic bones, the hol­
low of the auricles, nose, lips, tongue; prognatism and malocclusion, tooth spac­
ing widens (diastema).
Macroglossia, hypertrophy of pharyngeal and laryngeal tissue; this 
causes a deep, coarse voice.
The skin manifest hyperhydrosis, thickening, cystic acne, and areas 
of acanthosis nigricans, skin papillomas.
The hands enlarge and a doughy, moist handshake,the fingers wi­
den, causing patients to enlarge their rings.
Hypertrichosis.
Degenerative arthritis,overgrowth of vertebral bone; the thorax in­
creases in sizes, making the patient barrel-chested; the intercostals spaces wi­
dened.
Kyphosis and scoliosis of the spine.
The sternum, clavicles, and ribs thicken.
Weigth gain.
Obstructive sleep apnea.
Goiter.
Splanchnomegaly.
Bitemporal hemianopsia (blindness in the temporal half of the field 
of vision in each eye), primarily to the red and
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Fig. Foot of acromegaly patient.
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Fig. Acromegaly in a 42 year-old female. Hyperthrophy of the soft tissue of 
the face. Diastema, prognatism.
Fig . Acromegaly in 61 years-old patient.. Enlargement of the tongue (ma-
croglossia).
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Fig. Acromegaly in 64 years-old patient.
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Laboratory and investigations
X -rays shows: the long bones are wide, thick, with coarse bony 
trabecular pattern tufting of the terminal phalanges.
X -rays shows: the vault of the scull is increased in thickness, para­
nasal sinuses are large, mandible shows prognathism and malocclusion of the 
teeth.
Plain Radiograph of the pituitary fossa: sella turcica is widened, 
deep and ballooned.
CT scan or MR1 shows a pituitary tumor in 90% of acromegalics. 
Elevated IGF -1 levels (normal 202 -  453 ng/ml).
Basal GH level (normal 0-264 nmol/L in male ,and 0-440 nmol/L in
female).
GH levels are measured during an oral glucose tolerance test. A 
failure of suppression or paradoxical rise of GH indicates acromegaly. 
Demonstration of GH rise after TRH administration.
Insulin resistance causing diabetes mellitus (30%).
Collon polyps are common, especially in patients with skin pappi-
lomas
Picture. Different types of sella turcica ( by M.Julies, I. Hollo)
ХЯ tP 1Я Sn
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T ab le .IG F  -1 levels acco rd in g  th e  age.
Age, years Normal response nmol/L
19-24 48 - 450
25-29 62 -280
30 -39 40 -280
40-49 40 -256
50 -59 66-310
>60 118-314
Treatment
1. Surgery.
2. Medical therapy.
3. Radiosurgery.
Surgery
Endoscopic transnasal, transsphenoidal pituitary microcrosurgery 
removes the adenoma.
Medical therapy
Dopamine agonist (Bromocriptine or Carbergoline ). The initial 
dose is 0,25 mg orally twice weekly, which is gradually increased to a maximum 
dosage of 1 mg twice weekly
Somatostatin analogue (Octreotide or Lanreotide).Short-acting Oc­
treotide acetate in doses of 50pg is injected subcutaneously 3 times daily. Res­
ponders who tolerate the drug are swirched to long-acting octreotide acetate in­
jectable suspension in a dosage of 20 mg intraglutereally per month. The dosage 
may be adjusted -  up to maximum of 40 mL monthly -  to maintain the serum 
GH between 1 and 2,5 ng/mL, keeping IGF-1 levels normal.Lanreotide SR is 
given by subcutaneous injection at a dosage of 30 mg every 7-14 days. Lanreo- 
tide Autogel is a newer formulation that is administrated by deep subcutaneous 
injection in doses of 60-120 mg every 28 days.
GH receptor antagonist. Pegvisomant: the starting dosage is 10 mg 
subcutaneously daily. The maintenance dosage can be increased by 5-10 mg 
every 4-6 weeks, based on serum IGF-1 levels and liver transaminase lrvrls. 
This drug does not shrink GH-secreting tumors.
Radiosurgery
External radiotherapy by gamma knife, heavy particle radiation, or 
adapted liner accelerator
Stereotactic radiosurgery : implantation of yttrium into the pituitary.
Prognosis
Patients with untreated or persistent acromegaly tend to have pre­
mature cardiovascular disease and progressive acromegalic symptoms.
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Transsphenoidal pituitary surgery is successful in 80-90% of pa­
tients with tumors less than 2 cm in diameter and GH levels less than 50 ng/mL.
Conventional radiation therapy (alone) produces a remission in 
about 40% of a patients by 2 years and 75 % of patients by 5 years after treat­
ment.
Hypopituitarism may occur, due to the tumor itself, pituitary sur­
gery, or radiation therapy.
4. Gigantism.
Definition
Gigantizm is a disease characterized by a proportional intensified 
growth of the skeleton and other organs and tissues as a result of the GH hyper­
secretion occurring in the period of sexual maturation.
Gigantism is considered the height more than 200 sm at male and 
more than 190 sm at female.
A child is considered to be tall when the height is greater than 2 
standart deviations above the mean for the age.
Ethiology
Pituitery tumor or diffuse hyperplasia of eosinophil cells in the an­
terior pituitary.
Pituitary neuroinfection or a trauma.
Pathogenesis
Excessive GH causes tall stature and gigantism if it occurs before 
closure of epiphyses.
Hyperproduction of the GH leads to intensified proportional growth 
of the skeleton and of other organs.
Fast uncontrollable growth of a body at the length, proceeding 
throughout all life, resulting to posture disturbance, peripheric angiopathy, poly­
neuropathy, insulinresistance.
30 % of patients have depression of libido, a potency and a dysme­
norrhea because of hyperprolactinemia.
80 % of patients are IGT, and at 25 % the obvious diabetes with 
ketoacidosis develops.
In the course of time there are signs of disproportionality of the
body
Symptoms and signs
Normally, in adults, the height of the person is equal to the length of arm 
span. The apper segment (from vertex to the pubic symphysis) is equal to the 
lower segment (from pubic syphysis to the heel).
There are signs of disproportionality of a gigant persone:
long-legged, long arms ,but short trunk,and reduced head;
acromegalic features (so-called acromegalic gigantism).
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height of giants measure in position standing, sitting, laying be­
cause at them the scoliosis, a kyphoscoliosis, shift vertebra disks take place;
the length of arm span exceeds length of feet;
- The sizes of a head small;
- The length of feet is more than length of a trunk;
- Augmentation of the sizes of a brush at length (from the beginning of a 
brush till the end of a long finger);
- Augmentation of the sizes of feet.
Secondary sexual signs are developed badly. The hypogenitalism are 
at young men.
- Dysmenorrheal/amenorrhea/ anovulatory menstrual cycles are at girls .A 
mammary glands are developed badly.
- Quite often have trophic ulcers or gangrene of the bottom extremities
- A secondary hypothyrosis, adrenal insufficiency, diabetes insipidus may 
occur with the age
Complaints:
headache,giddinesses, fast fatigability ,the memory impairment
unpleasant sensations in the field of heart
paresthesias in distal departments of extremities, cold intolerance 
of the extremities,
Good-quality tumour can not be accompanied by other symptoms.
Differencial diagnosis
GH-induced gigantism must be differentiated:
1. Simple or primary gigantism: Racial, familial or constitutional
Great heaight and body weight of the parents, normal sexual and
physical development.
2. Endocrine: sexual precocity, hypogonadism.
Sexual precocity may be due to premature secretion of gonadotrop­
ic hormones.Acceleration of linear growth occurs with simultaneously with 
signs of premature sexual development.
Primary hypogonadism is marked by high disproportional growth; a 
relatively short trunk, a small head, long extremities with signs of underdeve­
lopment of sexual organs and absence of secondary sex characters.
3. Genetic: Klinefelter’s syndrome.
Lower segment more than the upper segment, gynicomastia, 
small,firm testes, azoospermia, chromatin (Barr) body usually present, 47xxy.
4. Metabolic: Marfan’s syndrome
Abnormal shape of the ears, congenital heart defects, dolichoce­
phalic cranium, arachnodactyly, high arched palate, arm span greater than the 
height and the lower segment more than the upper segment.
5. Miscellaneous: Cerebral gigantism (Soto’s syndrome)
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Large elongated head, prominent forehead, large ears and jaws, 
elongated chin, antimongoloid slant to the eyes and coarse facial features.They 
have subnormal intelligence and impaired coordination. The cause is not known. 
Treatment (see “Acromegaly”).
5. Dwarfism. (Short Stature, Nanism, Microsomia).
General consideration
Dwarfism is the term applied when the patient’s height is 2 standart devia­
tions less than that for his/her age and sex (adult males no higher than 130 sm 
and adult females below 120 sm).
Definition
Pituitary nanism is a genetic disease caused by an absolute or relative de­
ficiency of GH, which leads to the retarding of the growth of the skeleton and 
other organs and tissues.
Is characterized by deficient stature in adul males no higher than 
130 sm and adult females below 120 sm
Bigins after two-three years of age.
Ethiology
A genetic disease which is inherited as an autosomal-recessive 
trait,or more seldom, as an autosonal-dominant trait
Occur as a result of the isolated insufficiency of the GH 
Occur in people with a normal level oa GH , but when GH is not 
biologically active or the peripheral tissues not sensitivity to it (somatomedins 
insufficiency).
May develop as a conswquence of the lesion of the pituitary b y ' 
trauma, tumors or vascular.
Phatogenesis
Genetic defects : prop-1, pit-1 gene deficiency 
GH deficiency leads to the retarding of the growth of the skeleton 
and internal organs, hypoplasia and atrophy in the thyroid gland, sexual glands.
Symptoms and signs
The infantile body proportion (the apper srgment is greater than the 
lower segment and the height is greater than the arm span).
Skeletal age and dental age delayed by more than 2 years 
The growth rate is less than 4 sm/year 
The skin pale, at times with a yellowish shade, wrinkled, dry 
The subcutaneous fat is poorly developed but obesity over abdo­
men, in the area of the mammary glands, the pubis and thighs 
The muscular system is poor
Splanchnomicria, but the function of the internal organs is usually 
not disturbed
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The sexual system is underdeveloped.Male sometimes have cryp­
torchidism (failure of the testes to descend into the scrotum). Female do not 
have menstruation.Secondary sex characters and libido are absent
In nanism caused by tumor or hydrocephalus general cerebral 
symptoms present, may occur bitemporal hemianopia
MRI shows hypoplastic or aplastic pitutaries
Fig. Pituitary nanism in a 18 -year-old female (height -  110 cm, 
weigth -26 kg).
Differencial diagnosis
Short stature are divided into two broad categories:
1. Disproportionate dwarfism.
If body size is disproportionate, some parts of the body are small 
and others are of average size or above-average size. Disorders causing dispro­
portionate dwarfism inhibit the development of bones.
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Fig. 46 years -old patient with disproportional short stature. Chon- 
drodisplasia (Pseudopseudohypoparathyroidism).
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2. Proportionate dwarfism.
A body is proportionately small if all parts of the body are small to 
the same degree and appear to be proportioned like a body of average stature.
Causes
1. Herediatary/Genetic.
If there is a family history of short stature -  genetic.
If there is no family history of short stature -  primordial short sta­
ture
The bone age and dental age are normal.
They are short, they grow at a constant rate of 4 -5 csm a year
Normal body proportions for age.
There is no endocrine abnormality and require no endocrine treat­
ment.
2. Chromosomal(Tumer’s syndrome .Down’s syndrome, Noonan’s 
syndrome)
Turner’s syndrome (SHOX gene deficiency):
Are girls who have agenesis of their ovaries
The chromosomal pattern is 45 XO
Grow at the rate of less than 4 sm each year with normal bone age 
and dental age but absent pubertal growth spurt, so that during adolescence, the 
skeletal age is delayed due to the absence of sex hormones
P icture . C hond rodystrophy .
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A characteristically short webbed neck, low hairline, square and 
shield-like chest, cubitus valgus and mental retardation
Puffy hands and feet at birth and during infancy 
Heart and blood vessel defects 
Kidney problems
No development of breasts or onset of menstruation during adoles­
cence
Infertility
Oxandrolone 0,15 mg/kg/day with growth hormone from early ado­
lescence till puberty can increase the height.After the age of 15 years cyclical 
estrogen replacement therapy in physiological doses is given for life.GH re­
placement is recommended before epiphyseal fusion.
3. Constitutional growth delay and Delayed puberty.
Is common among adolescent boys
There is a history of delay in growth and pubertal development in 
the father and other male relatives
Is no true endocrine deficiency
They grow at a constant rate of about 4 sm a year but their bone age 
and dental age is delayed by about 2 years 
Immature but later nomal
If puberty does not occur spontaneously by 15 years og age, it can 
be induced by testosterone enanthate 250 mg intramuscular once a month for 3 
months.
4. Nutritional,Malnutrition,Malabsorption
5. Rickets
6. Endocrine: Hypothyroidism,Cushings syndrome,Congenital adrenal 
hyperplasia
Hypothyroidism:
Mental retardation since birth
Dry skin,body proportions is infantile (upper segment is more than 
lower segment), constipation
Lifelong thyroxine replacement is required
7. Skeletal: Achondroplasia, skeletal dysplasias,spinal deformities 
Achondroplasia
Short limbs resulting in short stature
The lower segment is always less than the upper segment
Mental and dental ages are normal
Endocrine functions are normal
8. Systemic diseases:Uremia, renal tubular acidosis, Cirrhosis of liver, 
Congenital cyanotic heart disease
Can cause growth failure during childhood
Growth failure is a secondary problem
Can be recognized by their own specific clinical features
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Laboratory and investigations
Decrease GH, LH, FSH, TRH, ACTH
Diagnostic tests (Thyroliberin test)
X-rays: the zones of growth do not close ,the cranium has the pro­
portions typical of a child, the skull-cap is thin
When there is a tumor: sella turcica is enlarged, deformed with its 
walls destroyed
MRI
Treatment
The treatment of Dwarfism’s depends on the cause of the disease.
If pituitary tumor is revealed, radiotherapy is applaid or the tumor is 
removed surgically.
Somatotromine therapy is prescribed in insufficient GH secretion: 
using recombinant DNA technology, two forms of synthetic GH were devel­
oped, somatropin and somatrem. Somatropin is identical to the endogenous pi­
tuitary-derived GH, whereas somatrem has an extra amino acid on the N- 
terminus. Both synthetic forms have similar biological actions and potencies as 
the endogenous GH polypeptide.
GH is administered by subcutaneous or intramuscular injection. The 
circulating half-life of GH is relatively short (20-30 minutes), while its biologi­
cal half-life is much longer (9-17 hours) due to its indirect effects.
Symptomatic adults with severe GH deficiency (serum 1GF-1 below 
85 mcg/L) may be treated with subcutaneous recombinant human GH (rhGH) 
injection starting at a dosage of about 0,2 mg (0,61U)/day, administered three or 
four times weekly. The dosage of recombinant human GH is increased every 2-4 
weeks by increments of 0,1 mg (0,3IU) until side effects occur or a sufficient sa­
lutary response and a normal serum IGF-1 level are achieved.A sustained- 
release injectable suspension of GH has been developed. It can be given once 
monthly and is therefore more convenient than standard rhGH preparations.lf 
the desired effects are not seen within 3-6 months at maximum tolerated dosage, 
rhGH therapy is discontinued.
Side effects of rhGH therapy: peripheral edema, hand stiffness, arr- 
thralgias, myalgias, headache, pseudotumor cerebri, gynecomastia, carpal tunnel 
syndrome, hepertension, proliferative retinopathy
Thyroid hormones, synthetic anabolic steroids, chorionic gonado­
tropin to stimulate and develop the sexual glands, androgens and oestrogens for 
individuals plans.
The indication for the treatment termination is the osteal age of 13 
years and growth of 160 sm at girls, osteal age of 15 years and growth of 170 sm 
at boys. Now there is an opinion on expediency of continuation of treatment of
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the adult persons GH having its deficiency since the childhood, in connection 
with necessity of metabolic effect GH (anabolic, lipolytic).
Prognosis
Working capacity is broken. The group of physical inability since the 
childhood is defined. Patients are infertility.
Chapter X. Obesity
Definition
Obesity is a discord in system of regulation of mass of the body, leading 
excessive deposition of fat of a body, characterised by superfluous stocks of 
triglycerides in adiposites, that promotes occurrence of some serious metabolic 
diseases which lead to increased health risk.
This is a chronic disease with no known cure.
20 % or greater above ideal body weight
170% of ideal body weight or BMI>40 is morbid obesity
BMI <20 or >27 to increased health risk
Extends such accompanying diseases:
- cardiovascular: hypertention.CAD, varicose veins,sudden death from 
arrhythmia
- respiratory: sleep apnea, dyspnea, pulmonary embolus, infections
- gastrodigestinal: fatty liver, gallbladder disease
- metabolic and endocrine: DM type 2, 1GT, hyperlipide-
mia,hyperuricemia,dismenorrea, infertility, hirsutism
- increased risk of neoplastic diseases:endometrial, post-menopausal 
breast, prostate, colorectal cancers.
Fat tissue is not uniform in its metabolic characteristics. Fat cells from the 
organs are more likely to break down under the influence of catecholamines 
(brain trancmitters). Making matters worse, these abdominal fat cells do not al­
low insulin to come to their rescue and slow their breakdown. Fat cell break­
down liberates FFA from the cell. While FFA are important metabolic fuels, 
they may well be the villains in a number of metabolic processis. It is suspected 
that FFA prevent the body from using glucose, which may cause insulin resis­
tance and glucose intolerance, hyperinsulinemia and increased glucose prodac- 
tion by the liver, a typical finding in DM Type 2. FFA’s also stimulate die syn­
thesis of TG in the liver, VLDL, LDL.
Epidemiology
Incidence reaches 50% among females and 30% among males, and 
10% among children
Occurs at any age but obesity prevails in age groups after 50 years.
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Hereditary predisposition: if mother and father have obesity risk 
at the child - 78 %; if one of parents is sick risk to have obesity at the child - 56 
%. The chance development of obesity in the child who was bom from parents 
without adiposity - 14 %.
Risk Factors
Increasing age
Genetic variants in energy expenditure
Behaviour and lifestyle : regular overeating, particularly abuse of 
foodstuffs rich in carbonhydrates and fats; a sedentary lifestyle
Secondary causes:endocrine:Cushing”s syndrome, hypothyroidism;
drugs.
Hypothalamic injury:trauma, surgical, lesions in ventromedial or 
paraventricular median nucleus 
Pathogenesis
Positive energy balance:energy input >energy output 
Functional disorders of the feeding centre of the hypothala- 
mus:satiety centres of the ventromedial nuclei and appetite centres of the ventro­
lateral nuclei of the hypothalamus
Increased supply of food due to stimulation of the feeding centre in 
insufficient physical activity leads to the accumulation of the fat in the fat de­
pots: in the skin, subcutaneous fat, mesentery, omentum, pararenal and mediast- 
tinal tissue,epicardium, myocardium, liver, and pancreas.
Several novel hormones appear to act upon brain receptors to regu­
late appetite and metabolism:
Leptin
Congenital leptin deficiency accounts for 1-2% of early-onset mor­
bid obesity
Is a hormone secreted by subcutaneous adipose tissue in response to 
fat storage or overfeeding.
-It binds to brain @-melanocortin receptors and influences the se­
cretion of neuropeptides, inhibiting neuropepttide Y and agouti-related peptide 
It promotes satiety and increase the body’s metabolic rate 
It required for gonadotropin secretion.
Grelin
Is a 28-amino-acid hormone 
Is secreted by the empty stomach 
It stimulate appetite 
@-MSH
Alfa-melanocyte-stimulating hormone is a neuropeptide that regu­
lates the hypothalamic control of food intake
Defect in the @-MSH receptor are present in up to 5% of morbidly 
obese patients
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Citocins
FNO-@- factor necrosis of tumor is a product of adipocites secre­
tion response insulinresistance by decreasing of GIuT4 excretion 
Classification
The generally accepted classification of obesity does not exist. 
Anatomo-morphological classification 
Is based on morphology of a fatty tissue:
1. Hypertrophic type 
- Arises at mature age;
It is characterised by augmentation of the sizes adiposites without 
augmentation of their general number.
2. Hyperplastic type
It is characterised by augmentation of total of fatty cells.
3. The admixed or hypertrophic-hyperplastic type
Table. Classification of overweight and obesity (WHO, 1998).
Fenotype BMI Risk of comorbided dis­
eases
< 18,5 The low risk, but risk of 
other clinical problems 
increases
Normal mass of a body 18,5-24,9 usual
Overweight
Overweight 25,0 -  29,9 moderated
Obesity of 1st degree 30,0 -  34,9 raised
Obesity of 2nd degree 35,0 -39,9 high
Obesity of 3rd degree >40,0 Very high
Degree of obesity should be defined with the account of a sex, age and 
growth surveyed and BMI is not authentic and does not reflect degree of adipos­
ity at certain categories of the population:
- persons aged is more senior 65 years;
- sportsmen and at people with very developed musculation;
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- teenagers with the neoterminated period of growth;
- at pregnant women.
Worldwide tables are developed for calculation of ideal body mass in 
different age groups for persons from the asthenic, normosthenic and hyper­
sthenic constitution, and also for children of various age groups.
Topography and terminology
Allocate various types of adiposity depending on an aetiology,of the fat 
localization and its anatomo-histologic characteristics. Adipose tissue distribute 
differently in men and women.
The term “android” to describe the upper body (abdominal) distri­
bution. Abdominal obesity are an increase association with DM, CVD and gout.
The term “gynoid” to discribe for the lower body (gluteo-femoral) 
fat accumulation more commonly seen in women.
Proportional.
Disproportional.
Fig. Femenine type of obesity. Fig. Android obesity in 56-years-old 
women with DM Type 2.
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Picture. Abdominal obesity in climacteric period in female and in a
male.
Fig. A45-years-old patient: hypothyroidism, obesity (BMI =39), secondary 
hypogonadism, DM type 2.
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Calculations Body Fat
Gold standart is hydrodensitometry (underwater weighing) and 
dual-energy x-ray absorptometry ( both for research)
Clinics use BM1( Body Mass index) : weight in kg/(height in me­
ters) squared (Wt/Ht2):
Clinics use WHR ( waist:hip circumference ratio): at men less than 
1,0 and women less - 0,85.This is the most objective sign of abdominal adiposi­
ty .The waist is measured at its narrowest point and hip circumference at its wid­
est, while standing.
Table. Obesity Classification according of BM1
Males ,BM1 Females, BM1
Underweight 21 19
Average 21 25
Overweight 27-28 30- 32
Moderately Obese 31 -40 32-40
Extreme Obesity 41 -45 41-45
| Morbidly Obese >45 >45
Table. Obesity Classification according of WHR
Sex Normal Overweight Obesity
Males <94 sm 9 4 - 1 0 2
CM
> 102sm
Females <80 sm 80 -  88 c m > 88sm
Classification of Obesity according of the Ethiology
I.Primary obesity (exogenous causes of obesity)
1. Alimentary constitutional obesity
2. Acquired hypothalamic lesion: tumor,infection,trauma,vascular lesion.
11. Secondary obesity (endogenous causes of obesity)
1. Acquired hypothalamic lesion due to infection,sarcoid, vascular 
malformation
2. Hormonal: hypothyroid, hypo-ovarian; climacteric; adrenal, prima­
ry hyperinsulinism.
II. Genetic syndroms: Prader-Willi; Alstrom syndrome; Carpenter syn­
drome; Cohen syndrome;
111. Medications causing weight gain: insulin, sulfonaureas, atypical 
neuroleptics, antidepressants, glucocorticoids, cyproheptadine, progestins, alfa-1 
and beta -2 adrenergic antagonists
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Fig. Hypothalamic obesity in Fig. Disproportional accumulation of 
32-years-old patient. the fat: lypodysthrophy of the upper
part of the body (“witch’s face”) but ex­
cessive accumulation of the fat for the 
lower part of the body.
Symptoms and signs
Increased appetite,lassitude, apathy, somnolence, fatiguability, 
headache, poor memory
Excessive sweating (hyperhidrosis), eczema, pyoderma, furunculo­
sis
Umbilical and inguinal hernias
The cardiac sounds are dull, the heart boundaries are distended, ar­
terial hypertention, bradicardia
Ischaemic heart disease and circulatory insufficiency: pain in the 
region of the heart, dyspnoea, cyanosis, odema
Respiratory: the vital, respiratory, and reserve lung capacity dimi­
nishes, which leads to oxygen lack in the body.; bronchitis and pneumonia oc­
curs often.
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Gactrointestinal: gastroptosis,fatty liver, cholecystitis and cholangi­
tis, cholelitiasis, acute and chronic pancreatitis
Urinary: pyelitis, urethritis, cystitis, urolithiasis 
Genital :dismenorrea, infertility, spontaneous abortion;decrease li­
bido and potency
Pickwick syndrome: is characterized by morbidly obesity combined 
with hypersomnia,difficult breathing, particularly during sleep and often cyano­
sis of the mucous membranes and skin.
Fig. Extreme Obesity ( BMI>40)) in a 65 years-old patient with DM Type 2, 
dislipidemias, ischemic disease and atrial hypertention.
Laboratory
ACTH,LH,ADH,insulin is often increased 
TRH,PRL decreased
Cholesterol, beta-lipoproteins, and free fatty acids increased 
DM type 2 or IGT
Uric acd in the blood increased often 
The total amount of protein decreased 
Secondary aldosteronism may occur
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The basal metabolism and the iodine cumulative capacity of the 
thyroid are often diminished
Diagnosis and differential diagnosis
Alimentary obesity is differentiated from obesity in Cushing’s syndrome 
and adipose-genital dystrophy, hypothyroidism,hyperinsulinism, primary hypo­
gonadism and diseases of the central nervus system.
As distinct from ordinary obesity:
Cushing’s syndrome: selective deposition of fat on the 
face,neck,chest,abdomen combined with thin limbs;hirsutism; the corresponding 
laboratory data and the x-ray examination and CT scan of the adrenals or sella 
turcica.
Adipose-genital dystrophy: feminine-type accumulation of fat -  on 
the chest, pubis, hips, and pelvis combined with hypoplasia of the genitals.
Hypothyroidism: the uniform accumulation of fat is combined with 
symptoms of hypothyroidism and the low values of the thyroid hormons
Hyperinsulinism: is characterized by uniform deposition of fat and
by attacks
of hypoglycaemia
Hypogenital obesity; is characterized by feminine-type deposition 
of fat, eunuchoid proportions of the body(tall height and long limbs with a rela­
tively short trank) is combination with underdeveloped genitals and secondary 
sex characters.
- Hypothalamic obesity:is a rapid gain of the body weight within a 
few months,feminine-type obesity,combination with bulimia and polydipsia,and 
with symptom of an organic lesion of the central nervous system
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Picture. Climacteric’s obesity in a male.
Picture. Cushing’s obesity. Picture. Eunuchoid fenotype
and obesity
Treatment
6 Step Treatment of Obesity
Goal is 10-15% reduction from baseline in 6 -12 month.
Step 1.General recommendation.Doctor Advice: “I belive it is impor­
tant to your health and well being that you lose weight. Together we can come 
up with a simple program for weight loss that will work for you if you follow it 
at lwast 80-90% of the time. 1 don’t expect you to be perfect all the time”.
Caloric reduction must be individualized
Step2. Diet.
Doctor Advice: Do nothing else when eating, eat only at the kitch­
en without watching TV. Wait 5 minits before another helping of foot. Do not 
“clean” your plate. Leave the table after eating. Advise patient to brush their 
teeth right after dinner or when they feel the urge to snack. Toothpaste taste does 
not mix well with foods and they may forgo eating a snack rather than having to 
re-brush, especially before bedtime.Shop from a list, do not shop when hun­
gry. Keep no snack foods in the house.Lay out exercise clothes the night before 
as a reminder to walk/jog in the moming.Avoid “night-eatingsyndrom”, seen as 
morning anorexia, evening hyperphagia and insomnia.
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Avoid trigger foods: nuts 9use air-popped popcorn), cheese, ice 
cream/frozen yogurt,chips,butter,cakes, red meat,salad dressings with oil,fatty 
fish.
Change 3 eating habits that contribute to weight problem.Snacking 
during day, eating after dinner, overeating at social events, eating in response to 
negative moods
Tо change where/when/how they eat
Need to emphasize weight control, not merely losing weight, but 
keeping it off.
Smoking cessation, stress reduction, exercise and group support
Diet
Meal - replacement plans: use meal-replacement bars or shkes (Ul­
tra-slim fast or nectle sweet success) for up to 2/3 meals. Can also get prescrip­
tion drinks such as Pro-Cal or medifast which have less total calories due to less 
sugars, but not as palatable.Aim for 1200 caloria intake.This plan is continued 
for 121 weeks.
Very low calorie diet -  1000- 1200 calorie diet.Patient needs to 
check vital signs 2 time a day (BP.temperature,pulse).
1. Protein -1 ,5g/kg/daily IB W (or 75g protein, 50g carbohydrates dai­
ly)-
2. Potassium 30mEq/daily
3. Multiple vitamin with minerals
4. NaCL 5g daily
5. Ca-carbonate 4 tablets daily (total dose 800 mg Ca)
6. 2,0 liters of fluid or more.
Weight Watchers Diet: attend weekly meetings, can only eat a cer­
tain number of food ppoints from each category. A healthy diet low in calories.
Jenny Craig Diet: carbohydrates are 60%, concentrating on com­
plex ones. Low fat foods. A healthy diet low in calories.
Dr.Dean Ornish Diet: avoid fat. Eat healthy natural food like fruits and 
vegetables, oatmeal, soy. Very healthy, but hard to maintain.Fatis <105, carbo­
hydrates 70%, protein 20%.Cholesterol intake of <5 mg/daily with vitamin sup­
plements and fish oil.
Zone diet: (40/30/30 diet), 40% complex carbohydrates, 30% pro­
tein and fat, with each meal in proper ration to avoid carhydrates craving from 
insulin bumps.
Low Carbohydrate Diets: Atkin’s Diet high protein low carbohy­
drates (<20g/daily).Can eat bacon,eggs,cheeseburger, shrimp,
fish,steak,cheese,sugarless foods. Have risk of loss of vitamine B, Ca and P. In­
duces a ketosis that leads to water loss and anorexia.
Suzanne Summers Diet: No fats with carbohydrates and if eat fruit 
need to wait at least 20 min before eat more carbohydrates.
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Step3. Exercise
Does not have to be unpleasant or punishing.
The best exrsise regime is the one the patient can perform comfort­
able and regulary
Start by walking: aim for 3.500 -5.000 extra steps per day (30-40 
min). 10.000 steps per day is optimal fro full health benefits
30 minutes/day of vigorous or 60-80 min of moderate intensi­
ty. Walr, stationary bike,low-impact aerobic video,clean house,park far 
away,take stairs
Step4. Behavior therapy
Individual or group therapy
Self-monitoring, stimulus control, stress management, cognive
change
Step5. Anti - Obesity Drugs.
No drugs cure obesity. Approved anti-obesity drugs only for short­
term use.
If BMI >30 kg/m2 or if >27 with comorbidities 
(CVD,DM,dyslipidemia)
Appetite Suppressants : work at the appetite center.
1. Noradrenergic agents (Xen-Phen) 15 mg 4 time daily.
2. Serotonergic agents : Prozac(Fluoxetine) 10-20 mgdaily, titrate to 
60 mg/daily.Antidepressant that does cause weight loss, but tend to regain by 1 
year.
3. Adrenergic/serotonergic agents : Meridia (Sibutramine): start 10 mg 
three time daily .give 1 month, then 15 mg if inadequate loss.
Metformin: antidiabetic drug has been proposed to be possible 
beneficial in improving insulin resistance and ultimately in weight loss.
Pancreatic lipase inhibitor: Xenical (Orlistat) found to be mildly to 
moderately effective. 120 mg per os three time daily with meals or within 1 hour 
after,give 3 month. Take multivitamin supplement 2 hours before or after dose. 
Leptin: a Protein that inhibits neuropeptide -y.
Cholecystokinin antagonists: feelings of satiety.
Fat substitutes: olestra (Olean)
Contraindications to obesity medsins 
ВМК27
Catabolic systemic illness 
Closed-angle glaucoma 
General anesthesia 
Medication specific contra 
Pregnancy or lactation 
Stroke
Unstable CVD
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Recent suicide attempt 
Step6. Surgery therapy.
Stomach band: the Lap-Band is an adjustable silicone band that is 
placed around the upper part of the stomach to create a small pouch.It’s limits a 
person’s food consumption and creates an earlier feeling of being full.Placed la- 
paroscopicaly.
Gactroplasty (“stomach stapling”) is treatment of last resort 
Jieunal bypass: induced global malabsorbtion. The cardia of the 
stomach is stapled is stapled across vertically leaving a small 10 ml gastric 
pouch. This helps to limit intake and prevent intake of high calorie sweets 
Liposuction 
Prognosis
With early and regularly applied treatment is favorable 
Cardiovascular diseases (myocardial infarction, cerebral stroke) and 
pneumonia are the main causes of death.
Chapter X I . Diseases of the Sexual Glands.
There are following concepts of a sex:
Chromosomal: 46XX - a female, 46ХУ - a male.
Gonadal: presence of ovaries at girls and testicles at boys.
Genital: is defined on a structure of external genitals, and hormonal 
on development of corresponding sexual hormones.
Psychological - conformity of feeling of the sex to character of ex­
ternal genitals.
Definition and terminology
Function of sexual glands, as well as all other glands of internal secretion, 
can be lowered and raised. Diseases of sexual glands can be parted on tree big 
groups:
1. Hypogonadism (Hypogenitalism)
- is a syndrome of deficiencies in gametogenesis or the secretion of 
gonadal hormones. The hypogonadism arises during the various periods of a 
life.
- Eunuchoidism :the most expressed form of a hypogonadism cha­
racterised by disproportions of a skeleton and adiposity.
2. Hypergenitalism (“early puberty”)
3. Delay o f sexual development:
- is called physiological feature of development of the organism
- not accompanied by any disorders
- often family.
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1. Diseases of the Male’s Gonads
Man's sexual system.
The testes are a paired glandulat organ situated in the scrotum
Sizes 3-5 cm ling, 2-3 cm wide (lower limit = 4 x 2,5 cm), weights 
15 -30 g, the right testicle is usually a little more than the left.
Testosterone (from the Leydig cell) is a male sex hormone.
Testosteron ation •
• The external genitals form and grow.
• The secondary sex characters develop.
• The prostate and seminal vesicles grow and develop.
• The skeletal and muscular systems form.
• Increased protein metabolism.
• The growth zones in the bones close.
• Determines libido.
• To delay of sodium, water, nitrogen.
• Provide man's socially-role behaviour.
Both positive and negative feedback may occur by androgens di­
rectly or after conversion to estrogen
Primarily involved in negative feedback on LH, whereas inhibin 
(from the Sertoli cell) suppreses FSH secretion.
Sexual development of boys.
At newborn boys testicles have length of 8-10 mm, width of 8 mm. The 
right testicle is more than left. In sexual development of boys distinguish two 
periods: 10-15 years when there is a development of genitals and secondary 
sexual signs and after 15 years - the genesial period, the spermatogenesis pe­
riod. Sexual development occurs gradually and begins with disappearance of 
hypodermic Adeps in a scrotum, its pigmentation. The doctor of the general 
practice, as well as the pediatrist should own a technique of a palpation of tes­
ticles and an estimation of results of their research. The mass of testicles of the 
adult man are on the average 25 g. The penis of the adult malei s on the average 
10-12 cm. At survey of genitals pay attention to volume of both half of scrotum, 
presence or absence in them of testicles (cryptorchism, an ectopia of testicles). 
To palpate testicles it is necessary fingers of both arms in vertical and horizon­
tal position of the patient. At survey and a palpation it is necessary to note:
1) the scrotum should be the bulb-shaped form droops (not to be tightened 
to a pubis), should be have pigmentation with numerous fine cords,
2) testicles should be lowered for a bottom of a scrotum, their configura­
tion should appear accurately visually and they should be palpated as roundish, 
elastic, mobile formations.
In the absence of one ex both testicles in a scrotum it is necessary to 
search for them by pappation in the inguinal channel in horizontal and vertical 
positions of the patient.
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There are various models testikulometer-orhidometer, representing a set 
ellipse’s models of testicles with gradual ascending of their volume from 1 to 
25 ml, with the indicating of age fluctuations of volume of testicles.
Man's secondary sexual signs:
“A male’s figure.
Growth of hair on a stomach in the form of a rhombus ("path" to a 
belly-button), in axillary fossas. Presence of growth of moustaches, beards, and 
high temples in temporal areas.
On a neck well developed guttural cartilages (“an Adam's apple”)
A Low voice timbre
Classification and ethiology
Depending on the maintenance of sexual and gonadotrophic hormones in 
blood and urine.
1. Primary Testicular Failure (hypergonadotrophic) hypogonad- 
ism.This is a syndrome caused by the direct effect of the pathological processis 
on the testis.
- characterized by increased LH/FSH
- Congenital: chromosomal defects (Klinefelter syndrome, Noonan syn­
drom), cryptorchidism, male pseudohermaphrodotism, bilateral anorchia
- germ cell defects ( Sertoli cell only syndrome; Leyding cell aplasia)
- Infection -  ТВ, mumps
- Trauma, irradiation
- Drugs, alcohol
- Poor secondary sexual development, poor muscle development
2. Secondary (hypogonadotrophic) hypogonadism. This is a syndrome 
as a result of hypothalamic-pituitary insufficiency which leads to diminished 
production of gonadotropic hormones and decreased secretion of androgens.
- characterized by decreased/normal LH
- endocrine (Cushing’s syndrome, hypothyroidism, hypopituitarism, oes­
trogen-secreting tumors)
- chronic illness
- malnutrition
- drugs (spirinolactone, GnRH agonists)
- alcohol, narcotics
- Regression of secondary sex signs: diminished of the external genitals 
(penis and testes), less of hair in axillary fossas, face, stomach, diminished of the 
muscle,ginecomastia
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Fig. Congenital hypothyroidism (cretinizm) in 17 -years-old boy. 
Height - 139 cm, weight - 39 kg. Absence of physical flexures of a backbone, 
hair on a pubis, in axillary fossa, a short neck, is not formed "an Adam's 
apple", testes is 1,5 cm in diameter, the penis corresponds to age of the 9- 
year-old child.
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3. Defects in Androgen Action
Testicular feminization (Complete androgen insensitivity) 
Incomplete androgen insensitivity (5-@-reductase deficiency)
Symptoms and signs
Clinical presentation depends on age of onset
1. Fetal life
Ambiguous genitalia and male pseudohermaphroditism
2. Prepubertal period
Poor secondary sexual development, poor muscle development 
Eunuch-like body proportions 
Underdeveloped the penis, testes, prostate gland
3. Postpubertal period
There is no disproportion of the body 
Decreased libido, erectile dysfunction, infertility 
Decreased facial and body hair if very significant androgen defi 
ciency
Fine wrinkles in the comers of mouth and eyes
Decreased in musculature
Osteoporosis with longstanding hypogonadism
Fig. 16-years-old guys.Cynoid obesity and gynecomastia (left), infan 
tile morfotype (right).
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Fig. Congenital hypogonadism .Cryptorchidism in 16-years-old. 
Height 142 cm, weight -38 kg.
Diagnosis and differential diagnosis
Is made on the basis of the medical history
Clinical picture: eunuchoidism, undevelipment of the testes, penis 
and secondary sex characters, increased LH/FSH are caracterised for primary 
hypogonadism
Development of hypogonadism following diseases of the hypotha­
lamic-pituitary system, tumor of the pituitary(confirmed by x-ray examination), 
decreased LH is confirmed secondary hypogonadism 
Treatment
Consider testosterone replacement 
Prognosis
Primary hypogonadism: is favorable for life, to full recovery is
poor.
Secondary hypogonadism: is determined by the principal disease.
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2.Gynecomastia
Proliferation of the glandular component of the malr breast 
Estrogen/androgen imbalance -  increased estrogen/androgen ratio 
Ethiology
Physiologic: neonatal (maternal hormone), puberty, aging 
Pathologic
• Primary hypogonadism,hyperthyroidism, adrenal disease, hyperpro­
lactinemia
• Tumors -  pituitary,breast, testicular, adrenal
• Chronic disease -  liver, renal, mulnutrutition
• Congenital/genetic -  Klinefelter’s syndrome
• Drugs -  cimetidine,spirinolactone,digoxin,chemotherapy,narcotics
• Familial, idiopathic
Fig. Pubertal dispituitarizm . Gynecomastia in 16 years-old boy.
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Diagnosis
Is based on history, age, onset, chronic disease,pain, drugs
Physical examination: feminization, general observe (thyroid, liver, 
testicular exam)
Laboratory and investigationsrserum TSH,PRL,LH,FSH, testoste­
rone,estradiol
Treatment
Medical: androgens for hypogonadism.Anti-estrogens -  tamox­
ifen,clomiphene
Surgical: required if gynecomastia present for > 1 year (reduction 
mmamoplasty).
3.Congenital Disorders of Sex Differentiation: Klinefelter’s 
Syndrome
Definition
Dysgenesis of the siminiferous tubules (Klinefelter’s syndrome ) is a dis­
ease caused by anomaly of the sex chromosomes
Is disturbed spermatogenesis
Occur is 1:1100 with male phenotype, among sterile 1:9
Ethiology and Pathogenesis
The cause of the disease is unknown
Is due to chromosome anomaly: extra X-chromosome kariotype 
47XXY, 48XXXY, 49XXXXY or mosaicism 46XY/47XXY
The formation of the testicles and the male genitals in the embrional 
period is normal because of the presence of the Y-chromosome in the kyriotype.
In the pubertal period, degerative changes occur in the testis with 
impairment of its normal development and insufficient secretion of testosterone
Deficiency of testosterone leads to increase in gonadotropic hor­
mones
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Picture. Klinefelter’s syndrome in a boy with karyotype 47XXXY.
Syptoms and signs
Is manifested during puberty
Patients are tall, with eunuchoid body proportions: the limbs are 
disproiportially long in relation to the trunk
Is female-type fat localization, gynaecomastia, wide pelvis, narrow
shoulders
Absence of hair growth on the fase and in the axillae, growth of hair 
on a pubis in the form of a triangle
The testes are small, flabby, firm; cryptorchidism 
The penis is usually normal in size
Libido is preserved, but patient are sterile because of azoospermia 
Mental retardation
Diagnosis and differencial diagnosis
Increased GH,LH,FSH,PRL
Testosterone decreased, but estrogens may be increased 
Is azoospermia
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Kariotype 47XXy or mosaicism with negative sex chtomatin 
Differentiated from pubertal gynecomastia and hypogonadism 
Treatment
Male sex hormone or their synthetic analogs replacement therapy 
Prognosis
Is unfavorable for full recovery 
Sterility
The working capacity depends on the degree of mental retardation
4. Diseases of the Female Gonads : Hypogonadism
The female’s sexual system
The ovary is one of the paired organs, each ovary is 3-4 cm long, 2 
-2.5 cm wide, weighs 6-7g.
Situated in the small pelvis
Two female sexual hormones (oestradiol and progesterone) are pro- 
ducted of the follicles in ovaries and reticular zone of the adrenals cortex. In 
pregnancy progesterone is also formed in the placenta.
The cells of the inner theca and the hilum of the ovary produce a 
small amount of androgens
Is controlled by pituitary FSH/LH 
Estogens action
Promote enlargent of the uterus and vagina, proliferation of the en- 
do- and myometrium
Provide the development of female secondary sex characters : the 
development of the mammary glands, shaping of a feminine figure and the cor­
responding features of the skeleton
Accelerate the differentiation and ossification of the skeleton 
Possess a protein anabolic effect 
stimulate a glycogenolysis.
Progesterone action
In the uterus creates conditions for receiving the fertilized ovum 
and maturation of the foetus
Inhibits the contractile muscular excitability of the uterus 
Stimulates the growth of the alveoli in the mammary glands 
Suppresses the effect of estrogens on the uterine mucosa during the 
menstrual cycle
In a man's organism estrogens are formed as a result of conversion of an­
drogens of testicles and adrenals in a fatty tissue and a liver in estrogens.
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Sexual developm ent o f girls. The length of ovaries of the newborn 
girl to 3 cm., by 16 years-old they become more are enlarged at length. In the 
first days of newborn girls can have a special condition - a hormonal crisis or, 
so-called "small puberty it becomes perceptible enlargement of the mammary 
glands, a desquamative vulvovaginitis, a cutaneous dropsy of external genitals. 
And by 5-8 day later there is a short metrorrhagia (1-2 days). It is bound by that 
in an organism of mother the placenta sates an organism of a foetus with estro­
gens, and in the first days after sorts their level falls. In sexual development of 
girls allocate two periods: prepuberty - since 8 years to menarche, puberty - 
from menarche till a full sexual maturity. At children growth of a follicle does 
not wear cyclic character, there is no ovulation. In the first 1-2 years the menses 
comes owing to sharp depression of level of estrogens at the moment of an atre­
sia of follicles.
Female secondary sexual signs: “feminine” figure, the developed peripa­
pillary mugs with the palpated glandular tissue, acting dummies; growth of hair 
on a pubis in the form of a triangle, presence of hair in axillary fossas, a regular 
menstrual cycle.
Hypogonadism
Classification and Ethiology
1. Primary Female’s hypogonadism :
Is a syndrome caused by direct effect of a pathological process on 
the activity of the ovaries as a result of which the secretion of the estrogens is 
reduced
Congenital : disorders of sexual differentiation (gonadal dysgene­
sis)
Damage to the ovaries by infection (mumps, ТВ)
Surgical removal
2. Secondary Female’s hypogonadism:
Is a syndrome caused by diminished production og gonadotrophic 
hormones as a result of which the secretion of estrogens is reduced
Congenital : anrenocortical dysfunction
May be caused by pituitary disease: tumor.ischemia.necrosis, 
trauma,infection (panhypopituitarism, Simmonds-Sheehan's syndrome, cranio- 
pharyngiom)
Endocrine diseases: hypothyroidism, Cushing's disease, adrenal in­
sufficiency
Mulnutritition or obesity
Amenorrhoea
Regression of secondary sex signs : hypoplasia of the external ge­
nitals and uterus, mammary glands
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Symptoms and signs
Clinical presentation depends on age of onset
1. Fetal life
Ambiguous genitalia and female pseudohermaphroditism
2. Prepubertal period
Poor secondary sexual development, poor muscle development 
Underdeveloped the uterus, vagina and ovaries 
Primary amenorrhoea 
Eunuch-like body proportions
3. Postpubertal period
Decreased LH,FSH,PRL,estrogens 
There is no disproportion of the body
Involution of secondary sex signs: mammary glands, loss of hair in 
axillary fossas and pubis, obesity
Secondary amenorrhoea, infertility 
Hypoplasia of the uterus and external genitals
Fig. Loss of hair in axillary fossae. In 38 years-old woman.Secondary 
hypogonadism.
T reatment
Consider testosterone replacement 
Prognosis
Primary hypogonadism: is favorable for life, to full recovery is
poor.
Secondary hypogonadism: is determined by the principal disease.
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5. Hirsutism and Virilization
Definition and Term inology
Both term refer to states of androgens exess 
Hirsutizm &  H yperthrichosis
Hirsutism this is male patent of hair growth in women: back, chest, 
upper abdomen
Hyperthrichosis this is excessive growth of hair in the non­
androgen-mediated areas of the body ( upper and low extremities)
Fig. Hirsutism  but w ith loss o f hair on the head as in men. Downy hair pre- 
vails on the face in a 52- years- old fem ale.__________________________________
179
Picture. Hisutizm
Virilization
Hirsutizm, frontal balging 
Deepening of voice 
Clitoral enlagment 
Increase in musculature 
Acne
D efem inization
Amenorrhea 
Decreased breast size 
Ethiology
1. Constitutional: family history, ethnic background
2. Adrenal: congenital hyperplasia or tumor
3. Ovarian: polycystic ovarian disease (PCOD) or tumor
4. Pituitary : Cushing’s disease
5. Medications. Androgen-mediated: ACTH, anabolic steroids, andro­
gens, progestational agents. Non-androgen-mediated : cyclosporine, diazoxide, 
phenytoin
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Laboratory
Increased testosterone
Increased LH/FSH, seen commonly in PCOD as ratio >2.5 
DHEA-s as measure of adrenal androgen production 
Treatment
Discontinue causative medicatuins: oral contraceptives, low dose 
glucocorticoid
Peripherial androgen antagonist: spirinolactone 
Diane -35 (combination of cyproterone acetate and estradiol) 
:blocks receptor binding
6. Congenital Disorders of Sex Differentiation; Shereshevsky 
-Turner syndrome.
Definition
Gonadal dysgenesis or Shereshevsky-Temer syndrome is caused by ano­
maly of the sex chromosomes as a consequence of which gonadal development 
in the erly embrional period is disturbed.
Occur rare 1:3000 girls that are bom 
Ethiology and Pathogenesis 
The cause of the disease is unknown
Non-separation of the sex-chromosomes during meiosis in the par­
ents
Kariotype 45X0 or varios mosaic variants: 45X0746XX; 
45XO/46XY; 45xO/47XXX etc.
Congenital absence of the gonads causes hypogenitalism 
Varios congenital defects : anomalies of the kidneys, congenital 
heart diseases, retarded growth, double ureters, occlusion of the renal arteries 
The gonads are absent are replaced by connective-tissue strands 
The uterus is hypoplastic
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Picture. Turner syndrome in a female patient with 45 X-chromosome 
complex:webbed neck,absence of secondary sex characters, retarded 
growth.
Symptoms and signs
Proportional short stature (<150 cm)
The ears are situated lower than usual, the lower jaw is often short­
ened
The hairline at ther nape of the neck is low, the neck is usually short 
Webbed neck -  skin folds pass from the head to the shoulders giv­
ing the patient a sphinx-like appearance
Skeleton abnormality: the chest is broad;a depression in the region 
of the stemum;a shortening of the fourth and fifth metacarpal bones, a moderate 
retardation of bone age from the actual age; a high hard palate 
Eayes defects: daltonism,ptosis, strabismus
Absent secondary sex characters, hypoplasia of the large and small 
pudendal lips and uterus ana a narrow vagina 
Diagnosis and differential diagnosis
Is based on the characteristic clinical picture 
Kariotype and sex chromatin investigation
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X-ray exam of the skeleton 
Differential diagnosis with Dwarfism 
T reatm ent
Hormone replacement therapy: femail sex hormones, anabolic ste­
roids
Surgery of the congenital defects of the viscers (ventricular septal 
defect, the isthmus of the aorta etc)
Prognosis
Is unfavourable to full recovery 
The patients remain sterile
Death may occur from congenital defects of the viscera
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Chapter XII. Medical Documentation. Recomendatios for 
the Taking case history of the patient with endocrine pa­
thology.
The case history is the accounting, legal, archival and historical document 
in which the part of a life of the patient is reflected, concerning its states of 
health and a site during the certain moment of time. On a case history it is possi­
ble to judge chronology of a current of disease at the concrete patient, about that 
what diagnostic and medical actions were spent to the patient and planned in the 
future at an outpatient observation for the patient. Consultations of experts of a 
different profile, consultations and their conclusions and the reference are re­
flected in a case history. On a case history it is possible to judge not only how 
the doctor estimates a state of health of the patient, what plan of its treatment 
and inspection, but also about a skill level of the attending physician, adequacy 
of spent medical-diagnostic actions. Features of a writing of a case history of the 
patient with an endocrine pathology depend on the information on some addi­
tional symptoms which allow to tap possible disturbances from endocrine sys­
tem and from the analysis and correct generalisation of already available data on 
the patient. Your problem at a case history writing consists not in simple transfer 
of that you were informed by the patient and that you have taped at physical and 
laboratory-tool inspection, and in generalisation of the received information for 
the purpose of an establishment of the correct diagnosis, drawing up of the clear 
and logically bound report on strategy and tactics of inspection, treatment and 
aftertreatment of the patient. The practical and clinical experience, a certain lex­
icon, practical both theoretical knowledge and skills is necessary for ordering of 
data. Pay attention to following principles:
- Study to state the thoughts competently, in detail stating the information 
received from the patient;
- Write down all information received by you necessary for an establish­
ment of the diagnosis, it is not necessary to make the diagnosis if you do not 
have sufficient for this purpose information;-alIocate separate headings of sec­
tions, write them on the centre of a line or with the big spaces;
- Complaints describe only in section "complaints of the patient at the 
moment of entering" and "complaints at the moment of inspection". If the pa­
tient does not show complaints from cardiovascular system, do not write it in 
section "breath organs". It is better to write down words of the patient, instead of 
how you interpret them. For example, the patient cannot show the complaint to a 
polyuria and a polydipsia as he does’t know medical terminology, is better to 
write down, that the patient notes the expressed thirst and frequent urination. 
Sometimes the patient states the purpose of the entering to hospital: "for high- 
grade inspection", "for passage of a course of special treatment".
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- Anamnesis data write in section "the anamnesis of the present disease", 
instead of at the description of clinical inspection of organs and systems;
Especially significant information underline, designate a point, an asterisk 
or allocate with other colour;
- Distinguish the essential information from minor which can be lowered. 
Lower the most part negative results and note in a case history only what have 
the immediate relation to complaints of the patient and a substantiation of your 
judgements in the course of a diagnosis establishment.
- Do not list all deviations which you have not found out in the patient, be 
limited to the indicating only the most important in the clinical relation of symp­
toms. For example, "at auscultation breath over lungs vesicular, rhonchuses are 
not present". Do not describe, that breath at the patient through a nose free and 
выделений from both nasal courses is not present. You even can not describe in 
detail border of lungs on all pulmonary fields if at the patient such pathology is 
not taped. Describe that you have taped at inspection, instead o f  that that is not 
present.
- Try to describe a condition of organs of systems it is compressed, lacon­
ically and positively, using short phrases and separate words which should be 
written it is legible;
- The sizes describe in centimetres, not using for comparison in the sizes 
of fruit and vegetables. For example, "in the right share of a thyroid gland for­
mation in the sizes about 3 cm in diameter" (but not in size with a string bean or 
a bean as such record does not reflect the true sizes of formation) is palpated.
Before the beginning of conversation with the patient be presented and, 
explain to the patient your role of the student as the fiiture doctor, the purpose of 
your conversation. Address to the patient on a name and a patronymic, instead 
of on a surname or using a sexual sign "man" - "woman" or die term of "patient" 
it is tactless and disrespectful in relation to the person.
Pay attention to that it was convenient to patient to conduct with you con­
versation: if it is necessary, let will visit a toilet, will say goodbye to relatives, 
signs nutrition. Short expectation will allow to frame necessary contact and will 
arrange to you of the patient. Speak with the patient considering its educational 
level, age, the social state. Start reception of the information, which preliminary 
write down in a notebook not to miss and to forget further the valuable informa­
tion, relying only on your memory, after all you can start to make out a case his­
tory in other day.
Case History
Biodata of the patient 
Name Aee_____Sex____
Home Adress_____Occupation Religion____Marital status
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Complaints of the__________________pa­
tient 
1. In the beginning complaints of the patient are stated at entering in a 
hospital and their detailed elaboration on systems. Begin with questions of the 
general character: "As you now feel yourselves?", "that you has resulted in a 
hospital?" Give to the patient the initiative that he has told about herself (him­
self) easy. In the beginning of conversation you do not know with what patient 
and in what mood you should deal. It can be закнутый and the silent patient or 
the patient too talkative. Probably is a patient in a grave condition it is difficult 
to them to communicate or with hostility adjusted patient. That it to find out be­
have activly. Activly listen to the patient encouraging it to conversation the be­
haviour, interest, benevolent confidence, inducing it to give about itself the addi­
tional information. Will feel for it the sympathy words "Yes, I understand you", 
a head nod, a sympathetic view, correctly understanding a situation. Do not en­
courage patients to insignificant stories about difficulties of travel to a hospital 
or about incompetence of doctors, a carelessness and callousness of medical 
staff and furthermore do not cry together with the patient. Activly listen to the 
patient and activly interfere with a narration, referring its story in the necessary 
direction for you.
2. Set direct questions :"Where is you ill ? On what the pain and when 
it has appeared is similar?" Prompt to the patient some possible answers: "This 
pain a constant or arises only after meal or to meal is not bound? A pain of stu­
pid character or acute?"During conversation with the patient it is necessary to 
avoid leading questions of type of the help: "you love salty nutrition?" It is bet­
ter to ask doubly: "That you prefer more salty or sweet?" Do not set at once 
some questions. If the patient speaks: " 1 had a strong pain in a pancreas con­
cretise its complaint. Why he considers, that this pain has arisen in a pancreas, 
will define its localisation. Do not state the sceptical relation to knowledge to 
patients of anatomy, especially do not lose time for the collecting of the neces­
sary information, leading discussion about pancreas topography. Be attentive, 
friendly, benevolent and remember, that contact between the doctor and the pa­
tient promotes finding-out of the major details of the anamnesis of disease and a 
life of the patient which can affect diagnostic and medical tactics essentially. 
Besides, a number of complaints of the patient is that, that the patient cannot tell 
about them to anybody, except the attending physician, and sometimes hesitates 
to inform on them even to it, therefore it is necessary to adhere to medical ethics 
and a deontology.
Anamnesis morbi (Origin, duration and progress):
Details of each symptom must be recorded separately .The mode of onset, 
whether sudden or gradual, the duration of each symptom and its progress and 
finally the present status of the symptom must be noted
Date of hospitalization
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Find out at what age there were first signs of disease and to what reasons 
binds its occurrence the patient: the transferred infection, a trauma, stress, influ­
ence of physical factors and others.
- What were dynamics of symptoms of illness before hospitalization, the 
reasons of the present hospitalisation (an illness exacerbation, treatment of com­
plications etc.);
- What medicinal preparations were accepted by the patient and their effi­
ciency (the name, a dose, the reception scheme, side effects).
The description of the present disease should include the relation of the 
patient to the condition: that promoted occurrence of complications or disease 
exacerbations, whether the way of life of the patient and its working capacity 
has changed. All symptoms which have forced the patient to address for the first 
time to the doctor, it is necessary to state in a chronological order. The informa­
tion is given to you by the patient, but correctly to interpret it and not to miss the 
important episodes are an indicator of your level of clinical thinking and medical 
qualification
History of the past illness
Similar illness in the past with their time of occurrence, duration and re­
sults should be noted. Chilhood illnesses, tuberculosis, hypertention, jaundice 
etc. must be inquired into. Past injuiries, accidents, operations or hospital stay 
and blood transfusion history must also be noted in details.
Anamnesis vitae (Personal history)
Patient’s appetite, food habits, type of diet, bowel and micturition habits, 
sleep and addictions like alcohol, smoking, narcotics etc., must be inquired into.
Family history:
The state of health of parents, peers and children should be noted. If any 
member is deceased, the cause of death should be noted. Some genetically 
transmitted disease should be noted into.
Physical examination
Status presents (Objective examination of the patient’s.)
To define a morphotype of the patient growth and body proportions:
- To pay attention to conformity of growth to age and the sex of the pa­
tient. The relation of length of feet to length of a trunk (at children - short; at 
adults the length of feet is more than length of a trunk; the distance between 
fingers of the arms extended in the parties is more than length of a body). An 
appreciable shorting of arms and feet ("children's proportions of a structure of a 
body") - at the hypothyrosis congenital or got in the early childhood, Dwar­
fism’s. Short and thin arms and feet - at Dwarfism; short and thick - at prema­
ture puberty. Long arms and feet are at a primary hypogonadism. The brushes 
enlarged in the cross-section size and stops, the wide thorax acting forward a 
mandible and arch of a eyebrow; big tongue and the big auricles are taped at an 
acromegalia.
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- Definition of a phenotype of the patient: adiposity degree and its topo­
graphy; at
Progressing depression of mass of a body at the kept appetite is characte­
ristic for a thyrotoxicosis, DM.
To define conformity of the sexual development to calendar age , 
sex, and degree of expression of secondary sexual signs
To estimate of topography of growth of hair and their properties 
(dry, fat, fragile, the early grey hair, abaissement) to consider racial features of 
the patient, a heredity. More expressed growth of hair becomes perceptible at 
southern nationalities. Magnificent growth of thin hair on a head at men at 
weakly developed secondary sexual signs, rare moustaches and a beard - a hy­
pogonadism sign, however at blondes and brown-haired persons The rare type 
of a pilosis becomes perceptible at normally developed external genitals. Ab­
aissement of hair in axillary fossas and on a pubis both at men, and at women is 
a sign of a secondary hypogonadism.Growth of hair on the person at women in 
the form of the Scottish small beard, on a stomach in the form of a rhombus - a 
virilescence sign
Low line of growth of hair on a nape and in the field of a forehead in a 
combination to small growth, wide pterygoid cords of a skin between mastoid 
and acromial processes ("a sphinx neck"), widely placed not developed dum­
mies of mammary glands, absence in them a glandular tissue it is characteristic 
fora Shereshevsky-Tuemersyndrome.
To pay attention to: colour, humidity, presence on a skin of separate 
elements, puffiness, a hyperpegmentation. Colour of the skin of sunburn on sites 
of a friction of clothes (ulnar, knee joints, girdle area, axillary hollows, palmar 
cords) in a combination to pigmentation of gums, a mucosa of cheeks are a 
symptom, characteristic for the primary adrenal failures .
Pigmentation of is dirty-brown colour on elbows, a neck is characteristic 
for Cushing’s syndrome; a hyperpegmentation of a skin round eyes is for a dif­
fusive toxic goiter; a hyperpegmentation palmar creases and on a brush of inter­
phalanx joints and open sites of a body are at chronic primary adrenal insuffi­
ciency.
Brown with various shades in the form of maculae xanthopathy of feet 
against shining, the varnished cold skin is a dermopathy at DM.
Hot, diffusively wet on all body, velvety skin is characteristic for a thyro­
toxicosis. Cold, shelled, dense skin in a combination to edemas of back of brush­
es, supraclavicular fossas (at pressing by a finger of hydropic fossas it is not 
formed) is characteristic for a hypothyrosis . The rugosity, thin, dry, flabby, yel­
lowish skin in a combination to an atrophy of face muscles is typical for Dwar­
fism and panhypopituitarism.
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Strips of a stretching of purple-red colour (stria) - places of local disappear­
ance of the fat on a stomach, an internal surface of hips, a breast, lumbar area are 
typical for a hypercorticoidism . Shorter and light pink colour strias are typical for 
a hypothalamic pubertal syndrome.
Spend a palpation of a thyroid gland and define degree of its aug­
mentation; to estimate gland structure, mobility, morbidity; to define a condition 
of cervical, submandibular and peripheric lymph nodes. Moderately dense, pain­
ful, rather quickly enlarged thyroid gland testifies about subacute thyroiditis. 
Dense, irregularly enlarged, with the indistinct contours, bound to surrounding 
tissues testifies a malignant degeneration of a struma. Diffusively enlarged, 
dense - autoimmune thyroiditis. At an endemic struma a thyroid gland mod­
erately dense, smooth, equal, mobile, enlarged in sizes.
Spend if necessary the special methods of objective inspection tap­
ing diseases thyroid and parathyroid glands, diabetes complications.
Independently carry out research of cardiovascular, nervous, respiratory, 
digestive, genitourinary, joints system, sense organs and result their description, 
using the skills received at studying of propaedeutics of internal illnesses. For­
mulate the preliminary diagnosis on the basis of anamnestic data and results of 
objective inspection of the patient
tem
Respiratory sys-
tem
Circulatory sys-
tem
Digestive sys-
tem
Genitourinary sys-
tem
Nervous sys-
Laboratory finding and special investigations
In the beginning state results of traditional laboratory researches and tool 
data: the general analysis of blood, the general analysis of urine, biochemical 
blood analysises, an electrocardiogram, a X-ray inspection of organs of a tho­
racal cavity.
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Conclusions of consulting physician 
Substantiation of the provisional diagnosis 
Differential diagnosis
Make the differentsialn diagnostic table, where bring data of the su­
pervised patient (the complaint, objective data, additional methods of research) 
in comparison with diseases with similar semiology.
At each concrete disease the differential diagnosis is based on the 
main symptoms of disease at the supervised patient.
Substantiation of clinical diagnosis
Should state in the short form the main complaints and the disease 
signs, anamnesis morbid and vitae, objective inspection with the indicating of 
the major clinico-biochemical, hormonal, radiological researches in concrete 
units of measure for the supervised patient, and in brackets to specify normal 
parametres of the given research.
To cite data of additional methods of research, the conclusion of 
advisers (the neuropathologist, the oculist etc.), allowing to prove the diagnosis.
should prove a disease stage (compensation, a decompensation, 
subcompensation). In the presence of complications of the given disease it is ne­
cessary to prove and define them severity level. Then the definitive diagnosis of 
disease is formulated: nosological unit, a stage of disease, complication and de­
gree of their expression, disease severity level.
Treatment
Calculate to your patient a daily calory depending on disease and its 
state, performed work to the supervised patient
To define necessary quantity of alimentary ingredients in grammes 
and calories (fibers, fats, carbohydrates) to the supervised patient
The student should show ability to combine medicinal preparations, ways 
of their introduction. Medicinal preparations to be noted in Latin transcriptions 
with the indicating of a dose, a rhythm and how use.
Name of medicine Trade name How use ( per orally,
(pharmacology) i/v, s/c, i/m)
Prognosis
The forecast is underlined concerning a life, recovery, working ca­
pacity .
Give to the supervised patient doctor’s advices
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List of diabetes-related terms and their definitions.
(ADA Diabetes World -  Professional education, 2008 Adapted from 
N1DDK.)
Below is a list of diabetes-related terms and their definitions. Use the let­
ter groupings to jump to words beginning with those letters.
A1C
a test that measures a person's average blood glucose level over the past 2 to 3 
months. Hemoglobin (HEE-mo-glo-bin) is the part of a red blood cell that car­
ries oxygen to the cells and sometimes joins with the glucose in the bloodstream. 
Also called hemoglobin A1C or glycosylated (gly-KOH-sih-lay-ted) hemoglo­
bin, the test shows the amount of glucose that sticks to the red blood cell, which 
is proportional to the amount of glucose in the blood.
acanthosis nigricans (uh-kan-THO-sis NIH-grih-kans) 
a skin condition characterized by darkened skin patches; common in people 
whose body is not responding correctly to the insulin that they make in their 
pancreas (insulin resistance). This skin condition is also seen in people who 
have pre-diabetes or Type 2 diabetes, 
acarbose (AK-er-bose)
an oral medicine used to treat Type 2 diabetes. It blocks the enzymes that digest 
starches in food. The result is a slower and lower rise in blood glucose through­
out the day, especially right after meals. Belongs to the class of medicines called 
alpha-glucosidase inhibitors. (Brand name: Precose)
ACE inhibitor
an oral medicine that lowers blood pressure; ACE stands for angiotensin (an- 
gee-oh-TEN-sin) converting enzyme. For people with diabetes, especially those 
who have protein (albumin) in the urine, it also helps slow down kidney dam­
age.
acesulfame potassium (a-see-SUL-fame puh-TAS-ee-um) 
a dietary sweetener with no calories and no nutritional value. Also known as 
acesulfame-K. (Brand name: Sunett)
acetohexamide (a-see-toh-H EX-uh-myde) 
an oral medicine used to treat Type 2 diabetes. It lowers blood glucose by help­
ing the pancreas make more insulin and by helping the body better use the insu­
lin it makes. Belongs to the class of medicines called sulfonylureas. (Brand 
name: Dymelor) 
acute
describes something that happens suddenly and for a short time. Opposite of 
chronic.
adhesive capsulitis (ad-HEE-sive cap-soo-LITE-is)
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a condition of the shoulder associated with diabetes that results in pain and loss 
of the ability to move the shoulder in all directions.
adult-onset diabetes 
former term for Type 2 diabetes.
AGEs (A-G-EEZ)
stands for advanced glycosylation (gly-KOH-sih-LAY-shun) end products. 
AGEs are produced in the body when glucose links with protein. They play a 
role in damaging blood vessels, which can lead to diabetes complications.
albu min u ria (al-B YOO-mih-N OO-ree-uh) 
a condition in which the urine has more than normal amounts of a protein called 
albumin. Albuminuria may be a sign of nephropathy (kidney disease), 
alpha cell (AL-fa)
a type of cell in the pancreas. Alpha cells make and release a hormone called 
glucagon. The body sends a signal to the alpha cells to make glucagon when 
blood glucose falls too low. Then glucagon reaches the liver where it tells it to 
release glucose into the blood for energy.
alpha-glucosidase inhibitor (AL-fa-gloo-KOH-sih-days) 
a class of oral medicine for Type 2 diabetes that blocks enzymes that digest 
starches in food. The result is a slower and lower rise in blood glucose through­
out the day, especially right after meals. (Generic names: acarbose and miglitol) 
amylin (AM-ih-lin)
a hormone formed by beta cells in the pancreas. Amylin regulates the timing of 
glucose release into the bloodstream after eating by slowing the emptying of the 
stomach.
amyotrophy (a-my-AH-truh-fee)
a Type of neuropathy resulting in pain, weakness and/or wasting in the muscles, 
anemia (uh-NEE-mee-uh)
a condition in which the number of red blood cells is less than normal, resulting 
in less oxygen being carried to the body's cells, 
angiopathy (an-gee-AH-puh-thee)
any disease of the blood vessels (veins, arteries, capillaries) or lymphatic ves­
sels.
antibodies (AN-ti-bod-eez)
proteins made by the body to protect itself from "foreign" substances such as 
bacteria or viruses. People get Type 1 diabetes when their bodies make antibo­
dies that destroy the body's own insulin-making beta cells.
ARB
an oral medicine that lowers blood pressure; ARB stands for angiotensin (an- 
gee-oh-TEN-sin) receptor blocker.
arteriosclerosis (ar-TEER-ee-oh-skluh-RO-sis) 
hardening of the arteries.
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artery
a large blood vessel that carries blood with oxygen from the heart to all parts of 
the body.
aspart insulin (ASS-part)
a rapid-acting insulin. On average, aspart insulin starts to lower blood glucose 
within 10 to 20 minutes after injection. It has its strongest effect 1 to 3 hours af­
ter injection but keeps working for 3 to 5 hours after injection, 
aspartame (ASS-per-tame)
a dietary sweetener with almost no calories and no nutritional value. (Brand 
names: Equal, NutraSweet)
atherosclerosis (ATH-uh-row-skluh-RO-sis) 
clogging, narrowing and hardening of the body's large arteries and medium­
sized blood vessels. Atherosclerosis can lead to stroke, heart attack, eye prob­
lems and kidney problems.
autoimmune disease (AW-toh-ih-MYOON) 
disorder of the body's immune system in which the immune system mistakenly 
attacks and destroys body tissue that it believes to be foreign.
autonomic neuropathy (aw-toh-NOM-ik ne-ROP-uh-thee) 
a type of neuropathy affecting the lungs, heart, stomach, intestines, bladder or 
genitals.
background retinopathy (REH-tih-NOP-uh-thee) 
a type of damage to the retina of the eye marked by bleeding, fluid accumulation 
and abnormal dilation of the blood vessels. Background retinopathy is an early 
stage of diabetic retinopathy. Also called simple or nonproliferative (non-pro- 
LIF-er-uh-tiv) retinopathy, 
basal rate
a steady trickle of low levels of longer-acting insulin, such as that used in insulin 
pumps.
beta cell
a cell that makes insulin. Beta cells are located in the islets of the pancreas, 
biguanide (by-GWAH-nide)
a class of oral medicine used to treat Type 2 diabetes that lowers blood glucose 
by reducing the amount of glucose produced by the liver and by helping the 
body respond better to insulin. (Generic name: metformin) 
blood glucose
the main sugar found in the blood and the body's main source of energy. Also 
called blood sugar.
blood glucose level
the amount of glucose in a given amount of blood. It is noted in milligrams in a 
deciliter, or mg/dL.
blood glucose meter
a small, portable machine used by people with diabetes to check their blood glu­
cose levels. After pricking the skin with a lancet, one places a drop of blood on a
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test strip in the machine. The meter (or monitor) soon displays the blood glucose 
level as a number on the meter's digital display, 
blood glucose monitoring
checking blood glucose level on a regular basis in order to manage diabetes. A 
blood glucose meter (or blood glucose test strips that change color when touched 
by a blood sample) is needed for frequent blood glucose monitoring, 
blood pressure
the force of blood exerted on the inside walls of blood vessels. Blood pressure is 
expressed as a ratio (example: 120/80, read as "120 over 80"). The first number 
is the systolic (sis-TAH-lik) pressure, or the pressure when the heart pushes 
blood out into the arteries. The second number is the diastolic (DY-uh-STAH- 
lik) pressure, or the pressure when the heart rests.
blood urea nitrogen (BUN) (yoo-REE-uhNY-truh-jen) 
a waste product in the blood from the breakdown of protein. The kidneys filter 
blood to remove urea. As kidney function decreases, the BUN levels increase, 
blood vessels
tubes that carry blood to and from all parts of the body. The three main types of 
blood vessels are arteries, veins and capillaries, 
body mass index (BMI)
a measure used to evaluate body weight relative to a person's height. BMI is 
used to find out if a person is underweight, normal weight, overweight or obese, 
bolus (BOH-lus)
an extra amount of insulin taken to cover an expected rise in blood glucose, of­
ten related to a meal or snack, 
borderline diabetes
a former term for Type 2 diabetes or impaired glucose tolerance, 
brittle diabetes
a term used when a person's blood glucose level moves often from low to high 
and from high to low.
bunion (BUN-yun)
a bulge on the first joint of the big toe, caused by the swelling of a fluid sac un­
der the skin. This spot can become red, sore and infected.
C-peptide (see-peptide)
"Connecting peptide," a substance the pancreas releases into the bloodstream in 
equal amounts to insulin. A test of C-peptide levels shows how much insulin the 
body is making, 
callus
a small area of skin, usually on the foot, that has become thick and hard from 
rubbing от pressure, 
calorie
a unit representing the energy provided by food. Carbohydrate, protein, fat and
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alcohol provide calories in the diet. Carbohydrate and protein have 4 calories per 
gram, fat has 9 calories per gram, and alcohol has 7 calories per gram, 
capillary (KAP-ih-lair-ee)
the smallest of the body's blood vessels. Oxygen and glucose pass through capil­
lary walls and enter the cells. Waste products such as carbon dioxide pass back 
from the cells into the blood through capillaries, 
capsaicin (kap-SAY-ih-sin)
an ingredient in hot peppers that can be found in ointment form for use on the 
skin to relieve pain from diabetic neuropathy, 
carbohydrate (kar-boh-HY-drate)
one of the three main nutrients in food. Foods that provide carbohydrate are 
starches, vegetables, fruits, dairy products and sugars, 
carbohydrate counting
a method of meal planning for people with diabetes based on counting the num­
ber of grams of carbohydrate in food.
cardiologist (kar-dee-AH-luh-jist) 
a doctor who treats people who have heart problems.
cardiovascular disease (KAR-dee-oh-VASK-yoo-ler) 
disease of the heart and blood vessels (arteries, veins and capillaries).
cataract (KA-ter-act) 
clouding of the lens of the eye.
cerebrovascular disease (seh-REE-broh-VASK-yoo-ler) 
damage to blood vessels in the brain. Vessels can burst and bleed or become 
clogged with fatty deposits. When blood flow is interrupted, brain cells die or 
are damaged, resulting in a stroke.
certified diabetes educator (CDE)
a health care professional with expertise in diabetes education who has met eli­
gibility requirements and successfully completed a certification exam.
Charcot's foot (shar-KOHZ)
a condition in which the joints and soft tissue in the foot are destroyed; it results 
from damage to the nerves.
chlorpropamide (klor-PROH-pah-mide) 
an oral medicine used to treat Type 2 diabetes. It lowers blood glucose levels by 
helping the pancreas make more insulin and by helping the body better use the 
insulin it makes. Belongs to the class of medicines called sulfonylureas. (Brand 
name: Diabinese)
cholesterol (koh-LES-ter-all)
a type of fat produced by the liver and found in the blood; it is also found in 
some foods. Cholesterol is used by the body to make hormones and build cell 
walls.
chronic
describes something that is long-lasting. Opposite of acute.
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circulation
the flow of blood through the body's blood vessels and heart, 
coma
a sleep-like state in which a person is not conscious. May be caused by hyper­
glycemia (high blood glucose) or hypoglycemia (low blood glucose) in people 
with diabetes.
combination oral medicines
a pill that includes two or more different medicines. See Glucovance. 
combination therapy
the use of different medicines together (oral hypoglycemic agents or an oral hy­
poglycemic agent and insulin) to manage the blood glucose levels of people with 
Type 2 diabetes.
complications
harmful effects of diabetes such as damage to the eyes, heart, blood vessels, 
nervous system, teeth and gums, feet and skin, or kidneys. Studies show that 
keeping blood glucose, blood pressure, and low-density lipoprotein cholesterol 
levels close to normal can help prevent or delay these problems.
congenital defects (kun-JEN-ih-tul) 
problems or conditions that are present at birth, 
congestive heart failure
loss of the heart's pumping power, which causes fluids to collect in the body, es­
pecially in the feet and lungs, 
conventional therapy
a term used in clinical trials where one group receives treatment for diabetes in 
which A 1C and blood glucose levels are kept at levels based on current practice 
guidelines. However, the goal is not to keep blood glucose levels as close to 
normal as possible, as is done in intensive therapy. Conventional therapy in­
cludes use of medication, meal planning and exercise, along with regular visits 
to health care providers.
coronary heart disease (KOR-uh-ner-ee) 
heart disease caused by narrowing of the arteries that supply blood to the heart. 
If the blood supply is cut off, the result is a heart attack, 
creatinine (kree-AT-ih-nin)
a waste product from protein in the diet and from the muscles of the body. Crea­
tinine is removed from the body by the kidneys; as kidney disease progresses, 
the level of creatinine in the blood increases.
D-phenylalanine derivative (dee-fen-nel-AL-ah-neen) 
a class of oral medicine for Type 2 diabetes that lowers blood glucose levels by 
helping the pancreas make more insulin right after meals. (Generic name: nateg- 
linide)
dawn phenomenon (feh-NAH-meh-nun) 
the early-morning (4 a.m. to 8 a.m.) rise in blood glucose level.
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dehydration (dee-hy-DRAY-shun)
the loss of too much body fluid through frequent urinating, sweating, diarrhea or 
vomiting.
dermopathy (dur-MAH-puh-thee) 
disease of the skin.
desensitization (dee-sens-ih-tiz-A-shun) 
a way to reduce or stop a response such as an allergic reaction to something. For 
example, if someone has an allergic reaction to something, the doctor gives the 
person a very small amount of the substance at first to increase one's tolerance. 
Over a period of time, larger doses are given until the person is taking the full 
dose. This is one way to help the body get used to the full dose and to prevent 
the allergic reaction.
Dextrose, also called glucose (DECKS-trohss) 
simple sugar found in blood that serves as the body's main source of energy.
Diabetes Control and Complications Trial (DCCT) 
a study by the National Institute of Diabetes and Digestive and Kidney Diseases, 
conducted from 1983 to 1993 in people with Type 1 diabetes. The study showed 
that intensive therapy compared to conventional therapy significantly helped 
prevent or delay diabetes complications. Intensive therapy included multiple dai­
ly insulin injections or the use of an insulin pump with multiple blood glucose 
readings each day. Complications followed in the study included diabetic reti­
nopathy, neuropathy and nephropathy.
diabetes educator
a health care professional who teaches people who have diabetes how to manage 
their diabetes. Some diabetes educators are certified diabetes educators (CDEs). 
Diabetes educators are found in hospitals, physician offices, managed care or­
ganizations, home health care and other settings, 
diabetes insipidus (in-SIP-ih-dus)
a condition characterized by frequent and heavy urination, excessive thirst and 
an overall feeling of weakness. This condition may be caused by a defect in the 
pituitary gland or in the kidney. In diabetes insipidus, blood glucose levels are 
normal.
diabetes mellitus (MELL-ih-tus)
a condition characterized by hyperglycemia resulting from the body's inability to 
use blood glucose for energy. In Type 1 diabetes, the pancreas no longer makes 
insulin and therefore blood glucose cannot enter the cells to be used for energy. 
In Type 2 diabetes, either the pancreas does not make enough insulin or the 
body is unable to use insulin correctly.
Diabetes Prevention Program (DPP)
a study by the National Institute of Diabetes and Digestive and Kidney Diseases 
conducted from 1998 to 2001 in people at high risk for Type 2 diabetes. All
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study participants had impaired glucose tolerance, also called pre-diabetes, and 
were overweight The study showed that people who lost 5 to 7 percent of their 
body weight through a low-fat, low-calorie diet and moderate exercise (usually 
walking for 30 minutes 5 days a week) reduced their risk of getting Type 2 di­
abetes by 58 percent. Participants who received treatment with the oral diabetes 
drug metformin reduced their risk of getting Type 2 diabetes by 31 percent, 
diabetic diarrhea (dy-uh-REE-uh)
loose stools, fecal incontinence, or both that result from an overgrowth of bacte­
ria in the small intestine and diabetic neuropathy in the intestines. This nerve 
damage can also result in constipation.
diabetic ketoacidosis (DKA) (KEY-toe-ass-ih-DOH-sis) 
an emergency condition in which extremely high blood glucose levels, along 
with a severe lack of insulin, result in the breakdown of body fat for energy and 
an accumulation of ketones in the blood and urine. Signs of DKA are nausea and 
vomiting, stomach pain, fruity breath odor and rapid breathing. Untreated DKA 
can lead to coma and death, 
diabetic mastopathy
a rare fibrous breast condition occurring in women, and sometimes men, with 
long-standing diabetes. The lumps are not malignant and can be surgically re­
moved, although they often recur.
diabetic myelopathy (my-eh-LAH-puh-thee) 
damage to the spinal cord found in some people with diabetes.
diabetic retinopathy (REH-tih-NOP-uh-thee) 
diabetic eye disease; damage to the small blood vessels in the retina. Loss of vi­
sion may result.
diabetogenic (DY-uh-beh-toh-JEN-ic)
causing diabetes. For example, some drugs cause blood glucose levels to rise, 
resulting in diabetes.
diabetologist (DY-uh-beh-TAH-luh-j ist) 
a doctor who specializes in treating people with diabetes, 
diagnosis (DY-ug-NO-sis)
the determination of a disease from its signs and symptoms, 
dialysis (dy-AL-ih-sis)
the process of cleaning wastes from the blood artificially. This job is normally 
done by the kidneys. If the kidneys fail, the blood must be cleaned artificially 
with special equipment. The two major forms of dialysis are hemodialysis and 
peritoneal dialysis.
dietitian (DY-eh-TIH-shun)
a health care professional who advises people about meal planning, weight con­
trol and diabetes management. A registered dietitian (RD) has more training 
dilated eye exam (DY-lay-ted)
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a test done by an eye care specialist in which the pupil (the black center) of the 
eye is temporarily enlarged with eyedrops to allow the specialist to see the in­
side of the eye more easily.
Dupuytren's contracture (doo-PWEE-trenz kon-TRACK-chur) 
a condition associated with diabetes in which the fingers and the palm of the 
hand thicken and shorten, causing the fingers to curve inward.
edema (eh-DEE-muh)swelling caused by excess fluid in the body, 
electromyography (EMG) (ee-LEK-troh-my-AH-gruh-fee) 
a test used to detect nerve function. It measures the electrical activity generated 
by muscles.
Endocrine gland (EN-doh-krin)
a group of specialized cells that release hormones into the blood. For example, 
the islets in the pancreas, which secrete insulin, are endocrine glands.
endocrinologist (EN-doh-krih-NAH-luh-jist) 
a doctor who treats people who have endocrine gland problems such as diabetes, 
enzyme (EN-zime)
protein made by the body that brings about a chemical reaction, for example, the 
enzymes produced by the gut to aid digestion.
euglycemia (you-gly-SEEM-ee-uh) 
a normal level of glucose in the blood, 
exchange lists
one of several approaches for diabetes meal planning. Foods are categorized into 
three groups based on their nutritional content. Lists provide the serving sizes 
for carbohydrates, meat and meat alternatives, and fats. These lists allow for 
substitution for different groups to keep the nutritional content fixed, 
fasting blood glucose test
a check of a person's blood glucose level after the person has not eaten for 8 to 
12 hours (usually overnight). This test is used to diagnose pre-diabetes and di­
abetes. It is also used to monitor people with diabetes, 
fat
1. One of the three main nutrients in food. Foods that provide fat are butter, 
margarine, salad dressing, oil, nuts, meat, poultry, fish and some dairy products.
2. Excess calories are stored as body fat, providing the body with a reserve 
supply of energy and other functions.
fluorescein angiography (fluh-RESS-ee-in an-gee-AH-grah-fee 
a test to examine blood vessels in the eye; done by injecting dye into an arm 
vein and then taking photos as the dye goes through the eye's blood vessels.
fructosamine test (ffook-TOH-sah-meen) 
measures the number of blood glucose molecules (MAH-leh-kyools) linked to 
protein molecules in the blood. The test provides information on the average 
blood glucose level for the past 3 weeks.
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fructose (FROOK-tohss)
a sugar that occurs naturally in fruits and honey. Fructose has 4 calories per 
gram.
gangrene (GANG-green)
the death of body tissue, most often caused by a lack of blood flow and infec­
tion. It can lead to amputation.
gastroparesis (gas-tro-puh-REE-sis)
a form of neuropathy that affects the stomach. Digestion of food may be incom­
plete or delayed, resulting in nausea, vomiting, or bloating, making blood glu­
cose control difficult.
gestational diabetes mellitus (GDM) (jes-TAY-shun-ul MELL-ih-tus) 
a type of diabetes mellitus that develops only during pregnancy and usually dis­
appears upon delivery, but increases the risk that the mother will develop di­
abetes later. GDM is managed with meal planning, activity, and, in some cases, 
insulin.
gingivitis (JIN-jih-VY-tis)
a condition of the gums characterized by inflammation and bleeding, 
gland
a group of cells that secrete substances. Endocrine glands secrete hormones. Ex­
ocrine glands secrete salt, enzymes and water, 
glargine insulin (GLAR-jeen)
very-long-acting insulin. On average, glargine insulin starts to lower blood glu­
cose levels within 1 hour after injection and keeps working evenly for 24 hours 
after injection.
glaucoma (glaw-KOH-muh)
an increase in fluid pressure inside the eye that may lead to loss of vision, 
glimepiride (gly-MEH-per-ide)
an oral medicine used to treat Type 2 diabetes. It lowers blood glucose by help­
ing the pancreas make more insulin and by helping the body better use the insu­
lin it makes. Belongs to the class of medicines called sulfonylureas. (Brand 
name: Amaryl)
glipizide (GLIH-pih-zide)
an oral medicine used to treat Type 2 diabetes. It lowers blood glucose by help­
ing the pancreas make more insulin and by helping the body better use the insu­
lin it makes. Belongs to the class of medicines called sulfonylureas. (Brand 
names: Glucotrol, Glucotrol XL)
glomerular filtration rate (glo-MEHR-yoo-lur) 
measure of the kidney's ability to filter and remove waste products, 
glomerulus (glo-MEHR-yoo-lus)
a tiny set of looping blood vessels in the kidney where the blood is filtered and 
waste products are removed.
glucagon (GLOO-kah-gahn)
a hormone produced by the alpha cells in the pancreas. It raises blood glucose.
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An injectable form of glucagon, available by prescription, may be used to treat 
severe hypoglycemia, 
glucose
one of the simplest forms of sugar, 
glucose tablets
chewable tablets made of pure glucose used for treating hypoglycemia. 
Glucovance
an oral medicine used to treat Type 2 diabetes. It is a combination of glyburide 
and metformin.
glyburide (GLY-buh-ride)
an oral medicine used to treat Type 2 diabetes. It lowers blood glucose by help­
ing the pancreas make more insulin and by helping the body better use the insu­
lin it makes. Belongs to the class of medicines called sulfonylureas. (Brand 
names: DiaBeta, Glynase PresTab, Micronase; ingredient in Glucovance) 
glycemic index (gly-SEE-mik)
a ranking of carbohydrate-containing foods, based on the food's effect on blood 
glucose compared with a standard reference food.
glycogen (GLY-koh-jen) 
the form of glucose found in the liver and muscles.
glycosuria (gly-koh-SOOR-ee-ah) 
the presence of glucose in the urine, 
gram
a unit of weight in the metric system. An ounce equals 28 grams. In some meal 
plans for people with diabetes, the suggested amounts of food are given in 
grams.
HDL cholesterol, stands for high-density-lipoprotein cholester­
ol (kuh-LESS-tuh-rawl LIP-oh-PRO-teen)
a fat found in the blood that takes extra cholesterol from the blood to the liver 
for removal. Sometimes called "good" cholesterol, 
heredity
the passing of a trait from parent to child, 
honeymoon phase
Some people with type 1 diabetes experience a brief remission called the "ho­
neymoon period." During this time their pancreas may still secrete some insulin. 
Over time, this secretion stops and as this happens, the child will require more 
insulin from injections. The honeymoon period can last weeks, months, or even 
up to a year or more, 
hormone
a chemical produced in one part of the body and released into the blood to trig­
ger or regulate particular functions of the body. For example, insulin is a hor­
mone made in the pancreas that tells other cells when to use glucose for energy. 
Synthetic hormones, made for use as medicines, can be the same or different 
from those made in the body.
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human leukocyte antigens (HLA)
proteins located on the surface of the cell that help the immune system identify 
the cell either as one belonging to the body or as one from outside the body. 
Some patterns of these proteins may mean increased risk of developing Type 1 
diabetes.
hyperglycemia (HY-per-gly-SEE-mee-uh) 
excessive blood glucose. Fasting hyperglycemia is blood glucose above a desir­
able level after a person has fasted for at least 8 hours. Postprandial hypergly­
cemia is blood glucose above a desirable level 1 to 2 hours after a person has ea­
ten.
hyperinsulinemia (HY-per-IN-suh-lih-NEE-mee-uh) 
a condition in which the level of insulin in the blood is higher than normal. 
Caused by overproduction of insulin by the body. Related to insulin resistance.
hyperlipidemia (HY-per-li-pih-DEE-mee-uh) 
higher than normal fat and cholesterol levels in the blood.
hyperosmolar hyperglycemic nonketotic syndrome (HHNS) (HY-per- 
oz-MOH-lur HY-per-gly-SEE-mik non-kee-TAH-tik)
an emergency condition in which one's blood glucose level is very high and ke­
tones are not present in the blood or urine. If HHNS is not treated, it can lead to 
coma or death.
hypertension (HY-per-TEN-shun)
a condition present when blood flows through the blood vessels with a force 
greater than normal. Also called high blood pressure. Hypertension can strain 
the heart, damage blood vessels, and increase the risk of heart attack, stroke, 
kidney problems and death.
hypoglycemia (hy-po-gly-SEE-mee-uh) 
a condition that occurs when one's blood glucose is lower than normal, usually 
less than 70 mg/dL. Signs include hunger, nervousness, shakiness, perspiration, 
dizziness or light-headedness, sleepiness, and confusion. If left untreated, hy­
poglycemia may lead to unconsciousness. Hypoglycemia is treated by consum­
ing a carbohydrate-rich food such as a glucose tablet or juice. It may also be 
treated with an injection of glucagon if the person is unconscious or unable to 
swallow. Also called an insulin reaction.
hypoglycemia unawareness (un-uh-WARE-ness) 
a state in which a person does not feel or recognize the symptoms of hypogly­
cemia. People who have frequent episodes of hypoglycemia may no longer ex­
perience the warning signs of it.
hypotension (hy-poh-TEN-shun)
low blood pressure or a sudden drop in blood pressure. Hypotension may occur 
when a person rises quickly from a sitting or reclining position, causing dizzi­
ness or fainting.
IDDM (insulin-dependent diabetes mellitus) 
former term for Type 1 diabetes.
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immune system (ih-MYOON)
the body's system for protecting itself from viruses and bacteria or any "foreign" 
substances.
immunosuppressant (ih-MYOON-oh-suh-PRESS-unt) 
a drug that suppresses the natural immune responses. Immunosuppressants are 
given to transplant patients to prevent organ rejection or to patients with au­
toimmune diseases.
impaired fasting glucose (IFG)
a condition in which a blood glucose test, taken after an 8- to 12-hour fast, 
shows a level of glucose higher than normal but not high enough for a diagnosis 
of diabetes. IFG, also called pre-diabetes, is a level of 100 mg/dL to 125 mg/dL. 
Most people with pre-diabetes are at increased risk for developing type 2 di­
abetes.
impaired glucose tolerance (IGT)
a condition in which blood glucose levels are higher than normal but are not 
high enough for a diagnosis of diabetes. IGT, also called pre-diabetes, is a level 
of 140 mg/dL to 199 mg/dL 2 hours after the start of an oral glucose tolerance 
test. Most people with pre-diabetes are at increased risk for developing type 2 
diabetes. Other names for IGT that are no longer used are "borderline," "subclin- 
ical," "chemical," or "latent" diabetes.
implantable insulin pump (im-PLAN-tuh-bull) 
a small pump placed inside the body to deliver insulin in response to remote- 
control commands from the user, 
impotence (IM-po-tents)
the inability to get or maintain an erection for sexual activity. Also called erec­
tile (ee-REK-tile) dysfunction (dis-FUNK-shun). 
incidence (IN-sih-dints)
a measure of how often a disease occurs; the number of new cases of a disease 
among a certain group of people for a certain period of time, 
incontinence (in-KON-tih-nents)
loss of bladder or bowel control; the accidental loss of urine or feces, 
inhaled insulin
an experimental treatment for taking insulin using a portable device that allows a 
person to breathe in insulin, 
injection (in-JEK-shun)
inserting liquid medication or nutrients into the body with a syringe. A person 
with diabetes may use short needles or pinch the skin and inject at an angle to 
avoid an intramuscular injection of insulin, 
injection site rotation
changing the places on the body where insulin is injected. Rotation prevents the 
formation of lipodystrophies, 
injection sites
places on the body where insulin is usually injected.
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insulin
a hormone that helps the body use glucose for energy. The beta cells of the pan­
creas make insulin. When the body cannot make enough insulin, it is taken by 
injection or through use of an insulin pump, 
insulin adjustment
a change in the amount of insulin a person with diabetes takes based on factors 
such as meal planning, activity and blood glucose levels, 
insulin analogues
An insulin analogue is a tailored form of insulin in which certain amino acids in 
the insulin molecule have been modified. The analogue acts in the same way as 
the original insulin, but with some beneficial differences for people with di­
abetes. Analogues are sometimes referred to as "designer" insulins, 
insulin pen
a device for injecting insulin that looks like a fountain pen and holds replaceable 
cartridges of insulin. Also available in disposable form, 
insulin pump
an insulin-delivering device about the size of a deck of cards that can be worn 
on a belt or kept in a pocket. An insulin pump connects to narrow, flexible plas­
tic tubing that ends with a needle inserted just under the skin. Users set the pump 
to give a steady trickle or basal amount of insulin continuously throughout the 
day. Pumps release bolus doses of insulin (several units at a time) at meals and 
at times when blood glucose is too high, based on programming done by the us­
er.
insulin reaction
when the level of glucose in the blood is too low (at or below 70 mg/dL). Also 
known as hypoglycemia, 
insulin receptors
areas on the outer part of a cell that allow the cell to bind with insulin in the 
blood. When the cell and insulin bind, the cell can take glucose from the blood 
and use it for energy.
insulin resistance
the body’s inability to respond to and use the insulin it produces. Insulin resis­
tance may be linked to obesity, hypertension, and high levels of fat in the blood.
insulin-dependent diabetes mellitus (1DDM) 
former term for Type 1 diabetes.
insulinoma (IN-suh-lih-NOH-mah)
a tumor of the beta cells in the pancreas. An insulinoma may cause the body to 
make extra insulin, leading to hypoglycemia, 
intensive therapy
a treatment for diabetes in which blood glucose is kept as close to normal as 
possible through frequent injections or use of an insulin pump; meal planning; 
adjustment of medicines; and exercise based on blood glucose test results and 
frequent contact with a person’s health care team.
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intermediate-acting insulin
a type of insulin that starts to lower blood glucose within 1 to 2 hours after injec­
tion and has its strongest effect 6 to 12 hours after injection, depending on the 
type used. See lente insulin and NPH insulin.
intermittent claudication (IN-ter-MIT-ent CLAW-dih-KAY-shun) 
pain that comes and goes in the muscles of the leg. This pain results from a lack 
of blood supply to the legs and usually happens when walking or exercising.
intramuscular injection (in-trah-MUS-kyoo-lar)
inserting liquid medication into a muscle with a syringe. Glucagon may be given 
by subcutaneous or intramuscular injection for hypoglycemia.
islet cell autoantibodies (ICA) (EYE-let aw-toe-AN-ti-bod-eez) 
proteins found in the blood of people newly diagnosed with Type 1 diabetes. 
They are also found in people who may be developing Type 1 diabetes. The 
presence of ICA indicates that the body's immune system has been damaging 
beta cells in the pancreas, 
islet transplantation
moving the islets from a donor pancreas into a person whose pancreas has 
stopped producing insulin. Beta cells in the islets make the insulin that the body 
needs for using blood glucose, 
islets
groups of cells located in the pancreas that make hormones that help the body 
break down and use food. For example, alpha cells make glucagon and beta cells 
make insulin. Also called islets of Langerhans (LANG-er-hahns). 
jet injector (in-JEK-tur)
a device that uses high pressure instead of a needle to propel insulin through the 
skin and into the body, 
juvenile diabetes
former term for insulin-dependent diabetes mellitus (IDDM), or Type 1 diabetes, 
ketone
a chemical produced when there is a shortage of insulin in the blood and the 
body breaks down body fat for energy. High levels of ketones can lead to diabet­
ic ketoacidosis and coma. Sometimes referred to as ketone bodies, 
ketonuria (key-toe-NUH-ree-ah)
a condition occurring when ketones are present in the urine, a warning sign of 
diabetic ketoacidosis.
ketosis (ke-TOE-sis)
a ketone buildup in the body that may lead to diabetic ketoacidosis. Signs of ke­
tosis are nausea, vomiting, and stomach pain, 
kidney failure
a chronic condition in which the body retains fluid and harmful wastes build up 
because the kidneys no longer work properly. A person with kidney failure 
needs dialysis or a kidney transplant. Also called end-stage renal (REE-nul) dis­
ease or ESRD.
205
kidneys
the two bean-shaped organs that filter wastes from the blood and form urine. 
The kidneys are located near the middle of the back. They send urine to the 
bladder.
Kussmaul breathing (KOOS-mall)
the rapid, deep, and labored breathing of people who have diabetic ketoacidosis, 
lancet
a spring-loaded device used to prick the skin with a small needle to obtain a 
drop of blood for blood glucose monitoring, 
laser surgery treatment
a type of therapy that uses a strong beam of light to treat a damaged area. The 
beam of light is called a laser. A laser is sometimes used to seal blood vessels in 
the eye of a person with diabetes. See photocoagulation.
latent autoimmune diabetes in adults (LADA) 
a condition in which Type 1 diabetes develops in adults.
LDL cholesterol, stands for low-density lipoprotein cholesterol (kuh- 
LESS-tuh-rawl LIP-oh-PRO-teen)
a fat found in the blood that takes cholesterol around the body to where it is 
needed for cell repair and also deposits it on the inside of artery walls. Some­
times called "bad" cholesterol.
Jente insulin (LEN-tay)
an intermediate-acting insulin. On average, lente insulin starts to lower blood 
glucose levels within 1 to 2 hours after injection. It has its strongest effect 8 to 
12 hours after injection but keeps working for 18 to 24 hours after injection. Al­
so called L insulin.
limited joint mobility
a condition in which the joints swell and the skin of the hand becomes thick, 
tight, and waxy, making the joints less able to move. It may affect the fingers 
and arms as well as other joints in the body, 
lipid (LIP-id)
a term for fat in the body. Lipids can be broken down by the body and used for 
energy.
lipid profile
a blood test that measures total cholesterol, triglycerides, and HDL cholesterol. 
LDL cholesterol is then calculated from the results. A lipid profile is one meas­
ure of a person's risk of cardiovascular disease, 
lipoatrophy (LIP-oh-AT-ruh-fee)
loss of fat under the skin resulting in small dents. Lipoatrophy may be caused by 
repeated injections of insulin in the same spot, 
lipodystrophy (LIP-oh-DIH-struh-fee)
defect in the breaking down or building up of fat below the surface of the skin, 
resulting in lumps or small dents in the skin surface. (See lipohypertrophy or li-
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poatrophy.) Lipodystrophy may be caused by repeated injections of insulin in 
the same spot.
lipohypertrophy (LIP-oh-hy-PER-truh-fee) 
buildup of fat below the surface of the skin, causing lumps. Lipohypertrophy 
may be caused by repeated injections of insulin in the same spot, 
lispro insulin (LYZ-proh)
a rapid-acting insulin. On average, lispro insulin starts to lower blood glucose 
within 5 minutes after injection. It has its strongest effect 30 minutes to 1 hour 
after injection but keeps working for 3 hours after injection, 
liver
an organ in the body that changes food into energy, removes alcohol and poisons 
from the blood, and makes bile, a substance that breaks down fats and helps rid 
the body of wastes.
long-acting insulin
a type of insulin that starts to lower blood glucose within 4 to 6 hours after injec­
tion and has its strongest effect 10 to 18 hours after injection. See ultralente in­
sulin.
macrosomia (mack-roh-SOH-mee-ah)
abnormally large; in diabetes, refers to abnormally large babies that may be bom 
to women with diabetes.
macrovascular disease (mack-roh-VASK-yoo-ler) 
disease of the large blood vessels, such as those found in the heart. Lipids and 
blood clots build up in the large blood vessels and can cause atherosclerosis, co­
ronary heart disease, stroke, and peripheral vascular disease, 
macula (MACK-yoo-la)
the part of the retina in the eye used for reading and seeing fine detail.
macular edema (MACK-yoo-lur eh-DEE-mah) 
swelling of the macula.
mastopathy, diabetic
a rare fibrous breast condition occurring in women, and sometimes men, with 
long-standing diabetes. The lumps are not malignant and can be surgically re­
moved, although they often recur.
maturity-onset diabetes of the young (MODY) 
a kind of Type 2 diabetes that accounts for 1 to 5 percent of people with di­
abetes. Of the six forms identified, each is caused by a defect in a single gene, 
meglitinide (meh-GLIH-tin-ide)
a class of oral medicine for Type 2 diabetes that lowers blood glucose by help­
ing the pancreas make more insulin right after meals. (Generic name: repagli- 
nide)
metabolic syndrome
the tendency of several conditions to occur together, including obesity, insulin 
resistance, diabetes or pre-diabetes, hypertension, and high lipids.
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metabolism
the term for the way cells chemically change food so that it can be used to store 
or use energy and make the proteins, fats, and sugars needed by the body, 
metformin (met-FOR-min)
an oral medicine used to treat Type 2 diabetes. It lowers blood glucose by reduc­
ing the amount of glucose produced by the liver and helping the body respond 
better to the insulin made in the pancreas. Belongs to the class of medicines 
called biguanides. (Brand names: Glucophage, Glucophage XR; an ingredient in 
Glucovance) 
mg/dL
milligrams (MILL-ih-grams) per deciliter (DESS-ih-lee-tur), a unit of measure 
that shows the concentration of a substance in a specific amount of fluid. In the 
United States, blood glucose test results are reported as mg/dL. Medical journals 
and other countries use millimoles per liter (mmol/L). To convert to mg/dL from 
mmol/L, multiply mmol/L by 18. Example: 10 mmol/L x 18 = 180 mg/dL.
microalbumin (MY-kro-al-BYOO-min) 
small amounts of the protein called albumin in the urine detectable with a spe­
cial lab test.
microalbuminuria (MY-kro-al-BYOO-min-your-EE-ah) 
the presence of small amounts of albumin, a protein, in the urine. Microalbumi­
nuria is an early sign of kidney damage, or nephropathy, a common and serious 
complication of diabetes. The ADA recommends that people diagnosed with 
type 2 diabetes be tested for microalbuminuria at the time they are diagnosed 
and every year thereafter; people with type 1 diabetes should be tested 5 years 
after diagnosis and every year thereafter. Microalbuminuria is usally managed 
by improving blood glucose control, reducing blood pressure, and modifying the 
diet.
microaneurysm (MY-kro-AN-yeh-rizm) 
a small swelling that forms on the side of tiny blood vessels. These small swel­
lings may break and allow blood to leak into nearby tissue. People with diabetes 
may get microaneurysms in the retina of the eye.
microvascular disease (MY-kro-VASK-yoo-ler) 
disease of the smallest blood vessels, such as those found in the eyes, nerves, 
and kidneys. The walls of the vessels become abnormally thick but weak. Then 
they bleed, leak protein, and slow the flow of blood to the cells, 
miglitol (MIG-lih-tall)
an oral medicine used to treat Type 2 diabetes. It blocks the enzymes that digest 
starches in food. The result is a slower and lower rise in blood glucose through­
out the day, especially right after meals. Belongs to the class of medicines called 
alpha-glucosidase inhibitors. (Brand name: Glyset) 
mixed dose
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a combination of two types of insulin in one injection. Usually a rapid- or short­
acting insulin is combined with a longer acting insulin (such as NPH insulin) to 
provide both short-term and long-term control of blood glucose levels. 
mmol/L
millimoles per liter, a unit of measure that shows the concentration of a sub­
stance in a specific amount of fluid. In most of the world, except for the United 
States, blood glucose test results are reported as mmol/L. In the United States, 
milligrams per deciliter (mg/dL) is used. To convert to mmol/L from mg/dL, di­
vide mg/dL by 18. Example: 180 mg/dL ч 18 = 10 mmol/L. 
monofilament
a short piece of nylon, like a hairbrush bristle, mounted on a wand. To check 
sensitivity of the nerves in the foot, the doctor touches the filament to the bottom 
of the foot.
mononeuropathy (MAH-noh-ne-ROP-uh-thee) 
neuropathy affecting a single nerve.
myocardial infarction (my-oh-KAR-dee-ul in-FARK-shun) 
an interruption in the blood supply to the heart because of narrowed or blocked 
blood vessels. Also called a heart attack.
nateglinide (neh-TEH-glin-ide)
an oral medicine used to treat Type 2 diabetes. It lowers blood glucose levels by 
helping the pancreas make more insulin right after meals. Belongs to the class of 
medicines called D-phenylalanine derivatives. (Brand name: Starlix)
necrobiosis lipoidica diabeticorum (NEK-roh-by-OH-sis lih-POY-dik- 
ah DY-uh-bet-ih-KOR-um)
a skin condition usually on the lower part of the legs. Lesions can be small or 
extend over a large area. They are usually raised, yellow, and waxy in appear­
ance and often have a purple border.
neovascularization (NEE-oh-VASK-yoo-ler-ih-ZAY-shun) 
the growth of new, small blood vessels. In the retina, this may lead to loss of vi­
sion or blindness.
nephrologist (neh-FRAH-luh-jist) 
a doctor who treats people who have kidney problems, 
nephropathy (neh-FROP-uh-thee)
disease of the kidneys. Hyperglycemia and hypertension can damage the kid­
neys' glomeruli. When the kidneys are damaged, protein leaks out of the kidneys 
into the urine. Damaged kidneys can no longer remove waste and extra fluids 
from the bloodstream.
nerve conduction studies
tests used to measure for nerve damage; one way to diagnose neuropathy, 
neurologist (ne-RAH-luh-jist)
a doctor who specializes in problems of the nervous system, such as neuropathy.
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neuropathy (ne-ROP-uh-thee)
disease of the nervous system. The three major forms in people with diabetes are 
peripheral neuropathy, autonomic neuropathy, and mononeuropathy. The most 
common form is peripheral neuropathy, which affects mainly the legs and feet.
noninsulin-dependent diabetes mellitus (NIDDM) 
former term for Type 2 diabetes.
noninvasive blood glucose monitoring (NON-in-VAY-siv) 
measuring blood glucose without pricking the finger to obtain a blood sample. 
NPH insulin
an intermediate-acting insulin; NPH stands for neutral protamine Hagedom. On 
average, NPH insulin starts to lower blood glucose within 1 to 2 hours after in­
jection. It has its strongest effect 6 to 10 hours after injection but keeps working 
about 10 hours after injection. Also called N insulin, 
nutritionist (noo-TRJH-shuh-nist)
a person with training in nutrition; may or may not have specialized training and 
qualifications. See dietitian.
obesity
a condition in which a greater than normal amount of fat is in the body; more 
severe than overweight; having a body mass index of 30 or more.
obstetrician (ob-steh-TRIH-shun) 
a doctor who treats pregnant women and delivers babies.
ophthalmologist (AHF-thal-MAH-luh-jist) 
a medical doctor who diagnoses and treats all eye diseases and eye disorders. 
Opthalmologists can also prescribe glasses and contact lenses, 
optician (ahp-TI-shun)
a health care professional who dispenses glasses and lenses. An optician also 
makes and fits contact lenses.
optometrist (ahp-TAH-meh-trist)
a primary eye care provider who prescribes glasses and contact lenses. Opto­
metrists can diagnose and treat certain eye conditions and diseases, 
oral glucose tolerance test (OGTT)
a test to diagnose pre-diabetes and diabetes. The oral glucose tolerance test is 
given by a health care professional after an overnight fast. A blood sample is 
taken, then the patient drinks a high-glucose beverage. Blood samples are taken 
at intervals for 2 to 3 hours. Test results are compared with a standard and show 
how the body uses glucose over time.
oral hypoglycemic agents (hy-po-gly-SEE-mik) 
medicines taken by mouth by people with Type 2 diabetes to keep blood glucose 
levels as close to normal as possible. Classes of oral hypoglycemic agents are 
alpha-glucosidase inhibitors, biguanides, D-phenylalanine derivatives, megliti- 
nides, sulfonylureas, and thiazolidinediones.
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overweight
an above-normal body weight; having a body mass index of 25 to 29.9. 
pancreas (PAN-kree-us)
an organ that makes insulin and enzymes for digestion. The pancreas is located 
behind the lower part of the stomach and is about the size of a hand.
pancreas transplantation
a surgical procedure to take a healthy whole or partial pancreas from a donor 
and place it into a person with diabetes.
Pediatric endocrinologist (pee-dee-AT-rik en-doh-krih-NAH-luh-jist) 
a doctor who treats children who have endocrine gland problems such as di­
abetes.
pedorthist (ped-OR-thist)
a health care professional who specializes in fitting shoes for people with dis­
abilities or deformities. A pedorthist can custom-make shoes or orthotics (spe­
cial inserts for shoes).
periodontal disease (PER-ee-oh-DON-tul) 
disease of the gums.
periodontist (PER-ee-oh-DON-tist) 
a dentist who specializes in treating people who have gum diseases.
peripheral neuropathy (puh-RIF-uh-rul ne-ROP-uh-thee) 
nerve damage that affects the feet, legs, or hands. Peripheral neuropathy causes 
pain, numbness, or a tingling feeling.
peripheral vascular disease (PVD) (puh-RIF-uh-rul VAS-kyoo-ler) 
a disease of the large blood vessels of the arms, legs, and feet. PVD may occur 
when major blood vessels in these areas are blocked and do not receive enough 
blood. The signs of PVD are aching pains and slow-healing foot sores, 
pharmacist (FAR-mah-sist)
a health care professional who prepares and distributes medicine to people. 
Pharmacists also give information on medicines.
photocoagulation (FOH-toh-koh-ag-yoo-LAY-shun) 
a treatment for diabetic retinopathy. A strong beam of light (laser) is used to seal 
off bleeding blood vessels in the eye and to bum away extra blood vessels that 
should not have grown there.
pioglitazone (py-oh-GLIT-uh-zone)
an oral medicine used to treat Type 2 diabetes. It helps insulin take glucose from 
the blood into the cells for energy by making cells more sensitive to insulin. Be­
longs to the class of medicines called thiazolidinediones. (Brand name: Actos) 
podiatrist (puh-DY-uh-trist)
a doctor who treats people who have foot problems. Podiatrists also help people 
keep their feet healthy by providing regular foot examinations and treatment 
podiatry (puh-DY-uh-tree) 
the care and treatment of feet, 
point system
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a meal planning system that uses points to rate the caloric content of foods.
polydipsia (pah-lee-DIP-see-uh) 
excessive thirst; may be a sign of diabetes.
polyphagia (pah-lee-FAY-jee-ah) 
excessive hunger; may be a sign of diabetes.
polyuria (pah-lee-YOOR-ee-ah) 
excessive urination; may be a sign of diabetes.
postprandial blood glucose (post-PRAN-dee-ul) 
the blood glucose level taken 1 to 2 hours after eating, 
pre-diabetes
a condition in which blood glucose levels are higher than normal but are not 
high enough for a diagnosis of diabetes. People with pre-diabetes are at in­
creased risk for developing Type 2 diabetes and for heart disease and stroke. 
Other names for pre-diabetes are impaired glucose tolerance and impaired fast­
ing glucose.
premixed insulin
a commercially produced combination of two different types of insulin. See 
50/50 insulin and 70/30 insulin.
preprandial blood glucose (pree-PRAN-dee-ul 
the blood glucose level taken before eating, 
prevalence
the number of people in a given group or population who are reported to have a 
disease.
proinsulin (proh-IN-suh-lin)
the substance made first in the pancreas and then broken into several pieces to 
become insulin.
proliferative retinopathy (pro-LIH-fur-ah-tiv REH-tih-NOP-uh-thee) 
a condition in which fragile new blood vessels grow along the retina and in the 
vitreous humor of the eye.
prosthesis (prahs-THEE-sis)
a man-made substitute for a missing body part such as an arm or a leg. 
protein (PRO-teen)
1. One of the three main nutrients in food. Foods that provide protein include 
meat, poultry, fish, cheese, milk, dairy products, eggs, and dried beans. 2. Pro­
teins are also used in the body for cell structure, hormones such as insulin, and 
other functions.
proteinuria (PRO-tee-NOOR-ee-uh)
the presence of protein in the urine, indicating that the kidneys are not working 
properly.
rapid-acting insulin
a type of insulin that starts to lower blood glucose within 5 to 10 minutes after 
injection and has its strongest effect 30 minutes to 3 hours after injection, de­
pending on the type used. See aspart insulin and lispro insulin.
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rebound hyperglycemia (HY-per-gly-SEE-mee-ah) 
a swing to a high level of glucose in the blood after a low level. See Somogyi 
effect.
Recognized Diabetes Education Programs
diabetes self-management education programs that are approved by the Ameri­
can Diabetes Association, 
regular insulin
short-acting insulin. On average, regular insulin starts to lower blood glucose 
within 30 minutes after injection. It has its strongest effect 2 to 5 hours after in­
jection but keeps working 5 to 8 hours after injection. Also called R insulin, 
renal (REE-nal)
having to do with the kidneys. A renal disease is a disease of the kidneys. Renal 
failure means the kidneys have stopped working.
renal threshold of glucose (THRESH-hold) 
the blood glucose concentration at which the kidneys start to excrete glucose in­
to the urine.
repaglinide (reh-PAG-lih-nide)
an oral medicine used to treat Type 2 diabetes. It lowers blood glucose by help­
ing the pancreas make more insulin right after meals. Belongs to the class of 
medicines called meglitinides. (Brand name: Prandin) 
retina (REH-ti-nuh)
the light-sensitive layer of tissue that lines the back of the eye. 
risk factor
anything that raises the chances of a person developing a disease, 
rosiglitazone (rose-ee-GLIH-tuh-zone)
an oral medicine used to treat Type 2 diabetes. It helps insulin take glucose from 
the blood into the cells for energy by making cells more sensitive to insulin. Be­
longs to the class of medicines called thiazolidinediones. (Brand name: Avan- 
dia)
saccharin (SAK-ah-rin)
a sweetener with no calories and no nutritional value, 
secondary diabetes
a type of diabetes caused by another disease or certain drugs or chemicals, 
self-management
in diabetes, the ongoing process of managing diabetes. Includes meal planning, 
planned physical activity, blood glucose monitoring, taking diabetes medicines, 
handling episodes of illness and of low and high blood glucose, managing di­
abetes when traveling, and more. The person with diabetes designs his or her 
own self-management treatment plan in consultation with a variety of health 
care professionals such as doctors, nurses, dietitians, pharmacists, and others, 
sharps container
a container for disposal of used needles and syringes; often made of hard plastic 
so that needles cannot poke through.
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short-acting insulin
a type of insulin that starts to lower blood glucose within 30 minutes after injec­
tion and has its strongest effect 2 to 5 hours after injection. See regular insulin, 
side effects
the unintended action(s) of a drug, 
sliding scale
a set of instructions for adjusting insulin on the basis of blood glucose test re­
sults, meals, or activity levels.
Somogyi effect, also called rebound hyperglycemia (suh-MOH-jee) 
when the blood glucose level swings high following hypoglycemia. The So­
mogyi effect may follow an untreated hypoglycemic episode during the night 
and is caused by the release of stress hormones, 
sorbitol (SORE-bih-tall)
1. A sugar alcohol (sweetener) with 2.6 calories per gram. 2. A substance pro­
duced by the body in people with diabetes that can cause damage to the eyes and 
nerves.
split mixed dose
division of a prescribed daily dose of insulin into two or more injections given 
over the course of the day. 
starch
another name for carbohydrate, one of the three main nutrients in food, 
stroke
condition caused by damage to blood vessels in the brain; may cause loss of 
ability to speak or to move parts of the body.
subcutaneous injection (sub-kyoo-TAY-nee-us) 
putting a fluid into the tissue under the skin with a needle and syringe, 
sucralose
a sweetener made from sugar but with no calories and no nutritional value, 
sucrose
a two-part sugar made of glucose and fructose. Known as table sugar or white 
sugar, it is found naturally in sugar cane and in beets, 
sugar
1. A class of carbohydrates with a sweet taste, including glucose, fructose and 
sucrose. 2. A term used to refer to blood glucose, 
sugar alcohols
sweeteners that produce a smaller rise in blood glucose than other carbohy­
drates. Their calorie content is about 2 calories per gram. Includes erythritol, 
hydrogenated starch hydrolysates, isomalt, lactitol, maltitol, mannitol, sorbitol, 
and xylitol. Also known as polyols (PAH-lee-alls.) 
sugar diabetes
former term for diabetes mellitus.
sulfonylurea (sul-fah-nil-yoo-REE-ah)
a class of oral medicine for Type 2 diabetes that lowers blood glucose by help­
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ing the pancreas make more insulin and by helping the body better use the insu­
lin it makes. (Generic names: acetohexamide, chlorpropamide, glimepiride, gli­
pizide, glyburide, tolazamide, tolbutamide) 
syringe (suh-RINJ)
a device used to inject medications or other liquids into body tissues. The sy­
ringe for insulin has a hollow plastic tube with a plunger inside and a needle on 
the end.
team management
a diabetes treatment approach in which medical care is provided by a team of 
health care professionals including a doctor, a dietitian, a nurse, a diabetes edu­
cator, and others. The team acts as advisers to the person with diabetes.
thiazolid inedione (THIGH-uh-ZOH-lih-deen-DYE-own) 
a class of oral medicine for Type 2 diabetes that helps insulin take glucose from 
the blood into the cells for energy by making cells more sensitive to insulin. 
(Generic names: pioglitazone and rosiglitazone) 
triglyceride (try-GLISS-er-ide)
the storage form of fat in the body. High triglyceride levels may occur when di­
abetes is out of control.
Type 1 diabetes
a condition characterized by high blood glucose levels caused by a total lack of 
insulin. Occurs when the body's immune system attacks the insulin-producing 
beta cells in the pancreas and destroys them. The pancreas then produces little or 
no insulin. Type 1 diabetes develops most often in young people but can appear 
in adults.
Type 2 diabetes
a condition characterized by high blood glucose levels caused by either a lack 
of insulin or the body's inability to use insulin efficiently. Type 2 diabetes de­
velops most often in middle-aged and older adults but can appear in young 
people.
ulcer (UL-sur)
a deep open sore or break in the skin.
ultralente insulin (UL-truh-LEN-tay)
long-acting insulin. On average, ultralente insulin starts to lower blood glucose 
within 4 to 6 hours after injection. It has its strongest effect 10 to 18 hours after 
injection but keeps working 24 to 28 hours after injection. Also called U insulin, 
unit of insulin
the basic measure of insulin. U-100 insulin means 100 units of insulin per milli­
liter (mL) or cubic centimeter (cc) of solution. Most insulin made today in the 
United States is U-100.
United Kingdom Prospective Diabetes Study (UKPDS)
a study in England, conducted from 1977 to 1997 in people with Type 2 di­
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abetes. The study showed that if people lowered their blood glucose, they lo­
wered their risk of eye disease and kidney damage. In addition, those with Type 
2 diabetes and hypertension who lowered their blood pressure also reduced their 
risk of stroke, eye damage, and death from long-term complications, 
urea (yoo-REE-uh)
a waste product found in the blood that results from the normal breakdown of 
protein in the liver. Urea is normally removed from the blood by the kidneys and 
then excreted in the urine.
uremia (yoo-REE-mee-ah)
the illness associated with the buildup of urea in the blood because the kidneys 
are not working effectively. Symptoms include nausea, vomiting, loss of appe­
tite, weakness, and mental confusion, 
urine
the liquid waste product filtered from the blood by the kidneys, stored in the 
bladder, and expelled from the body by the act of urinating, 
urine testing
also called urinalysis; a test of a urine sample to diagnose diseases of the urinary 
system and other body systems. Urine may also be checked for signs of bleed­
ing. Some tests use a single urine sample. For others, 24-hour collection may be 
needed. And sometimes a sample is "cultured” to see exactly what type of bacte­
ria grows.
urologist (yoo-RAH-luh-jist)
a doctor who treats people who have urinary tract problems. A urologist also 
cares for men who have problems with their genital organs, such as impotence.
vascular (VAS-kyoo-ler) 
relating to the body's blood vessels, 
vein
a blood vessel that carries blood to the heart, 
very-long-acting insulin
a type of insulin that starts to lower blood glucose within 1 hour after injection 
and keeps working evenly for 24 hours after injection.
very-low-density lipoprotein (VLDL) cholesterol 
a form of cholesterol in the blood; high levels may be related to cardiovascular 
disease.
vitrectomy (vih-TREK-tuh-mee)
surgery to restore sight in which the surgeon removes the cloudy vitreous humor 
in the eye and replaces it with a salt solution, 
vitreous humor (VIH-tree-us)
the clear gel that lies behind the eye's lens and in front of the retina, 
void
to urinate; to empty the bladder, 
wound care
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steps taken to ensure that a wound such as a foot ulcer heals correctly. People 
with diabetes need to take special precautions so wounds do not become in­
fected.
xylitol (ZY-lih-tall)
a carbohydrate-based sweetener found in plants and used as a substitute for sug­
ar; provides calories. Found in some mints and chewing gum.
50/50 insulin
premixed insulin that is 50 percent intermediate-acting (NPH) insulin and 50 
percent short-acting (regular) insulin 
70/30 insulin
premixed insulin that is 70 percent intermediate-acting (NPH) insulin and 30 
percent short-acting (regular) insulin.
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